NSW TAG NSW Therapeutic Advisory Group Inc. | Advancing quality use of medicines in NSW

TAG Mail: July to December 2026
Cumulative Listing of Reports, Publications, Medication Safety

Fortnightly TAG Mail – resources list 29th October 2026

NSW TAG ACTIVITIES

Updated NSW TAG publication
Know Your Insulins poster v3 Oct 2026- has incorporated new product and latest TGA advice re discontinuations- link

Recent Email Discussions:
Processes for out-of-session (OOS) IPU decision-making
Governance of Medicine Access Programs: How do DTCs manage MAPs?

TAG Mail
Searching Cumulative TAG Mail listings: Remember to search Cumulative TAG Mail listings, which are collated in 6 months batches from 2023. These cumulative listings are useful to survey whenever you have a medicine or condition you wish to explore as TAG mail covers the grey literature as well as the traditional academic literature. Just 'Control F' relevant terms to search for your query.

Contact Sasha Bennett at sasha.bennett@svha.org.au for information about any email discussions, publications or upcoming meetings.

EDITOR'S PICKS *highlighted with relevant NSW TAG and CATAG resources*

AJHP: Pharmacist-led preoperative medication management on elective surgical cancellation rates and economic implications - link CATAG MAIA Perioperative management of SGLT2 inhibitors and GLP-1 receptor agonists practice tool
AJHP: Pharmacist role in transforming Alzheimer's care: Anti-amyloid therapy experience- link
Cochrane: Pharmaceutical industry information and promotional strategies aimed at prescribers - link NSW TAG resource CATAG Managing medicine samples
Cochrane: Letter to the editor: Amyloid-beta-targeting monoclonal antibodies for people with mild cognitive impairment or mild dementia due to Alzheimer's disease - link
DOM: Cardiorenal Efficacy and Safety of SGLT2is and Finerenone in CKD with T2DM - link
DTB: Using genomics to personalise prescribing - link
EJHP: Post hoc analysis of pharmacist medication recommendations at discharge in geriatric inpatients - link NSW TAG Polypharmacy Resources and Deprescribing Tools CATAG MAIA Assessing the hidden risk of cumulative medicines toolkit
EJHP: Prescribing quality, documentation and opportunities for antithrombosis stewardship - link
IMJ:- Editorial: Is mainstreaming the answer? Genomics in practice or practising genomics - link
IMJ: Medical emergency response related to MedicAtion InciDents (MERRMAID) - link
IJQHC: FAME Analysis of the In-Hospital Medication Process: Identification of Systemic Risks and development of Improvement strategies - link NSW TAG QUM Indicators
IJQHC: Study on targeted double checks in parenteral medication administration - link
ISMP Canada: Advancing Appropriate Use of Antipsychotic Medications in Long-Term Care - link MEGA-MAC Indicators
JAMA: From Biological Insight to a New Class of Medicines for Hemophilia A - link
JAMA: The Orexin System—A Key Component of Sleep Regulatory Networks and Involvement in Narcolepsy - link NSW TAG Sleep Toolkit
JAMA IM: Communicating Uncertainties About the Benefits and Risks of New Cancer Drugs - link CATAG Emerging Medicines Guide
JACI: Guidelines for the management of adult penicillin allergy in community and specialist settings in Australia and New Zealand - link

JACC: Optimizing Blood Pressure Care in Patients with Resistant Hypertension - link
NHMRC Impact Case Studies: Preventing paracetamol overdose – 21 October NSW TAG IV Paracetamol Use
Paed QS: Quality Improvement Initiative to Reduce Medication-induced Kidney Injury – link CATAG MAIA Medicines and the Kidney toolkit
P'therapy: A Model for Estimating the Risk of Gastrointestinal Bleeding for Patients on Oral Anticoagulants and Interacting Medications - link CATAG MAIA Assessing the hidden risk of cumulative medicines toolkit

OTHER NEWS

NSW Health
- Nurse practitioners and prescribing of psychostimulant medicines - link
- Preventing and minimising restrictive practices in NSW Health settings (PD2026_055)

TGA
- TGA strengthening sunscreen regulation to improve confidence in Sun Protection Factor (SPF) claims - link

REPORTS AND PUBLICATIONS – AUSTRALIA

Agency for Clinical Innovation, NSW (ACI)
The latest weekly Evidence Digest can be found here

Australian Institute of Health and Welfare (AIHW)
- Health expenditure Australia 2024–25 – link
- Health system spending on disease and injury in Australia 2024–25 - link

NHMRC Impact Case Studies
- Preventing paracetamol overdose – 21 October

PBS
- Review of low-cost PBS-listed antidepressants - 28 October 2026

Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG)
- Management of Vasomotor and Genitourinary Symptoms of Menopause (C-Gyn 9) Guideline - link

TGA
- Database of section 19A approvals to import and supply medicines to address medicine shortages
- AusPARs:
-- Jaypirca (pirtobrutinib) is approved for the treatment of adults with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
-- Wainua (eplontersen) is approved for the treatment of hereditary transthyretin-mediated amyloidosis (ATTRv) in adults with stage 1 or stage 2 polyneuropathy
- Australian prescription medicine decision summaries:
-- Aflivu and Ahzantive (aflibercept) or wet age-related macular degeneration, macular oedema secondary to central retinal vein occlusion and branch retinal vein occlusion, diabetic macular oedema, and myopic choroidal neovascularisation
-- MS-2 Step (mifepristone and misoprostol) - extension of the current indication for the medical termination of an intrauterine pregnancy from up to 63 days' gestation to up to 70 days' gestation; new indication for the medical management of missed miscarriage up to 70 days' gestation, determined by ultrasound equivalence rather than menstrual period
-- Simulara, Solentis and Zivra (ranibizumab) for neovascular (wet) age-related macular degeneration, visual impairment due to diabetic macular oedema, proliferative diabetic retinopathy, visual impairment due to choroidal neovascularisation, visual impairment due to choroidal neovascularisation secondary to pathologic myopia, visual impairment due to macular oedema secondary to retinal vein occlusion

REPORTS AND PUBLICATIONS – INTERNATIONAL

British National Formulary
- BNF + BNFC Knowledge Updates – October 2026

Canadian Agency for Drugs and Technologies in Health
- Outpatient Parenteral Antibiotic Therapy - link

electronic Medicines Compendium (eMC) (UK)
- New products
-- Dyrupeg (pegfilgrastim) 6 mg solution for injection in a pre-filled syringe - for reduction in the duration of neutropenia and the incidence of febrile neutropenia in adults treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes)
-- Zefylti (filgrastim) solution for injection/infusion in pre-filled syringe - biosimilar to Neupogen for the treatment of neutropenia and the mobilisation of peripheral blood progenitor cells. It is available as 30 MU/0.5ml and 48 MU/0.5ml solution for injection or infusion in pre-filled syringe
- New indications
-- Gobivaz (golimumab) - now indicated in combination with methotrexate for treatment of polyarticular juvenile idiopathic arthritis in children 2 years of age and older, who have responded inadequately to previous therapy with methotrexate
-- Keytruda (pembrolizumab) - resectable muscle invasive bladder cancer indication revised to a single cisplatin-agnostic indication based on Keynote-B15 and 905 studies

European Medicines Agency (EMA)
- European CHMP recommendations for the EU – October 2026
-- for approval of 6 new medicines, including 2 biosimilars and one hybrid (daraxonrasib, orforglipron, navepegritide, temozolomide, Fovlussea (ranibizumab biosimilar) and Neuzafy (filgrastim biosimilar))
-- for extending/amending license indications for 5 medicines (pandemic influenza vaccine H5N1 AstraZeneca, insulin icodec/semaglutide, talquetamab, olezarsen, and tucatinib)
-- Refuses marketing authorization for narsoplimab (Yartemlea) for hematopoietic stem cell transplant (HSCT)-associated thrombotic microangiopathy (TA-TMA).The monoclonal antibody was intended for adults and children aged 2 years or older with high-risk TA-TMA - link

Food and Drug Administration (FDA) USA
- New Drug approvals
-- Awiqli (insulin icodec-abae), First once-weekly insulin for paediatric Type 2 Diabetes Mellitus
-- Brytly (apraclonidine) nonprescription eye drop for relief of eye redness – PI-label
-- Climara Pro (estradiol and levonorgestrel transdermal system), once-weekly generic hormone therapy patch for women
-- Hibsago (bepirovirsen) to treat chronic hepatitis B virus infection in certain adults without cirrhosis, in combination with existing antiviral therapy – PI-label
-- Jemperli (dostarlimab-gxly), immunotherapy that may allow certain patients with rectal cancer to avoid chemotherapy, radiation and surgery
-- Ryzumvi eye drops for presbyopia
-- talazoparib (Talzenna) with enzalutamide for metastatic androgen pathway modulation-naïve or -sensitive prostate cancer with HRR gene mutations

Health Foundation UK
- AI in health care is changing what we mean by risk - link

Medicines and Healthcare products Regulatory Agency (MHRA)
- Authorises plozasiran (Redemplo) for adults with familial chylomicronaemia syndrome - link
- Approves icotrokinra hydrochloride (Icotyde) for moderate to severe plaque psoriasis - link

Monthly Index of Medical Specialities (MIMS) UK
- 1mg dose of EURneffy nasal adrenaline spray now available for UK prescribing - link

- Fire-retardant emollient, Novamol Protect, now available in UK - link

NHS England
- Tirzepatide (Mounjaro®) for managing obesity – patient leaflet

National Institute for Health and Care Excellence (NICE) UK
- Insulin efsitora alfa for treating type 2 diabetes (TA1200)
- Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more lines of anti-HER2 treatment (TA1202)
- Olezarsen for treating familial chylomicronaemia syndrome (TA1203)
- Plozasiran for treating familial chylomicronaemia syndrome (TA1204)

UK Health Security Agency
- Influenza: treatment and prophylaxis using anti-viral agents - update

World Health Organisation (WHO)
- Guideline on the integrated management of obesity in children – link
- Guideline on the integrated management of obesity in adolescents - link
- Global roadmap for hypertensive disorders of pregnancy from 2026 to 2035 and beyond - link
- Target regimen profiles for long-acting injectables for tuberculosis prevention and treatment - link
- Tobacco and infertility - link

MEDICATION SAFETY

electronic Medicines Compendium (eMC) (UK)
- Revised SPCs
-- Besponsa (inotuzumab ozogamicin) - information on its use as monotherapy in paediatric patients and to clarify that to mitigate the risk of QT prolongation, the time of infusion should be increased to 1.5 hours in paediatric patients with a body weight <35 kg
-- Bevespi Aerosphere (formoterol fumarate dihydrate, glycopyrronium bromide) - as with other inhalation therapies, administration may result in paradoxical bronchospasm, which can be life-threatening
-- Eltroxin (levothyroxine sodium) - new interaction warning on the concurrent consumption of fibre supplements or fibre-containing medicinal products, as levothyroxine absorption could be reduced. Monitoring of thyroid function and dose adjustment may be required with concurrent use
-- Imdylltra (tarlatamab) - Monitoring requirements for cycle 1 updated to advise that patients should be monitored from the start of the infusion for 6 to 8 hours on days 1 & 8; additional monitoring, including monitoring after subsequent infusions, is at the discretion of the healthcare professional
-- Lipitor (atorvastatin) - although interaction studies with atorvastatin and colchicine have not been conducted, cases of myopathy have been reported with atorvastatin co-administered with colchicine, and caution should be exercised when prescribed together
-- Salazopyrin (sulfasalazine) - should not be administered concurrently with methenamine hippurate because of the risk of crystalluria
-- Sudafed (xylometazoline hydrochloride) Blocked Nose Spray should not be used for more than five (previously seven) consecutive days, and that at least 8 hours should be left between doses. Prolonged or excessive use may result in rhinitis medicamentosa and atrophy of the nasal mucosa
-- Scemblix (asciminib) - information on the drug-drug interactions of asciminib with BCRP and P-gp substrates updated, based on the results from a study with rosuvastatin and digoxin
-- Sinemet (carbidopa , levodopa) tablets – vitamin B6 deficiency as a common ADR, and warning of increased seizure risk from B6 deficiency, particularly with high doses and poor nutrition. Monitor levels and supplement pyridoxine in high-dose carbidopa/levodopa patients or those with suggestive symptoms
-- Transtec (buprenorphine) - seizures added as ADR of unknown frequency. SPC notes Transtec® has not been evaluated in patients with seizure disorder (SD), but like other analgesics with mu-opioid receptor agonist activity, buprenorphine may lower seizure threshold in patients with history of SD
-- Winrevair (sotatercept) - Thrombocytopenia reported more frequently in patients receiving prostacyclin infusion (7.7% to 24.5%) vs not receiving prostacyclin infusion (0.0% to 3.7%). GI tract

bleeding added as a 'very common' ADR; colonic angioectasia & skin hypopigmentation added as 'common' ADRs
-- Zilbrysq (zilucoplan sodium) - increases susceptibility to meningococcal and other Neisseria infections. Advice is given regarding vaccinations, and prophylactic antibiotic treatment (where appropriate). Patients should be counselled on this risk & monitored for signs of infection during treatment
- Risk minimisation materials
-- Remsima 100mg and 350mg concentrate for solution for infusion, a new IV formulation of infliximab. Letter advises of the risk of serious metabolic harm in patients with hereditary fructose intolerance, due to the sorbitol content (45mg per mL)
-- Caspofungin: use of polyacrylonitrile (PAN) membranes during continuous renal replacement therapy (CRRT). Letter contains recommendations for healthcare professionals related to the possibility that (PAN)-based membranes used in CRRT may adsorb caspofungin, potentially reducing systemic exposure and treatment effectiveness
-- Fabhalta (iptacopan) – confirmation of vaccine and/or antibiotic prophylaxis form (PNH indication) - Iptacopan can only be dispensed once Novartis receives written confirmation that each patient has received vaccination against N. meningitidis and S. pneumoniae infections and/or receipt of prophylactic antibiotic treatment
-- Remsima Liquid (infliximab concentrate for solution for infusion): Patient Reminder Card contains important safety information, including its contra-indication in people with hereditary fructose intolerance, and warnings regarding infection, pregnancy, breastfeeding and vaccinations

ISMP Canada – Safety Bulletins
- Advancing Appropriate Use of Antipsychotic Medications in Long-Term Care: Collaborative Action Needed across the Health Care System - link

Medicines and Healthcare products Regulatory Agency (MHRA) UK
- MHRA safety roundup: October 2026 includes:
-- IXCHIQ Chikungunya vaccine: UK marketing authorisation withdrawn following safety review - link
-- #MedSafetyWeek (2 to 8 November 2026): Don't ignore suspected side effects, report them! Updates to the Yellow Card website and app - link

TGA
- Updates to the Prescribing Medicines in Pregnancy database - October 2026
- Information about major medicine shortages – link
-- About the shortage of methylphenidate hydrochloride products - link
-- About the changes to the supply of insulin products - link
-- About the shortage of Creon (pancreatic extract) capsules - link
-- About the shortage of transdermal HRT patches - link

PAPERS OF INTEREST

American Journal of Health-System Pharmacy (AJHP)
- Effect of pharmacist-led preoperative medication management on elective surgical cancellation rates and economic implications - link
- Vial puncture mechanics with a mechanical assist device during anticancer drug compounding with a closed-system drug transfer device - link
- Micronutrient deficiencies in continuous renal replacement therapy: A literature review and the emerging role of the pharmacist - link
- Pharmacy performance evaluation: A single-center assessment of drug waste and mitigation strategies - link
- Pharmacist role in transforming Alzheimer's care: Anti-amyloid therapy experience at Vanderbilt University Medical Center - link
- Physical Simulated Y-Site Compatibility of Hypertonic Saline with Vasoactive Medications Commonly Used in Pediatric Intensive Care - link
- Upadacitinib and Warfarin Drug Interaction Resulting in Significantly Increased International Normalized Ratio: A Case Report and Review of the Literature - link

- Assessing Medication Confounders Before Determination of Brain Death/Death by Neurologic Criteria: A Primer, with Opioids as a Worked Example - link
- Symptom-monitored loading: An evaluation of prophylactic medications in patients with severe alcohol withdrawal - link
- An Evaluation of Insulin Use in Hospitalized Patients with Corticosteroid-Related Hyperglycemia - link
- Postoperative length of stay comparison associated with a switch from alvimopan to naloxegol in patients undergoing major small and large bowel procedures - link

Annals of Internal Medicine
- Periconception Parental Red Blood Cell Folate, Vitamin B12, and Birth Defects in Offspring: A Prospective Cohort Study - link
- Bemotrizinol Approval: A Step Toward U.S. Sunscreen Modernization - link
- Iron Deficiency in Women: A Silent Pandemic with Consequences That May Reach the Classroom - link
- Management of Menopausal Symptoms - link
- Obesity and Cancer Risk in Young Adults in Korea: A Nationwide Health Screening Cohort Study - link

Arthritis & Rheumatology
- Oral Glucocorticoid Dose Patterns and Organ Damage in Systemic Lupus Erythematosus—A Nationwide Cohort Study - link
- Higher risk of Long COVID among patients with autoimmune rheumatic diseases and immunomodulatory therapy: a retrospective cohort analysis of national US data - link
- Treatment Approaches to Macrophage Activation Syndrome in Real Life and Priorities for Future Research: Results from the International METAPHOR Project - link
- Comparative risks of mortality and fractures in patients with osteoarthritis initiating tramadol versus other opioids - link

Blood Advances
- American Society of Hematology 2026 guidelines for diagnosis of iron deficiency - link

British Journal of Clinical Pharmacology
- Drug repurposing in fibrosis: From molecular networks to antifibrotic therapeutics—A narrative review - link
- Cardiovascular outcomes of SGLT2 inhibitors across the spectrum of myocardial infarction: A systematic review and meta-analysis - link
- Analysis of queries in an HIV drug–drug interaction checker to explore changes in prescribing patterns: A 5-year analysis - link

British Journal of General Practice
- Non-antibiotic interventions to prevent recurrent urinary tract infections in women: overview of systematic reviews of randomised controlled trials - link

British Journal of Obstetrics and Gynaecology
- Efficacy and Safety of Lidocaine Compared to Other Agents for Intrauterine Device Insertion Pain: A Systematic Review and Meta-Analysis - link

BMC Medicine
- Left atrial appendage occlusion versus oral anticoagulation in atrial fibrillation: a meta-analysis of randomized controlled trials - link

British Medical Journal (BMJ)
- Bat-borne zoonoses: transmission, impact, prevention, and management - link
- GLP-1s and criminality: US trial will test whether semaglutide can fight crime - link
- Extreme weather events: A practical guide for clinicians - link
- Advances in the management of renal cell carcinoma - link

Circulation
- Consensus Guidance for the Female-Specific Prevention and Management of Cardiovascular Disease: A US Scientific Statement - link

Cochrane
- Pharmaceutical industry information and promotional strategies aimed at prescribers - link
- Letter to the editor: Amyloid-beta-targeting monoclonal antibodies for people with mild cognitive impairment or mild dementia due to Alzheimer's disease - link

Diabetes, Obesity and Metabolism
- Comparative Cardiorenal Efficacy and Safety of SGLT2 Inhibitors and Finerenone in Chronic Kidney Disease with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis - link
- Effects of a Low-Carbohydrate Diet Combined with Exercise on HbA1c in Adults With Type 2 Diabetes: A Bayesian Multilevel Network and Dose–Response Meta-Analysis - link
- SGLT2 Inhibitors Reduce Heart Failure Hospitalization, Cardiovascular Death and Kidney Outcomes in Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials - link

Drug and Therapeutics Bulletin
- Using genomics to personalise prescribing - link
- Lipid-lowering for people with chronic kidney disease: a narrative review - link

EClinical Medicine
- Adalimumab versus placebo as add-on to standard therapy for non-infectious uveitis in the United Kingdom: the ASTUTE randomised controlled trial with treatment run-in - link

European Heart Journal
- Acute heart failure in emergency settings: A clinical consensus statement of the Association for Acute CardioVascular Care and the Heart Failure Association of the European Society of Cardiology and the European Society for Emergency Medicine - link
- Sex differences in cardiovascular disease burden, risk factors, and disease spectrum in Europe: a global burden of disease 2023 analysis within the ESC Atlas framework - link

European Journal of Hospital Pharmacy
- Now or never: a post hoc analysis of pharmacist medication recommendations at discharge in geriatric inpatients from the ASPIRE trial - link
- Pharmacist-led renal medication safety and stewardship practices in adults with kidney disease: a scoping review - link
- Combination antiplatelet and anticoagulant therapy in general internal medicine: prescribing quality, documentation and opportunities for antithrombosis stewardship - link

Internal Medicine Journal
- Editorial: Is mainstreaming the answer? Genomics in practice or practising genomics - link
- Medical emergency response related to MedicAtion InciDents (MERRMAID): a case series and lessons to improve medication safety - link

International Journal for Quality in Health Care
- Failure Mode and Effects Analysis of the In-Hospital Medication Process: Identification of Systemic Risks and development of Improvement strategies - link
- Targeting what matters: a quasi-experimental controlled before-and-after study on targeted double checks in parenteral medication administration - link

JAMA
- What Is Alcohol-Related Liver Disease? - link
- From Biological Insight to a New Class of Medicines for Hemophilia A: The 2026 Lasker-DeBakey Clinical Medical Research Award - link

- The Orexin System—A Key Component of Sleep Regulatory Networks and Involvement in Narcolepsy: The 2026 Albert Lasker Basic Medical Research Award - link
- Effect of Vasopressin Initiation Threshold on Septic Shock Mortality: The VASSPR Cluster Crossover Randomized Strategy Trial - link
- Fluid Therapy in Mechanically Ventilated Critically Ill Adult Patients - link
- Intraoperative Dobutamine Plus Norepinephrine to Prevent Postoperative Acute Kidney Injury in Septic Shock: A Randomized Clinical Trial - link
- Isoflurane-Based Inhaled Sedation in Mechanically Ventilated Adults with Acute Hypoxemic Respiratory Failure: The SAVE-ICU Randomized Clinical Trial - link
- Therapy for Adults with Complicated Urinary Tract Infection - link
- Childhood Cancer Risk After Assisted Reproductive Technology – link
- Obesity in Children Aged 2 to 12 Years: A Review - link
- JAMA Patient Page: What Is Celiac Disease? - link
- Rituximab vs Azathioprine for Eosinophilic Granulomatosis with Polyangiitis Maintenance Therapy: A Randomized Clinical Trial - link
- Sodium-Glucose Cotransporter 2 Inhibitor Use and Levels of Hemoglobin, Markers of Iron Metabolism, and Erythropoiesis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials - link
- Trastuzumab Rezetecan in ERBB2-Low Advanced Breast Cancer: The HORIZON-Breast06 Randomized Clinical Trial – link
- Testosterone Use Rises Among Women, but Does the Evidence Support It? – link
- Preoperative Intranasal Oxytocin and Probable Acute Stress Disorder After Traumatic Fracture Surgery: A Randomized Clinical Trial - link

JAMA Cardiology
- Intensive vs Standard Blood Pressure Lowering in People with and without Chronic Kidney Disease: A Systematic Review and Meta-Analysis - link

JAMA Internal Medicine
- Communicating Uncertainties About the Benefits and Risks of New Cancer Drugs: Two Randomized Clinical Trials - link
- Preoperative Medicine for the Internal Medicine Clinician - link

JAMA Network Open
- Mortality Among People with Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-Analysis - link

JAMA Neurology
- Early Pregnancy Use of Anti-CGRP Monoclonal Antibodies and Propranolol and Spontaneous Abortion Risk - link

Journal of Allergy and Clinical Immunology
- Guidelines for the management of adult penicillin allergy in community and specialist settings in Australia and New Zealand: An AGREE II and Delphi-based approach - link

Journal of the American College of Cardiology
- Optimizing Blood Pressure Care in Patients with Resistant Hypertension: 2026 ACC Expert Consensus Decision Pathway: A Report of the American College of Cardiology Solution Set Oversight Committee - link

Journal of Antimicrobial Chemotherapy
- Oxazolidinones in the Clinical Management of Staphylococcal Infection—Linezolid or Tedizolid? A review on behalf of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Staphylococci and Staphylococcal Diseases (ESGS) - link

Journal of General Internal Medicine
- Does Intensive Therapy Targeting Modifiable Risk Factors Prevent Diabetic Neuropathy in Adults with Type 2 Diabetes? A Systematic Review and Meta-analysis of Randomized Clinical Trials - link

Journal of Hospital Infection
- Evaluation of preventive interventions addressing healthcare-associated infections and antimicrobial resistance: a systematic review – link
- Global randomised controlled trials in infection prevention and control: a bibliographic review from the past two decades - link

Lancet
- 14-day versus 28-day trifluridine–tipiracil plus bevacizumab for refractory metastatic colorectal cancer (PRABITAS): a pragmatic, multicentre, open-label, randomised, phase 3, non-inferiority trial in Japan - link

Lancet Diabetes & Endocrinology
- Disease modification outcomes in type 2 diabetes: a modified Delphi - link
- The development of obesity pharmacotherapy: from early challenges and setbacks to recognition by WHO - link

Lancet Infectious Diseases
- Effectiveness of respiratory syncytial virus immunisation in practice - link

Lancet Psychiatry
- Change in HbA1c and weight after initiation of antipsychotic treatment in people with severe mental illness in England: an individual-level interrupted time-series analysis - link
- GLP-1 receptor agonist initiation and risk of psychiatric hospitalisation and emergency department presentation in adults with schizophrenia and type 2 diabetes in the USA: an observational cohort study using electronic health records data - link

New England Journal of Medicine
- Continuous Glucose Monitoring in Non–Insulin-Treated Type 2 Diabetes - link
- Ponatinib–Blinatumomab or Imatinib–Chemotherapy for Adult Ph-Positive ALL - link
- Adult Attention Deficit–Hyperactivity Disorder - link
- Retatrutide Once Weekly for Treatment of Obstructive Sleep Apnea - link
- Ianalumab for the Treatment of Patients with Sjögren's Disease - link
- Helicobacter pylori Infection — Advances, Challenges, and the Road Ahead - link
- Atacicept in IgA Nephropathy — Phase 3 Trial Final Efficacy Analysis - link
- Sibeprenlimab in IgA Nephropathy — Final Phase 3 Trial Analysis - link
- Divarasib as Compared with Sotorasib or Adagrasib in KRAS G12C–Mutated NSCLC - link
- Durvalumab, Tremelimumab, and Enfortumab Vedotin in Muscle-Invasive Bladder Cancer - link
- Interim Analysis of a Phase 3 Trial of Povetacicept in IgA Nephropathy - link
- Osimertinib–Savolitinib in Advanced NSCLC after Progression during EGFR-TKI Therapy - link
- Ravulizumab in IgA Nephropathy — Interim Analysis of a Phase 3 Trial - link
- Sacituzumab Tirumotecan plus Pembrolizumab in PD-L1–Negative Advanced NSCLC Sacituzumab Tirumotecan plus Pembrolizumab in PD-L1–Negative Advanced NSCLC - link
- Tarlatamab–Durvalumab Maintenance for Extensive-Stage Small-Cell Lung Cancer - link
- Anbenitamab plus HB1801 for HER2-Positive Advanced Breast Cancer - link

Pediatric Quality & Safety
- Achieving Faster Bleeding Disorder Treatment in the Emergency Department: A Quality Improvement Initiative – link
- Impact of a Quality Improvement Initiative to Reduce Medication-induced Kidney Injury – link
- Quality Improvement Initiative: Implementation of a Unified Pediatric Asthma Pathway Reduces Critical Care Requirements - link

Pediatrics (American Academy of Pediatrics)
- Recommendations for Prevention and Control of Influenza in Children, 2026–2027: Technical Report - link
- Recommendations for Prevention and Control of Influenza in Children, 2026–2027: Policy Statement - link
- Recommendations for the Prevention of Respiratory Syncytial Virus Disease in Infants and Children: Policy Statement - link
- Recommendations for the Prevention of Respiratory Syncytial Virus Disease in Infants and Children: Technical Report - link
- Immunogenicity and Safety of PHH-1V COVID-19 Vaccine as a Heterologous Booster in Adolescents - link
- Vaccine-Induced Antibody and T Cell Immunity to Measles and Varicella in Children With ALL - link
- Recommendations for COVID-19 Vaccines in Infants, Children, and Adolescents, 2026–2027: Policy Statement - link
- Recommendations for COVID-19 Vaccines in Infants, Children, and Adolescents, 2026–2027: Technical Report - link

Pharmacotherapy
- A Model for Estimating the Risk of Gastrointestinal Bleeding for Patients on Oral Anticoagulants and Interacting Medications - link
- Incremental Predictive Value of Dynamic Platelet-to-Lymphocyte Ratio Beyond ESR and CRP for Glucocorticoid Sparing in Rheumatoid Arthritis: A Multi-Center Retrospective Cohort Study - link

CONSULTATIONS

Australian Commission on Safety and Quality in Health Care (ACSQHC)
- Pilot of the NSQHS Standards (third edition) – closes 20 November 2026 - link

TGA
- Consultation: High-moderate risk changes to permissible ingredients - Vitamin B6 (pyridoxine hydrochloride, pyridoxal 5-phosphate, and pyridoxal 5-phosphate monohydrate) - Closes on 25 November 2026 - link

WEBINARS & PODCASTS

Australian Prescriber Podcasts
- E225 | Glaucoma management in adults: an update

MJA Podcasts
- Building better bone health - link

Purple Pen Podcast
- PPP 198 - Pins, Needles, and Too Much Vitamin B6

UPCOMING EVENTS

Australian Commission on Safety and Quality in Health Care (ACSQHC)
- Registrations open – National Medicines Symposium NMS 2026, 'Medicines stewardship: safer use starts with all of us' - Wednesday, 11 November 2026 - register - program

Fortnightly TAG Mail – resources list 15th October 2026

NSW TAG ACTIVITIES

Updated NSW TAG publication
Know Your Insulins poster v3 Oct 2026- has incorporated new product and latest TGA advice re discontinuations- link

Current Email Discussion:
Processes for out-of-session (OOS) IPU decision-making: Closes COB 26th October 2026

Recent Email Discussion
Governance of Medicine Access Programs: How do DTCs manage MAPs?

Upcoming NSW TAG meeting dates
NSW TAG General Members' Meeting: 29th October 2026 4-5pm
NSW TAG Annual General Meeting: 29th October 2026 5-5.30pm

TAG Mail
Searching Cumulative TAG Mail listings: Remember to search Cumulative TAG Mail listings, which are collated in 6 months batches from 2023. These cumulative listings are useful to survey whenever you have a medicine or condition you wish to explore as TAG mail covers the grey literature as well as the traditional academic literature. Just 'Control F' relevant terms to search for your query.

Contact Sasha Bennett at sasha.bennett@svha.org.au for information about any email discussions, publications or upcoming meetings.

EDITOR'S PICKS *highlighted with relevant NSW TAG and CATAG resources*

AJHP: Transforming value-based deep vein thrombosis care through a pharmacist-led clinic - link NSW TAG QUM Ind 1.1-1.3
AJHP: Executive summary 2026 ASHP commission on goals: cell & gene therapy (cgt) and other ultra-high-cost drugs - link
AJHP: Polypharmacy and anticholinergic burden in hospitalized older patients - link NSW TAG Polypharmacy Ind 8.3
AIM: Anaemia in Chronic Kidney Disease: Synopsis of the KDIGO 2026 CPG - link
Aust Presc: COVID-19 vaccines on the National Immunisation Program with revised eligibility - link
BJCP: Patient preferences for medicines information in cardiovascular disease and the influence of unmet needs on medication adherence - link
BJCP: Pharmacist's role in managing drug–drug interactions in people with HIV receiving antiretroviral therapy or HIV pre-exposure prophylaxis - link
BMJ: Weight loss drugs: Does microdosing GLP-1s work? - link
BMJ: Clinical update: Assessment and management of Helicobacter pylori infection - link
CPJ: Editorial: The indispensable skills of the pharmacist in an era of AI - link
CPJ: An electronic tool to identify/manage medication in hospitalized elderly patients - link NSW TAG Polypharmacy Toolkit
Circ: Impact of Undertreated Antithrombotic Therapy on Adverse Patient Outcomes - link NSW TAG QUM Indicators Set 1
Circ: Anticancer Drugs and Cancer-Associated Thrombosis - link
Circ: Multidisciplinary Approach to Antiplatelet Management in Coronary Syndromes - link
Diabetol: Management of Type 2 Diabetes, 2026 - link
DOM: Cellular Mechanisms and Clinical Strategies for Preserving Lean Mass During GLP-1-Based Therapy - link
EHJ: Blinded withdrawal of randomized treatment with low-dose digoxin or placebo in HF - link
IMJ: Preventing infections after CD19-directed CART-cell therapies for lymphoma: a - link
IMJ: Semaglutide in type 2 diabetes and chronic kidney disease in Australia - link
JAMA: Effective Multimodal Care for Obesity and Comorbidities in the GLP-1 Therapy Era - link CATAG GLP1 Decision Making Framework
JAGS: Dual Orexin Receptor Antagonists for Insomnia and the Risk of Falls and Fractures - link
MHRA: Antidepressants: safety measures for all patients to improve communication of the risk of suicidal thoughts and behaviours and persistent sexual dysfunction - link CATAG MAIA Antidepressant Withdrawal
MJA**:** Patterns of Osteoporosis Treatment Initiation Following Low-Trauma Fracture: - link
MJA: Gabapentinoid Poisoning Presentations to Victorian Emergency Departments - link

P'therapy: Use of large language models in dosing recommendations in kidney impairment- link
CATAG Medicines and the kidney toolkit

OTHER NEWS

Australian Commission on Safety and Quality in Health Care (ACSQHC)
- New medicinal cannabis resources - link

NSW Health
- Multiple high-dose MDMA (ecstasy) tablets circulating in NSW [9 October 2026]
- Unapproved peptides - identifying and reporting harm [SI:009/26]

REPORTS AND PUBLICATIONS – AUSTRALIA

Agency for Clinical Innovation, NSW (ACI)
The latest weekly Evidence Digest can be found here

Australian Commission on Safety and Quality in Health Care (ACSQHC)
- Aged Care Infection Prevention and Control poster suite - link
- Better Care Everywhere: Medico-legal risks module

Australian Institute of Health and Welfare (AIHW)
- Polypharmacy in Australia in 2025 - link
- National palliative care measures – update

MIMS monthly updates
- New Products
-- Dengue vaccine tetravalent (live, attenuated) (Qdenga) for the prevention of dengue disease in individuals from 4 years of age. Qdenga is contraindicated in individuals with congenital or acquired immune deficiency, including those receiving immunosuppressive therapies such as high doses of systemic corticosteroids (e.g. 20 mg/day or 2 mg/kg/day of prednisone for 2 weeks or more) within 4 weeks prior to vaccination, or any other medicinal product with known immunosuppressive properties including chemotherapy; individuals with symptomatic human immunodeficiency virus (HIV) infection or with asymptomatic HIV infection when accompanied by evidence of impaired immune function; and in women who are pregnant or breastfeeding
-- Sodium oxybate (Sodium Oxybate-Reach) for narcolepsy in adult patients, adolescents and children from the age of 7 years. Sodium Oxybate-Reach is contraindicated in patients with major depression; with succinic semialdehyde dehydrogenase deficiency; and in those being treated with opiates or barbiturates
-- Tofersen (Qalsody) - provisional approval for adults with amyotrophic lateral sclerosis associated with a mutation in the SOD1 gene
- New Presentation
-- Perindopril arginine and amlodipine (besilate) (Coveram LD) - low dose combination tablet for initiation therapy of hypertension. In addition to the existing contraindications for Coveram, it is also contraindicated in patients with severe renal impairment (creatinine clearance below 30 mL/minute).
- New Indications
-- Capivasertib (Truqap) in combination with fulvestrant now also indicated for adult patients with hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy
-- Deucravacitinib (Sotyktu) now also indicated for adult patients with active psoriatic arthritis who have had an inadequate response/ who have been intolerant to, a prior disease modifying therapy (DMARD). May be used as monotherapy or in combination with conventional synthetic DMARDs
-- Estradiol (hemihydrate) (Sandrena) for prevention of osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of/contraindicated for, other medicinal products approved for osteoporosis prevention. Experience of treating women older than 65 years is limited.

-- Goserelin (acetate) (Zoladex 10.8 mg Implant) for the management of oestrogen-receptor (ER) positive early and advanced breast cancer in pre- and perimenopausal women
-- Pembrolizumab (rch) (Keytruda) in combination with paclitaxel, with or without bevacizumab, for the treatment of patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumours express programmed cell death-ligand 1 (PD-L1) (CPS ≥ 1) as determined by a validated test, and who have received one or two prior systemic treatment regimens

Pharmaceutical Benefits Scheme (PBS)
- Update to the Principles of broad (multi-cancer) listings for programmed cell death-1/programmed death ligand-1 (PD-(L)1) inhibitors - 15 October 2026 - link

TGA
- Withdrawal of TAVNEOS (avacopan) - link
- Vaccine reconstitution - link
- Database of section 19A approvals to import and supply medicines to address medicine shortages
-- Exdensur (depemokimab) is approved as an add-on maintenance treatment for severe asthma in adults and adolescents with eosinophilic airways inflammation, and for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in adults, with limited response to systemic corticosteroids or surge
-- Fetroja (cefiderocol) for infections due to proven or strongly suspected carbapenem-resistant aerobic Gram-negative organisms in adults with limited treatment options, including complicated urinary tract infections, pyelonephritis, hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia
-- Hibruka (orelabrutinib) has provisional approval in Australia for the treatment of adults with relapsed or refractory mantle cell lymphoma (MCL). Continued approval depends on verification and description of benefit in confirmatory trials.

REPORTS AND PUBLICATIONS – INTERNATIONAL

Canadian Agency for Drugs and Technologies in Health
- Topical Drugs for Pain Management - link
- Strategies to Reduce the Environmental Impact of Metered-Dose Inhalers for Pulmonary Function Testing Laboratories - link
- Detecting Compositions of Unregulated Substances: A Horizon Scan of Emerging Drug Checking Technologies - link

Department of Health and Social Care UK
- Levemir® (insulin detemir) FlexPen® 100units/ml solution for injection 3ml pre-filled pens and Levemir® (insulin detemir) Penfill® 100units/ml solution for injection 3ml cartridges - being discontinued – switch all existing Levemir® patients as soon as possible, do not to start new patients
- Independent review into mental health conditions, ADHD and autism: final report - link

electronic Medicines Compendium (eMC) (UK)
- New products
-- Korjuny (catumaxomab) for intraperitoneal treatment of malignant ascites in adults with epithelial cellular adhesion molecule (EpCAM)-positive carcinomas, who are not eligible for further systemic anticancer therapy
-- Jascayd (nerandomilast) film-coated tablets available as 9mg and 18mg film-coated tablets, selective inhibitor of phosphodiesterase 4 for adults with idiopathic pulmonary fibrosis & progressive pulmonary fibrosis
-- Vueway (gadopiclenol) - paramagnetic agent is indicated for paediatric and adult MRIs to enhance detection of blood-brain barrier disruption and abnormal vascularity. Its use is restricted to cases where unenhanced MRI fails to yield a diagnosis
- New indications
-- Gazyvaro (obinutuzumab) – now for adult patients with active systemic lupus erythematosus (SLE) who are receiving standard therapy via short duration infusion
-- Glecaprevir/Pibrentasvir (Maviret) 50mg/20mg and 100mg/40mg for acute hepatitis C virus (HCV) infection in adults and children aged 3 years and older (already licensed for chronic HCV)

-- Padcev (enfortumab vedotin) - in combination with pembrolizumab, as neoadjuvant treatment and then continued after radical cystectomy as adjuvant treatment, for the treatment of adult patients with resectable muscle invasive bladder cancer
-- Rapibloc (landiolol) - New paediatric (0-18 years) indication added for rapid heart rate control and conversion to sinus rhythm in patients with atrioventricular re-entry tachycardia and atrioventricular node re-entry tachycardia when adenosine is ineffective, contraindicated, or not tolerated

Food and Drug Administration (FDA) USA
- New Drug approvals
-- Anktiva (nogapendekin alfa inbakicept-pmln), first treatment for certain people with BCG-unresponsive bladder cancer
-- Atezolizumab with chemo combo for colon cancer
-- pirtobrutinib (Jaypirca) for previously untreated CLL/SLL
-- Hovilpri (pritelivir) for adults with weakened immune systems who have mucocutaneous lesions caused by herpes simplex virus infection and have not responded to other therapies
-- Remibrutinib oral medication for two main causes of chronic hives
-- Tucatinib for HER2+ breast cancer maintenance
-- vardenafil nasal spray for erectile dysfunction now available in us

General Pharmaceutical Council UK
- Open letter calls for NICE to review guideline in response to propranolol concerns - link

Medicines and Healthcare products Regulatory Agency (MHRA)
- Approves catumaxomab (Korjuny) for intraperitoneal treatment of malignant ascites in adults with epithelial cellular adhesion molecule (EpCAM)-positive carcinomas, who are not eligible for further systemic anticancer therapy - link
- Authorises Onswik (insulin efsitora alfa) for adults with type 2 diabetes - link

Monthly Index of Medical Specialities (MIMS) UK
- MIMS Learning: Pharmacokinetics of obesity - link
- New modified-release ADHD preparation (Addepta XL) for use in children launched in UK - link

Neonatal & Paediatric Pharmacy Group
- Use of steroid medication warning cards for children and young people - link
- Safe use of continuous intravenous propofol infusions in paediatric critical Care - link

National Institute for Health and Care Excellence (NICE) UK
- Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy (TA1197)
- Nirogacestat for treating desmoid tumours (TA1199)

Specialist Pharmacy Services NHS UK
- Understanding acute CAR-T cell therapy toxicities in adults - link

World Health Organisation (WHO)
- Issues first global guidance on child and adolescent obesity - link
- Launches TB in pregnancy and lactation research toolkit - link
- New global roadmap launched to tackle hypertension in pregnancy, a leading cause of maternal and newborn deaths - link

MEDICATION SAFETY

electronic Medicines Compendium (eMC) (UK)
- Revised SPCs
-- Bonjela (cetalkonium chloride, choline salicylate) - use with caution in patients with an active or recurring peptic ulceration, and that it should not be used with aspirin or other salicylates except under the direction of a doctor. A warning for risk of use in pregnancy has also been added

-- Buvidal (buprenorphine) - new contraindication of concomitant use with opioid antagonists (naltrexone, nalmefene) for the treatment of alcohol or opioid dependence
-- Darzalex (daratumumab) - hypotension and decreased weight added as common ADRs
-- Epilim (sodium valproate) - a study suggests an increased risk of neuro-developmental disorders in children born to men treated with valproate in the 3 months prior to conception compared to those born to men treated with lamotrigine or levetiracetam. Overall evidence is inconsistent
-- Kadcyla (trastuzumab emtansine) - updated to clarify the contraception requirements for male patients with female partners of childbearing potential, who should use effective contraception during treatment and for at least 4 months following the last dose
-- Kapruvia (difelikefalin acetate) - mental status changes (including confusional state) reported as a treatment-emergent ADR, mainly mild or moderate in severity. This should be taken into account especially in the more vulnerable population of the elderly
-- Kesimpta (ofatumumab) pre-filled pen - increased hepatic enzymes added as common ADR
-- Lunsumio (mosunetuzumab) - new subcutaneous route of administration, including highlighting the importance of checking the product labels to ensure that the correct formulation (intravenous or subcutaneous fixed dose) is being administered to the patient
-- Malarone (atovaquone, proguanil) – information added on 'severe cutaneous adverse reactions (SCARs)' and 'Drug reaction with eosinophilia and systemic symptoms (DRESS)', which have been reported during treatment (unknown frequency)
-- Mayzent (siponimod) hypersensitivity reactions, including rash, urticaria and angioedema, added as ADRs of unknown frequency
-- Nicorette (nicotine) Invisi Patch - change in the estimated minimum lethal dose of nicotine in a non-tolerant man from "40 to 60mg" to "30 to 60mg". Additionally, the reported adverse event "reversible atrial fibrillation" is replaced by "atrial fibrillation"
-- Monosorb (isosorbide mononitrate) - new contraindication of co-administration with riociguat, as concomitant use can cause hypotension
-- Tecentriq (atezolizumab) - myocarditis/myositis/myasthenia gravis overlap syndrome added as ADR, and to explicitly advise healthcare professionals to monitor for signs of this. Hypoalbuminemia, hypophosphatemia, hypocalcaemia, and increased GGT also added as ADRs
-- Welireg (belzutifan) - elevated exposure & increased risk of ADRs found in dual CYP2C19 & UGT2B17 poor metabolisers. Caution is advised for the co-administration with CYP3A4 inhibitors, especially for this cohort. Anaemia, dyspnoea & fatigue reported with clinical overdose (320-600mg daily)
-- Winrevar (sotatercept) - 'Pericardial effusions' added as an ADR (frequency not known), based on post-marketing reports & longer-term exposure data from the SOTERIA open-label study, including cases observed, despite stable or improved pulmonary arterial hypertension haemodynamic
-- Zolgensma (onasemnogene abeparvovec) - in animal fertility studies, onasemnogene abeparvovec did not impact fertility in male or female mice at doses up to 1.1 × 1014 vg/kg administered intravenously
- Risk minimisation materials
-- CSL Vifor - Avacopan Vifor (previously known as Tavneos) – suspension of use, sale, supply and offer for sale or supply due to unfavourable benefit–risk balance
-- Myqorzo (aficamten) - include a patient card and checklist to alert healthcare professionals to the important potential risk of heart failure due to systolic dysfunction and embryo-foetal toxicity

ISMP Canada – Safety Bulletins
- Risk of Dose Errors with Transition to New Formulation of Rybelsus - link

Medicines and Healthcare products Regulatory Agency (MHRA) UK
- Antidepressants: new safety measures for all patients to improve communication of the risk of suicidal thoughts and behaviours and persistent sexual dysfunction - link
- Continuous renal replacement therapy (CRRT): Consider delayed administration of concurrent echinocandins, such as caspofungin, to reduce the risk of adsorption onto new polyacrylonitrile (PAN)-based filter membranes - link

MIMS monthly updates
- New Contraindications

-- Goserelin (acetate) (Zoladex 10.8 mg Implant) is contraindicated in pregnancy and lactation

Specialist Pharmacy Services NHS UK
- Medication Safety Update: Sept 2026 - link

TGA
- Information about major medicine shortages – link
-- About the shortage of methylphenidate hydrochloride products - link
-- About the shortage of Creon (pancreatic extract) capsules - link
- Discontinuation of diltiazem 360 mg controlled-release capsules: substitutions available - link

UK Health Security Agency
- The safety of MMRV (measles, mumps, rubella and varicella) vaccine when given in pregnancy - link
- MMRV single dose selective catch up resources - link

PAPERS OF INTEREST

American Journal of Health-System Pharmacy (AJHP)
- Postoperative length of stay comparison associated with a switch from alvimopan to naloxegol in patients undergoing major small and large bowel procedures - link
- Evaluation of coagulation factor concentrates for persistent bleeding after cardiothoracic surgery - link
- Transforming value-based deep vein thrombosis care through a pharmacist-led clinic - link
- Labetalol-induced hyperkalemia in acute aortic dissection: A rare but clinically relevant adverse effect - link
- Genotype-guided dosing improves attainment of therapeutic troughs in CYP3A5 normal metabolizers after kidney transplantation - link
- Complement inhibition in transplantation: Infectious risk demands pharmacovigilance - link
- Immunoglobulin use, availability, and administration considerations in measles prevention - link
- Executive summary of the 2026 ASHP commission on goals: next-generation therapeutics: cell & gene therapy (cgt) and other ultra-high-cost drugs - link
- Effects of ketamine infusion rate and cumulative dosing on incidence of delirium in medical intensive care unit patients - link
- Polypharmacy and anticholinergic burden in hospitalized older patients: The role of medication recognition and reconciliation in therapeutic deprescribing - link

American Journal of Preventive Medicine
- Interventions to Improve Breast Cancer Preventive Medication Treatment Uptake: A Systematic Review - link

Annals of Internal Medicine
- Pharmacologic Treatments for Female Menopausal Vasomotor Symptoms: A Systematic Review and Meta-analysis for the American College of Physicians - link
- Effect of Fluvoxamine and Metformin for Fatigue in Patients with Long COVID: An Adaptive Randomized Trial - link
- Evaluation and Management of Anaemia in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2026 Clinical Practice Guideline - link
- Benzodiazepine Use Early in Pregnancy and Risk for Congenital Malformations - link
- Delirium - link

Arthritis & Rheumatology
- Outcomes of Tapering Biologic and Targeted Synthetic DMARDs in Rheumatoid Arthritis: A Multicenter Randomized Non-Inferiority Trial - link

Australian Prescriber
- Hepatitis B update: enabling progress towards elimination - link
- Endometriosis and adenomyosis: diagnosis and management - link
- Cardiac amyloidosis: recognition, diagnosis and management - link

- Glaucoma management in adults: an update - link
- Multiple myeloma: an overview of drug therapies and supportive care - link
- Management of acute hyperkalaemia: evidence, practice and pitfalls - link
- COVID-19 vaccines move to the National Immunisation Program with revised eligibility - link
- New Drugs: Delgocitinib for chronic hand eczema – link ; Vanzacaftor, tezacaftor and deutivacaftor fixed-dose combination for cystic fibrosis - link
- TGA Medicines Safety Update summary: Withania somnifera (Ashwagandha) and very rare risk of liver injury – link ; GLP-1 RAs and rare vision disorder - link

BMC Medicine
- Metformin and GLP-1 receptor agonists for antipsychotic-induced metabolic disturbances: a systematic review and network meta-analysis - link

British Journal of Clinical Pharmacology
- Lithium-related adverse drug reactions in children: A case–control study comparing lithium to second-generation antipsychotics in VigiBase - link
- Prevalence of pregnancy and birth outcomes following biologic exposure in immune-mediated inflammatory diseases: A population-based study - link
- A scoping review of adverse events associated with concomitant beta-adrenoreceptor blockers and selective serotonin reuptake inhibitors - link
- Patient preferences for medicines information in cardiovascular disease and the influence of unmet needs on medication adherence: A cross-sectional study - link
- Pharmacist's role in managing drug–drug interactions in people with HIV receiving antiretroviral therapy or HIV pre-exposure prophylaxis: A focus on polypharmacy and transitions of care in the United States - link

British Medical Journal (BMJ)
- Weight loss drugs: Does microdosing GLP-1s work? - link
- Quadrivalent human papillomavirus vaccination before pregnancy and pregnancy outcomes: nationwide, population based case-control study - link
- Clinical update: Assessment and management of Helicobacter pylori infection - link

Canadian Pharmacists Journal Sep-Oct issue includes:
- Editorial: The indispensable skills of the pharmacist in an era of AI - link
- Pharmacist-led prescribing for Lyme chemoprophylaxis on ED visits
- Pharmacist-led hypertension management in urgent care
- An electronic tool to identify/manage medication in hospitalized elderly patients - link

Circulation
- Impact of Undertreated Antithrombotic Therapy on Adverse Patient Outcomes: A Scientific Statement from the American Heart Association - link
- Anticancer Drugs and Cancer-Associated Thrombosis - link
- Multidisciplinary Approach to Antiplatelet Management in Coronary Syndromes: A Scientific Statement from the American Heart Association - link
- Bleeding with asundexian versus placebo in patients with noncardioembolic ischemic stroke or high-risk TIA: OCEANIC-STROKE randomized trial - link

Cochrane
- Interventions for treatment of herpes labialis (cold sores on the lips) - link
- Medical cannabis for the treatment of insomnia - link
- Daily sedation interruption versus no daily sedation interruption for critically ill adults and children requiring invasive mechanical ventilation - link

Developmental Medicine & Child Neurology
- Prenatal exposure to paracetamol and the risk of autism and attention-deficit/hyperactivity disorder: An umbrella review and meta-meta-analysis - link

Diabetologia
- Management of Type 2 Diabetes, 2026. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) - link

Diabetes, Obesity and Metabolism
- Contemporary Initial Glucose-Lowering Strategies for Type 2 Diabetes: A Systematic Review and Bayesian Network Meta-Analysis - link
- Weight Loss or Muscle Loss? Cellular Mechanisms and Clinical Strategies for Preserving Lean Mass During GLP-1-Based Therapy - link
- Efficacy and Safety of Dual GLP-1/Glucagon Receptor Agonism in Overweight and Obesity: A Class-Specific Systematic Review and Meta-Analysis - link

European Heart Journal
- Blinded withdrawal of randomized treatment with low-dose digoxin or placebo in heart failure: the DECISION trial - link
- Direct oral anticoagulants vs dual antiplatelet therapy after left atrial appendage occlusion: a meta-analysis of trials - link

Internal Medicine Journal
- Preventing infections after CD19-directed chimeric antigen receptor T-cell therapies for lymphoma: a consensus practice statement - link
- Semaglutide in type 2 diabetes and chronic kidney disease in Australia: practical clinical considerations from a multidisciplinary panel - link

International Journal of Clinical Pharmacy
- Pharmacovigilance signal detection of rilonacept using FAERS with exploratory Mendelian randomization analysis - link

JAMA
- Building Effective Multimodal Care for Obesity and Comorbidities in the GLP-1 Therapy Era - link
- Nicotinamide Riboside for Patients with Early-Stage Parkinson Disease: The NOPARK Randomized Clinical Trial - link
- Comparative Effectiveness of Phenobarbital vs Diazepam for Alcohol Withdrawal Syndrome - link
- Heart Transplant for Advanced Heart Failure - link

JAMA Internal Medicine
- Temporary Cessation of DMARD Therapy and COVID-19 Supplemental Dose Vaccine Immunogenicity in Patients with Inflammatory Arthritis: The COVER Randomized Clinical Trial - link

JAMA Network Open
- Prophylactic vs Therapeutic Anticoagulation in Hospitalized Patients With COVID-19: A Randomized Clinical Trial - link

Journal of the American Geriatrics Society
- Use of Dual Orexin Receptor Antagonists for Insomnia and the Risk of Falls and Fractures: A Systematic Review and Meta-Analysis - link

Lancet
- Migraine - link
- Oral deucrictibant for on-demand treatment of hereditary angioedema attacks: a phase 3, multicentre, randomised, double-blind, placebo-controlled crossover trial - link

Lancet Diabetes & Endocrinology
- Hashimoto's thyroiditis: two decades on - link

Lancet Infectious Diseases

- Daptomycin for enterococcal bloodstream infections and endocarditis: reconciling clinical evidence, susceptibility testing, and regulatory frameworks - link

Lancet Oncology
- Global burden of cancer attributable to infections in 2024: a worldwide incidence analysis - link

Lancet Psychiatry
- Sex differences in the efficacy, acceptability, and tolerability of antipsychotics in people with acute schizophrenia: individual participant data pairwise, dose–response, and network meta-analyses - link

Medical Journal of Australia
- A Summary for Non-Psychiatrists of the Australian and New Zealand Journal of Psychiatry Grading of Recommendations, Assessment, Development and Evaluations (GRADE) Guidelines for the Management of Schizophrenia - link
- Patterns of Osteoporosis Treatment Initiation Following Low-Trauma Fracture: A Population-Based Retrospective Cohort Study in New South Wales, Australia, Using Linked Administrative Health Data - link
- Gabapentinoid Poisoning Presentations to Victorian Emergency Departments: A 15-Year Trend Analysis - link

New England Journal of Medicine
- Giredestrant plus Everolimus in Advanced Breast Cancer - link
- Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes - link
- Advances in Systemic Treatment of Breast Cancer - link

Obstetrics and Gynecology
- Hormonal Options for Perimenopause: A Clinician Toolkit - link

Pediatrics (American Academy of Pediatrics)
- Optimizing Antibiotic Duration for Pneumonia and Sinusitis in the Pediatric Emergency Department - link
- Antibiotic Choice for Community-Acquired Pneumonia in Children With Medical Complexity - link

Pharmaceutical Journal
- Nine in ten patients had ‘clinically relevant’ genetic variation in pharmacogenomics pilot - link

Pharmacotherapy
- Cefepime-Zidebactam: Leveraging β-Lactam Enhancement Against Difficult-to-Treat and Metallo-β-Lactamase-Producing Gram-Negative Pathogens - link
- User Beware: Inaccuracy and Inconsistency of Large Language Models in Providing Precision Dosing Recommendations for Patients with Kidney Impairment—A Case Series - link

CONSULTATIONS

Australian Commission on Safety and Quality in Health Care (ACSQHC)
- Review of the Antimicrobial Stewardship Clinical Care Standard – closes 30 October 2026 - link
- Pilot of the NSQHS Standards (third edition) – closes 20 November 2026 - link

TGA
- Additional public consultation on amending the Poisons Standard regarding ethylene oxide, propylene oxide and epichlorohydrin - closes 26 October 2026 - link
- Consultation: High-moderate risk changes to permissible ingredients - Vitamin B6 (pyridoxine hydrochloride, pyridoxal 5-phosphate, and pyridoxal 5-phosphate monohydrate) - Closes on 25 November 2026 - link

WEBINARS & PODCASTS

Pharmaceutical Benefits Scheme (PBS)

- Webinar: Working together on access to affordable and innovative medicines and therapies - 23 October 2026 2-3pm AEST- link N.B. The session will be recorded and made available on the website afterwards.

UPCOMING EVENTS

Advanced Pharmacy Australia
- Medicines Management MM2026, 22-24 October 2026, Brisbane Convention & Exhibition Centre - register

Australian Commission on Safety and Quality in Health Care (ACSQHC)
- Registrations open – National Medicines Symposium NMS 2026, 'Medicines stewardship: safer use starts with all of us' - Wednesday, 11 November 2026 - register

APSA Annual Conference 2026
-RMIT City Campus, Melbourne, from Sunday 6 to Wednesday 9 December 2026- register

Fortnightly TAG Mail – resources list 1st October 2026

NSW TAG ACTIVITIES

Updated NSW TAG publication
Know Your Insulins poster v3 Oct 2026- has incorporated new product and latest TGA advice re discontinuations- link

Recent Email Discussion
Governance of Medicine Access Programs: How do DTCs manage MAPs?

Upcoming NSW TAG meeting dates
NSW TAG Management Committee Meeting: 16th October 9-10am
NSW TAG General Members' Meeting: 29th October 2026 4-5pm
NSW TAG Annual General Meeting: 29th October 2026 5-5.30pm

TAG Mail
Searching Cumulative TAG Mail listings: Remember to search Cumulative TAG Mail listings, which are collated in 6 months batches from 2023. These cumulative listings are useful to survey whenever you have a medicine or condition you wish to explore as TAG mail covers the grey literature as well as the traditional academic literature. Just 'Control F' relevant terms to search for your query.

Contact Sasha Bennett at sasha.bennett@svha.org.au for information about any email discussions, publications or upcoming meetings.

EDITOR'S PICKS *highlighted with relevant NSW TAG and CATAG resources*

ANZCA & FPM: Residual anaesthetic drugs in the dead space volume of IV lines - link
Age&Aging: Benzodiazepine influence the effectiveness of lifestyle intervention - link NSW TAG Deprescribing Tools
AJHP: Development and validation of a prior-to-admission medication list risk scoring tool - link CATAG MAIA Assessing the Hidden Risk of Cumulative Medicines Toolkit
AJHP: Comparison of vancomycin pharmacokinetics between ischemic and hemorrhagic stroke - link
AJHP: Use of antiobesity medications in a bariatric surgery population - link CATAG GLP-1 Decision-Making Framework
AJHP: Drug dosing in patients with low body weight - link
AJHP: Pharmacy-led transition of care services with positive readmissions impact in hospital - link *NSW TAG Transitioning Young People on Complex or High Cost Medicines from Paediatric to Adult Care Service*
AJHP: Summarizing the evidence on health-system impacts of smart pump interoperability - link
Anaes: Peri-operative glucagon-like peptide-1 receptor agonist use and outcomes - link
AIM: Tobacco Use Treatment - link

A&R: Comparative Safety of Common Immunosuppressant Therapies in SLE- link
AHR: Linking ED opioid prescribing with ongoing opioid use - link NSW TAG Deprescribing Tools CATAG MAIA Preventing Progression to Persistent Pain Toolkit
BJCP: Impact of pharmacogenetic-informed care on medication adherence and psychological factors associated with adherence - link
BJCP: Towards appropriate guidance for the ethical challenges of environmentally sustainable prescribing - link CATAG Formulary Listing of Desflurane
BJCP: Economic evaluations of antiobesity medications - link CATAG GLP-1 Decision-Making Framework
BJCP: Patient-reported outcomes and medication errors during oral antitumour therapy in paeds - link
BJCP: Gabapentinoids-duloxetine combination therapy for chronic pain - link NSW TAG Pain Guidance CATAG MAIA Preventing Progression to Persistent Pain Toolkit
BMJ: Daraxonrasib: How soon could the new drug for pancreatic cancer be available in the UK? - link
CPA: Break the Habit: A Pharmacist's Toolkit for Smoking Cessation Counselling - link
EClinMed: Pharmacological considerations for prescribing of small molecule inhibitors in NCSLC - link
JAMA: Blinatumomab for Replacing Chemotherapy in Pediatric Acute Lymphoblastic Leukemia - link
JAMA: Vaccines for Cancer: A Translational Science Review - link
JAMA: Polypharmacy and Drug-Drug Interactions Among Older Adults - link NSW TAG Polypharmacy Indicators and Resources CATAG MAIA Assessing the Hidden Risk of Cumulative Medicines Toolkit
JAMA Neur: Safety of Antiseizure Medications During DOAC Therapy in Epilepsy - link
JPPR: Universal AUC modelling on vancomycin-associated AKI at an Australian hospital - link
MJA: Intranasal Adrenaline Use for the Management of Insect Venom-Induced Anaphylaxis - link

OTHER NEWS

NSW Health
- SN:014/26 Safety Notice (Amber) Updated: Potential for error: respiratory syncytial virus (RSV) immunisation products - 21 September 2026

Pharmacy Board of Australia
- Empowering pharmacists for healthier futures - link

REPORTS AND PUBLICATIONS – AUSTRALIA

Aged Care Quality and Safety Commission
- Progress Report on the Joint Statement on the Inappropriate Use of Psychotropic Medicines to Manage the Behaviours of People with Disability and Older People - link

Agency for Clinical Innovation, NSW (ACI)
The latest weekly Evidence Digest can be found here
- Supporting treatment choices for people with kidney failure - toolkit
- NSW paediatric services - Supporting paediatric ADHD - link

Australian Commission on Safety and Quality in Health Care (ACSQHC)
- Antimicrobial Resistance Data Explorer Dashboards enhanced:
-- APAS Data Explorer - link
-- CARAlert Data Explorer - link
- Antimicrobial Use and Resistance in Australia (AURA) webpage - link

TGA
- Notice of final decisions to amend the current Poisons Standard in relation to New Chemical Entities (NCEs), 6-methylnicotine, and somatrogon, lonapegsomatropin and somapacitan - link
- Checklist for prescribing psychiatrists of MDMA and psilocybine - link
- Database of section 19A approvals to import and supply medicines to address medicine shortages
- AusPARs:
-- Cenrifki (tolebrutinib): in adults for the treatment of non-relapsing Secondary Progressive Multiple Sclerosis (nrSPMS) and to slow disability accumulation in the absence of relapse activity in adults with nrSPMS

-- Zoladex (goserelin): for management of oestrogen-receptor positive early and advanced breast cancer in pre- and peri-menopausal women
- Australian prescription medicine decision summaries:
-- Aujemflu (influenza virus haemagglutinin) approved for active immunisation against influenza in persons 50 years of age and older

REPORTS AND PUBLICATIONS – INTERNATIONAL

Canadian Pharmacists Association
- Break the Habit: A Pharmacist's Toolkit for Smoking Cessation Counselling - link

electronic Medicines Compendium (eMC) (UK)
- New products
-- Dazublys (trastuzumab) 150 mg concentrate powder for solution for infusion – biosimilar licensed in adults for treatment of HER2-positive early & metastatic breast cancer, and in HER2-positive metastatic adenocarcinoma of stomach or gastro-oesophageal junction in those who have not received prior anti-cancer treatment for their metastatic disease
-- Edurant (rilpivirine hydrochloride) 2.5 mg dispersible tablet - new formulation for use in combination with other antiretrovirals for the treatment of HIV-1 in paediatric patients (2 to <18 yrs) and weighing ≥14 kg to <25 kg without known mutations associated with resistance to the NNRTI class and viral load of ≤100,000
-- Enalapril maleate/Lercanidipine hydrochloride 20 mg/20 mg film-coated tablets for essential hypertension as substitution therapy in adult patients whose blood pressure is adequately controlled with enalapril 20mg and lercanidipine 20mg given concurrently as separate tablets
-- Lubion (progesterone) 25 mg SC injection pre-filled syringe - for luteal support as part of an Assisted Reproductive Technology treatment programme in infertile women unable to use/tolerate vaginal preparations. It is administered once daily from oocyte retrieval & usually continued until 12 weeks of confirmed pregnancy
-- Myqorzo (aficamten) film-coated tablets (5, 10, 15 and 20 mg) for symptomatic (NYHA class II-III) obstructive hypertrophic cardiomyopathy in adult patients. It works to reduce hypercontractility in the cardiac sarcomere, reducing LVOT obstruction
-New indications
-- Ocrevus (ocrelizumab) - new indication for paediatric patients aged 10 years and older with relapsing-remitting multiple sclerosis. Paediatric dosing included
-- Opzelura (ruxolitinib) cream - new indication moderate atopic dermatitis in adult patients for whom topical corticosteroids and topical calcineurin inhibitors are inadequate or inappropriate

European Medicines Agency (EMA)
- Meeting highlights from CHMP - September 2026
-- Approvals: 10 new medicines (denecimig, ensartinib, gefurulimab, relacorilant, povorcitinib, senaparib, VaxRabeo [rabies vaccine], glepaglutide), two biosimilars, and two generic medicines
-- License extensions: 12 medicines (Abiraterone Mylan, delgocitinib, secukinumab, trastuzumab deruxtecan, filgotinib, pembrolizumab, ocrelizumab, enfortumab vedotin, melphalan flufenamide, somapacitan, teclistamab, dabigatran)
- Benefits of sodium oxybate continue to outweigh risks in people with alcohol dependency - link

Food and Drug Administration (FDA) USA
- New Drug approvals
-- baricitinib, JAK inhibitor for alopecia approved for younger age group
-- belzutifan in combination with lenvatinib for advanced renal cell carcinoma with a clear cell component
-- imlunestrant in combination with abemaciclib for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer
-- Onswik (insulin efsitora alfa-gobe) to improve glycemic control in adults with type 2 diabetes mellitus, as an adjunct to diet and exercise
-- Aqneursa (levacetylleucine), for ataxia in patients with ataxia-telangiectasia, a rare genetic disorder
-- lirafugratinib for previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma – PI-label

-- Camzyos (mavacamten) capsules, first drug to improve functional capacity and symptoms in children with rare inherited heart condition
-- Gazyva (obinutuzumab) to treat idiopathic nephrotic syndrome in patients 2 years and older
-- Juvmo (tavapadon) to treat Parkinson's disease in adults
-- Emcitate (tiratricol) for peripheral thyrotoxicosis in patients with MCT8 deficiency (Allan-Herndon-Dudley syndrome) – PI-label
-- Atebrioz (zilurgisertib), third treatment for fibrodysplasia ossificans progressiva

Medicines and Healthcare products Regulatory Agency (MHRA)
- Approves lurbinectedin (Zepzelca) for adults with extensive-stage small cell lung cancer - link

National Institute for Health and Care Excellence (NICE) UK
- Digital technologies to support home monitoring of vision changes for people with advanced dry age-related macular degeneration: early-use assessment (HTG781)
- Ibrutinib with R-CHOP for untreated mantle cell lymphoma when a stem cell transplant is suitable (TA1193)
- Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma (TA1194)
- Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is suitable (TA1195)
- Sickle cell disease: managing acute painful episodes in hospital (CG143)
- Suspected sepsis in people aged 16 or over: recognition, assessment and early management (NG253)

Royal College of Pharmacy
- … publishes updated position statement setting out new expectations for pharmacists working in aesthetics - link

Specialist Pharmacy Services NHS UK
- Capacity planning in aseptic services - link
- Complementary products - link
- Record Keeping - link

The King's Fund (UK)
- Dementia is where cancer was 50 years ago: how we can use cancer as a blueprint for improving dementia care - link

UK Health Security Agency
- Patient Group Direction (PGD) and Vaccine Group Direction (VGD): COVID-19 vaccine (5 years and over) - link
- The health impacts from industrial sources of per- and polyfluoroalkyl substances (PFAS): a rapid review - link
- UKHSA and PACE make new bacteria available to support research into tackling antimicrobial resistance - link

World Health Organisation (WHO)
- Report of the Knowledge Community on responsible artificial intelligence in health. From promise to practice - link

MEDICATION SAFETY

Australian and New Zealand College of Anaesthetists (ANZCA) & Faculty of Pain Medicine
- Residual anaesthetic drugs in the dead space volume of IV lines - link

electronic Medicines Compendium (eMC) (UK)- link
- Revised SPCs

-- Aldurazyme (laronidase) - excretion in human milk is limited; no adverse effects reported in a small number of breastfed infants. Decision on whether to breastfeed during treatment should weigh benefits for mother & infant against potential risk of adverse reactions
-- Fetcroja (cefiderocol sulfate tosylate) - eosinophilia added as an ADR with frequency not known
-- Leqvio (inclisiran sodium) - 'Hypersensitivity including anaphylactic reaction' added as ADR with frequency not known
-- Metalyse (tenecteplase) - reference to myocardial infarction removed from pregnancy section and administration instructions clarified regarding use of a pre-existing intravenous line
-- Metoject (methotrexate) - epidermal necrosis added as an ADR with a frequency not known
-- Panmigrol migraine pain relief, Panmigrol migraine and headache relief - interaction with carbonic anhydrase inhibitors which increase the risk of salicylate toxicity; Kounis syndrome added as an ADR with an unknown frequency
-- Retacrit (epoetin zeta) - additional guidance on iron supplementation, emphasising correction of iron deficiency before and during therapy to optimise response. Recommendations are provided for patients with CKD, cancer, autologous blood donation and major elective orthopaedic surgery
-- Saizen (somatropin) - risk of osteonecrosis of femoral head (incl. Legg-Calvé-Perthes) is not limited to the indication of growth failure due to chronic renal failure
-- Tagrisso (osimertinib) - eosinophilic pneumonia added as ADR of unknown frequency. Final overall survival data added from FLAURA2 study of use with/without platinum plus pemetrexed chemotherapy, as first-line treatment in EGFR mutation positive, locally advanced/metastatic NSCLC
-- Trusopt (dorzolamide) eye drops - photophobia added as an ADR with a frequency not known
-- Tzield (teplizumab) - before starting, patients should be evaluated for active Epstein-Barr Virus (EBV) & cytomegalovirus infection to confirm undetectable viral load. EBV reactivation can occur at an unknown frequency; monitor for infection, including EBV reactivation, during & after treatment
-- Truqap (capivasertib) frequency of pyrexia ADR changed from 'common' to 'very common'
-- Ventolin (Salbutamol) Evohaler and Accuhaler - in common with other beta-adrenoceptor agonists, salbutamol can induce reversible metabolic changes e.g. increased blood sugar levels; caution is advised in patients with a history of diabetes mellitus or hyperglycaemia
- Risk minimisation materials
-- Asthalin 100 micrograms Inhaler (Salbutamol Sulphate) – Clarification of paediatric dosing information on the outer carton - link

EMA
- CHMP recommendations - September 2026
-- approvals for 12 new medicines: Frehemgo (denecimig), Gevalka (ensartinib), Klygefa (gefurulimab), Lifyorli (relacorilant), Povofortay (povorcitinib), Sepalna (senaparib), VaxRabeo (rabies virus (inactivated), 2 generics and 2 biosimilars
-- extensions of therapeutic indication for 11 medicines: Abiraterone Mylan, Cosentyx, Enhertu, Jyseleca, Keytruda, Ocrevus, Padcev, Pepaxti, Sogroya, and Tecvayli
-- application withdrawals: Isembyld (apitegromab), Zinmyleo (trilaciclib)
-- review of medicines containing ipidacrine finalised

Food and Drug Administration (FDA) USA
- Amplifies warning on Kybella adverse events - link

Health Canada – MedEffect Notice
- Health Product InfoWatch - September 2026

Medicines and Healthcare products Regulatory Agency (MHRA)
- MHRA Safety Roundup: September 2026

Specialist Pharmacy Services NHS UK
- Adverse drug reactions: resources to support clinical decisions - link
- A patient-centred approach to improving medication safety - link

TGA
- Andrographis recalls: concerns over allergy risk - link

- Andrographis removed from listed medicines framework because of allergy risk - link
- Information about major medicine shortages – link
-- Creon (pancreatic extract) capsules - link
-- Bicillin L-A (benzathine benzylpenicillin tetrahydrate) prefilled syringe for injection - link
-- methylphenidate hydrochloride products - link
-- dapsone 25 mg tablets - link

World Health Organisation (WHO)
- Vaccines, thiomersal and autism spectrum disorder. Evidence review 2010–2025 - link

PAPERS OF INTEREST

Age and Ageing
- Does the use of benzodiazepine influence the effectiveness of lifestyle intervention? Secondary analysis from the Sarcopenia and Physical fRailty iN older people strategies (SPRINTT) trial - link

American Journal of Cardiology
- Early Aspirin Discontinuation Versus 12-Month Dual Antiplatelet Therapy after Percutaneous Coronary Intervention for Acute Coronary Syndrome: A Meta-Analysis of Randomized Trials - link

American Journal of Health-System Pharmacy (AJHP)
- Garetosmab-grts - link ; Iberdomide Hydrochloride - link
- Assessing Impact of Health System Specialty Pharmacy Support on Initiation of Vigabatrin Therapy for Infantile Epileptic Spasms Syndrome - link
- Development and validation of a prior-to-admission medication list risk scoring tool - link
- Evaluation of vancomycin Bayesian dose-optimizing software in a neonatal intensive care unit population - link
- Comparison of vancomycin pharmacokinetics between ischemic and hemorrhagic stroke - link
- Use of antiobesity medications in a bariatric surgery population: A collaborative approach with ambulatory care pharmacy services - link
- Drug dosing in patients with low body weight - link
- Pharmacy-led transition of care services with positive readmissions impact in an acute care hospital - link
- Summarizing the evidence on health-system impacts of smart pump interoperability: A scoping review - link

Anaesthesia
- Peri-operative glucagon-like peptide-1 receptor agonist use and outcomes: a national prospective multicentre cohort study - link

Annals of Internal Medicine
- Tobacco Use Treatment: Synopsis of the 2026 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline - link

Archives of Disease in Childhood
- Who are the children and young people attending the UK's first ketamine-induced uropathy clinic for under 16s?: an early insight into sociodemographic features - link

Arthritis & Rheumatology
- Comparative Safety of Common Immunosuppressant Therapies in Systemic Lupus Erythematosus: A Target Trial Emulation Study - link
- Drug-Free Remission in Early Peripheral Spondyloarthritis, including Psoriatic Arthritis: 10-year follow-up from the CRESPA trial - link

Australian Health Review, Journal of the Australian Healthcare & Hospitals Association
- Evaluating discharge opioid prescribing practices in elective surgical patients: a retrospective audit from a tertiary surgical and rehabilitation centre - link

- Linking emergency department opioid prescribing with ongoing opioid use: a statewide data linkage study - link

BMC Medicine
- Comparative effectiveness of GLP-1 receptor agonists, SGLT2 inhibitors, DPP-4 inhibitors, and sulfonylureas on weight change among people with HIV: a real-world longitudinal cohort study - link

British Journal of Clinical Pharmacology
- The impact of pharmacogenetic-informed care on medication adherence and psychological factors associated with adherence: A narrative review - link
- Targeting the cardiohepatic–metabolic axis: GLP-1–based and incretin multi-agonist therapies in MASH - link
- Towards appropriate guidance for the ethical challenges of environmentally sustainable prescribing - link
- Economic evaluations of antiobesity medications: A systematic literature review - link
- Benzodiazepines use in primary care England: Prescribing patterns and adverse consequences - link
- Switching standard dosed intravenous to subcutaneous infliximab leads to similar drug exposure in inflammatory bowel disease patients independent of concomitant immunosuppressants (SHUFFLE study) - link
- Tegileridine vs. sufentanil for postoperative analgesia in general surgery: A prospective, randomized, controlled, non-inferiority trial - link
- Ceftriaxone-associated immune haemolytic anaemia: A patient-level systematic review - link
- Patient-reported outcomes and medication errors during oral antitumour therapy in paediatrics: Results from the youngAMBORA care programme - link
- Rapid onset and offset of the interaction between rifampicin and long-acting cabotegravir/rilpivirine: A pharmacokinetic case report - link
- Gabapentinoids-duloxetine combination therapy for chronic pain: A mechanism oriented rational to bridge theoretical knowledge and real life setting - link
- Managing HIV in the extreme: Viral load and drug monitoring in a patient with BMI > 60 on long-acting cabotegravir/rilpivirine therapy - link
- Psilocybin as serotonergic therapy in epilepsy: Narrative review of potentials and limitations - link

British Journal of Psychiatry
- Comparative efficacy of antipsychotics for reducing aggression in schizophrenia: systematic review and network meta-analysis - link
- Effect of pharmacological treatment of attention-deficit hyperactivity disorder on academic performance: registry-based population study - link

British Medical Journal (BMJ)
- Renal outcomes in people with type 2 diabetes with and without albuminuria treated with SGLT-2 inhibitors and GLP-1 receptor agonists: target trial emulation - link
- Contemporary menopausal hormone therapy and thrombotic disease: nationwide nested case-control study - link
- QTc changes and early major adverse cardiovascular events associated with antidepressant treatment for major depressive disorder in adults: individual participant data network meta-regression of double blind randomised trials - link
- Daraxonrasib: How soon could the new drug for pancreatic cancer be available in the UK? - link

BMJ Quality and Safety
- Implementation of a patient-centred complex intervention to improve Initial Medication Adherence to cardiovascular disease and diabetes treatments in primary care - link

Childhood Obesity
- Nutritional Deficiencies, Complications, and Nutrition Therapy/Counseling in Pediatric Patients Using GLP-1 Receptor Agonists - link

Circulation
- Clinical Management of Myocardial Infarction - link
- Women's Kidney Health in Focus: A Scientific Statement from the American Heart Association - link
- From Hippocrates to Biologics, The Evolving History of Pericarditis: A Review - link

Cochrane
- Zuclopenthixol acetate for acute schizophrenia and similar major mental illnesses - link
- Antifungal therapy for newborn infants with invasive fungal infection - link
- Mifepristone versus other interventions for the prevention of pregnancy in reproductive-age women using emergency contraception - link
- Progesterone receptor modulators for endometriosis - link
- Vitamin D supplementation for prevention of vitamin D deficiency in preterm and low birth weight infants - link

Diabetes, Obesity and Metabolism
- Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists as Adjuncts to Insulin Therapy in Type 1 Diabetes Mellitus: An Overlap-Informed Umbrella Review - link
- Effects of Renin–Angiotensin Inhibitors, Sodium–Glucose Cotransporter 2 Inhibitors, Mineralocorticoid Receptor Antagonists and Glucagon-Like Peptide 1 Receptor Agonists on Kidney Outcomes in Patients with Type 1 Diabetes: A Systematic Review and Meta-Analysis - link
- GLP-1 Receptor Agonist–Based Prandial Insulin De-Intensification in Outpatients with Type 2 Diabetes Receiving Basal–Bolus Insulin Therapy or Multiple Daily Injections: A Systematic Review and Meta-Analysis of Randomised Controlled Trials - link
- Comparative Cardiorenal Efficacy and Safety of Finerenone, SGLT2 Inhibitors, Semaglutide and Their Combination in Diabetic Kidney Disease - link

Drug and Therapeutics Bulletin
- Lipid-lowering for people with chronic kidney disease: a narrative review - link

EClinical Medicine
- Pharmacological considerations for prescribing of small molecule inhibitors in patients with non-small cell lung cancer - link

European Heart Journal
- Intracranial haemorrhage following tenecteplase fibrinolysis for acute myocardial infarction - link
- Semaglutide and cardiovascular risk reduction: a mediation analysis of the SELECT trial - link

European Journal of Hospital Pharmacy
- Think twice before labelling 'drug allergy': a case report - link

Internal Medicine Journal
- Clopidogrel and proton pump inhibitors: evaluating the clinical significance of their interaction - letter
- Economic evaluations of remifentanil versus fentanyl for analgo-sedation in mechanically ventilated adult ICU patients: a systematic review - link
- Transient global aphasia associated with daratumumab in monoclonal immunoglobulin light chain deposition disease - letter

JAMA
- JAMA Insights: Diagnosis and Treatment of Patients with Primary Aldosteronism - link
- Intrauterine Mepivacaine Instillation vs Placebo for Pain During IUD Placement: A Randomized Clinical Trial - link
- Blinatumomab for Replacing Chemotherapy in Pediatric Acute Lymphoblastic Leukemia - link
- Vaccines for Cancer: A Translational Science Review - link
- Tenecteplase Before Thrombectomy at 4.5 to 24 Hours for Basilar Artery Occlusion: The ATTENTION LATE Randomized Clinical Trial - link
- Polypharmacy and Drug-Drug Interactions Among Older Adults - link
- JAMA Patient Page: What Is Hodgkin Lymphoma? - link

JAMA Dermatology
- Delphi Consensus Statement on Treatment of Severe Alopecia Areata in US Adults - link

JAMA Internal Medicine
- Dexmedetomidine Use and Intensive Care Unit Admissions for Patients with Medetomidine Withdrawal - link

JAMA Network Open
- Intravenous vs Oral Iron for Treating Iron Deficiency Anaemia in Pregnancy - link
- Vedolizumab vs TNF Antagonists and Long-Term Outcomes in Ulcerative Colitis - link

JAMA Neurology
- Safety of Antiseizure Medications During Direct Oral Anticoagulant Therapy in Epilepsy - link

Joint Commission Journal on Quality and Patient Safety
- Developing and Validating a Trigger Tool to Improve Detection of Anticoagulation-Associated Bleeding in Hospitalized Adult Patients - link

Journal of Sleep Research
- All-Cause and Cardiovascular Mortality in Relation to Sleep Duration: A Community-Based Cohort with Over 30 Years of Follow-Up - link

Journal of Pharmacy Practice and Research (JPPR)
- Impact of universal area under the curve modelling on vancomycin-associated acute kidney injury at an Australian hospital - link

Lancet
- Lancet Series: Peripheral arterial disease - link

Lancet Diabetes & Endocrinology
- New genomic understanding and challenges in clinical care of Turner syndrome - link

Molecular Diversity Preservation International (MDPI) – Pharmacy Journal
- Translating Traditional Herbal Use into Medication-Safety Decisions: A Proposed Community-Contextualized Translational Ethnopharmacy Framework for Pharmacy Practice - link
- In Patients Experiencing Pain and Inflammation, the Use of Non-Steroidal Anti-Inflammatory Drugs Is More Likely a Marker of the Observed Cardiovascular Risk Rather than Its Cause: A Viewpoint - link

Medical Journal of Australia
- Intranasal Adrenaline Use for the Management of Insect Venom-Induced Anaphylaxis - link

New England Journal of Medicine
- Short or Long Antibiotic Regimens in Orthopedics - link
- Esophageal Cancer - link
- A Cure Out of Most Patients' Reach — Sickle Cell Disease in the Gene-Therapy Era - link
- Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity in adults - link

Neurology
- Diagnosis, Treatment, and Prognosis of Cerebral Venous Thrombosis - link

Pediatrics (American Academy of Pediatrics)
- A Systematic Review and Meta-Analysis of the Prevention and Management of Pediatric Urinary Tract Infection and Suspected Urinary Tract Infection: Technical Report - link
- Clinical Practice Guideline for the Diagnosis and Treatment of Urinary Tract Infection in Children From 8 Days to 5 Years of Age - link

Pharmaceutical Journal
- MHRA reviewing risks and safeguards for propranolol use in anxiety - link
- Medicines management policy for high-risk drugs introduced by GP practice, following death of patient - link
- Can immunotherapy stop the clock on type 1 diabetes? - link
- GLP-1s: what is behind the variation in efficacy? - link
- Lost in fine print: how patient information leaflets are failing patients - link

Prescrire International – October 2026 – includes:
- Hydroxyzine: increased incidence of hospitalisation for injuries or cardiovascular disorders
- GLP-1 agonists: Wernicke encephalopathy

CONSULTATIONS

Australian Commission on Safety and Quality in Health Care (ACSQHC)
- Consultation on draft Point of Care Testing Guide for Health and Aged Care Services – closes on Friday 30 October 2026 - link

TGA
- Consultation: Proposed amendments to the Poisons Standard in relation to nitrous oxide - Joint ACMS-ACCS meetings - November 2026 - closes 12 October 2026 - link
- Consultation: Proposed amendments to the Poisons Standard in relation to 4-methylbenzylidene camphor (4-MBC) - Joint ACMS-ACCS meetings - November 2026 - closes 12 October 2026 - link
- Consultation: Proposed amendments to the Poisons Standard - ACCS meeting - November 2026 - closes 12 October 2026 - link
- Additional public consultation on amending the Poisons Standard regarding ethylene oxide, propylene oxide and epichlorohydrin - closes 26 October 2026 - link

WEBINARS & PODCASTS

Australian Prescriber Podcasts
- E223 | Rheumatic fever and rheumatic heart disease: updates for clinical practice

Purple Pen Podcast
- PPP 197 - The Point of Injection with Anna Theophilos

UPCOMING EVENTS

Advanced Pharmacy Australia
- Medicines Management MM2026, 22-24 October 2026, Brisbane Convention & Exhibition Centre - register

Australian Commission on Safety and Quality in Health Care (ACSQHC)
- Registrations open – National Medicines Symposium NMS 2026, 'Medicines stewardship: safer use starts with all of us' - Wednesday, 11 November 2026 - register

Fortnightly TAG Mail – resources list 17th September 2026

NSW TAG ACTIVITIES

Recent Email Discussion
Governance of Medicine Access Programs: How do DTCs manage MAPs?

Upcoming NSW TAG meeting dates
NSW TAG General Members' Meeting: 29th October 2026 4-5pm
NSW TAG Annual General Meeting: 29th October 2026 5-5.30pm

TAG Mail

Searching Cumulative TAG Mail listings: Remember to search Cumulative TAG Mail listings, which are collated in 6 months batches from 2023. These cumulative listings are useful to survey whenever you have a medicine or condition you wish to explore as TAG mail covers the grey literature as well as the traditional academic literature. Just 'Control F' relevant terms to search for your query.

Contact Sasha Bennett at sasha.bennett@svha.org.au for information about any email discussions, publications or upcoming meetings.

EDITOR'S PICKS *highlighted with relevant NSW TAG and CATAG resources*

A&A: Editorial: Beyond single-drug indicators– link NSWTAG CATAG
A&A: Editorial: Targeting deprescribing where it matters most – link NSWTAG1 NSWTAG2 CATAG
A&A: Deprescribing interventions targeting specific drug classes in older adults across clinical settings - link NSWTAG CATAG
A&A: Editorial: Antidepressant prescribing around dementia diagnosis - link CATAG
AJHP: Medication preparation errors with very small & difficult-to-measure volumes in pediatrics - link
AJHP: Pharmacist-led steroid stewardship in inflammatory diseases - link CATAG
AIM: Management of anemia in CKD: Synopsis of the KDIGO 2026 Clinical Practice Guideline - link
A&R: Nonmelanoma skin cancer risk with JAKis compared to IL-6 Receptor Inhibitors in RA- link
A&R: Updated COVID-19 vaccines & health outcomes in autoimmune rheumatic conditions - link
BJCP: Medicines, misinformation and machines: Navigating infodemics in the generative AI era - link
BJCP: Potential impact of H1 antihistamines on NSCLC patient on EGFR-TKIs treatment - link
BJCP: HIV and anticholinergic burden: Towards a pragmatic stewardship algorithm - link NSWTAG CATAG
BJPsych: Psychotropic medications in mood disorders: to deprescribe or not? - link
BMJ: Exploring high priority potentially inappropriate prescribing cascades in older adults - link CATAG
CADTH: Dosing of Immune Checkpoint Inhibitors - link
Circ: Immune Checkpoint Inhibitor Myocarditis and Myotoxicity - link
Circ: Infective Endocarditis: Diagnosis, Antibiotic Therapy, and Management - link
Cochrane: Long-term hormone therapy for perimenopausal and postmenopausal women - link
DiabCare: Type 1 Diabetes Management in Adults- Updated 2026 Consensus Report- link NSW TAG
DTC: Precision medicine arrives in COPD - link
EMA: Safety of single aminoglycoside dose in EDs in patients with/without CKD - link CATAG
EJCP: Exploring the organisation, operation and inquiries of Centres for Medicines Information - link
EJCP: Excreta contamination after antibody–drug conjugates administration - link
IJQHC: A machine learning–based model for fall-related injury risk in hospitalized patients - link NSW TAG1 NSWTAG2
JAMA: Gene Silencer Therapy in Transthyretin Amyloid Cardiomyopathy - link
JACC: Protocol-based implementation of early intensive lipid management after ACS- link
MDPI: Secondary Prevention Bundle for Drug-Related Problems - link NSWTAG CATAG
MHRA: AI in Healthcare: Recommendations for a future regulatory framework - link
MJA: Patterns of osteoporosis treatment initiation following low-trauma fracture in NSW - link
NEJM**:** Treatment decisions in multiple myeloma - link
Peds: CART-Cell Therapy in Pediatric Acute Lymphoblastic Leukemia - link

OTHER NEWS

TGA
- TGA to consult on additional controls for an active sunscreen ingredient - link

REPORTS AND PUBLICATIONS – AUSTRALIA

Agency for Clinical Innovation, NSW (ACI)
The latest weekly Evidence Digest can be found here
- Postpartum interventions in women who have had gestational diabetes - link

NHMRC Impact Case Studies

- Expanding blood donation - link

TGA
- Bacteriophages - link ; Medicinal maggots - link
- Database of section 19A approvals to import and supply medicines to address medicine shortages
- Australian prescription medicine decision summaries:
-- Coveram Plus SR , Reaptan Plus SR , Triplixam SR (perindopril arginine, amlodipine, indapamide) approved as a substitution therapy for the treatment of hypertension, in patients already controlled with perindopril, amlodipine and indapamide, taken at the same dose level. Reaptan Plus SR contains the active ingredients perindopril arginine, amlodipine (as besilate) and indapamide
-- Fetroja (cefiderocol as sulfate tosilate) approved for the treatment of infections due to proven or strongly suspected carbapenem-resistant aerobic Gram-negative organisms in adults with limited treatment options. It has specifically been approved for the treatment of complicated urinary tract infections (cUTIs), including pyelonephritis, hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.

REPORTS AND PUBLICATIONS – INTERNATIONAL

British National Formulary
- Updated dosing of vaginal oestrogens for prophylaxis of recurrent urinary-tract infections (UTIs) - link

British Oncology Pharmacy Association
- UK multidisciplinary Consensus Document – Safe Management of Hazardous Medicinal Products in UK Healthcare Settings - link

Canadian Agency for Drugs and Technologies in Health
- Dosing of Immune Checkpoint Inhibitors - link

Department of Health and Social Care UK
- Viral haemorrhagic fever: ACDP algorithm and guidance on management of patients - updated

electronic Medicines Compendium (eMC) (UK)
- New products
-- EURneffy (adrenaline) 1 mg nasal spray, solution in single-dose container, lower strength for use in children aged 4 years and over weighing between 15-30 kg for the emergency treatment of severe allergic reactions. The 2mg strength already on the market is licensed for use in adults and children with a body weight ≥ 30 kg
-- Hyrnuo (sevabertinib) 10 mg film-coated tablets for treatment of advanced non-squamous non-small cell lung cancer in patients whose tumours have HER2 tyrosine kinase domain activating mutations and have received prior systemic therapy
-- Opdivo (nivolumab) 300 mg Solution for injection - new strength introduced to provide greater flexibility when preparing and administering approved dosing regimens. This is primarily to allow the approved 900 mg every 3 weeks dose to be made up exactly from one 600 mg vial and one 300 mg vial, helping minimise product wastage
-- Rezdiffra (resmetirom) film-coated tablets (multiple strengths) licensed, in conjunction with diet and exercise, for treatment of adults with noncirrhotic metabolic dysfunction-associated steatohepatitis with moderate to advanced liver fibrosis (consistent with fibrosis stages F2-F3)
-- Spikevax LP.8.1 Dispersion for injection (Covid-19 mRNA vaccine) for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older. Its use should be in accordance with official recommendations
-- Zynyz (retifanlimab) 500mg concentrate for solution for infusion - monotherapy for the first-line treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma not amenable to curative surgery or radiation therapy
-Expanded/New indications
-- Erbitux (cetuximab) for metastatic colorectal cancer with a BRAF V600E mutation has been expanded to include use in combination with both encorafenib and FOLFOX for first line use, based on interim results from study C4221015 (BREAKWATER)

-- Lidocaine Grunenthal 700 mg medicated plaster - for localised neuropathic pain in adults (as well as existing indication of neuropathic pain associated with previous herpes zoster infection)
-- Retsevmo (selpercatinib) – now indicated in patients ≥2 years for treatment of radioactive iodine-refractory advanced RET fusion-positive thyroid cancer & advanced RET-mutant medullary thyroid cancer. Updated to advise caution when used with BCRP substrates (e.g. rosuvastatin/prazosin)

Food and Drug Administration (FDA) USA
- New Drug approvals
-- Bexlutry, generic Lutathera for adults with GEP-NETs
-- camizestrant (Etcamah) to treat hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer upon detection of ESR1 mutation during aromatase inhibitor and CDK4/6 inhibitor therapy – label-PI
-- Fayuvi (rebisufligene etisparvovec-hopf), first gene therapy for pediatric patients with Sanfilippo Syndrome Type A
-- Finerenone for CKD in adults with Type 1 Diabetes
-- Isembyld (apitegromab-mstn) to treat spinal muscular atrophy in adults and pediatric patients 2 years of age and older who are currently receiving an SMN2-targeted treatment – label-PI
-- Joenja (leniolisib), first treatment for children aged 4-11 years with APDS, a rare genetic disorder of the immune system
-- Pixclara floretyrosine F18 to use with positron emission tomography to differentiate recurrent or progressive glioma from treatment-related change in conjunction with other diagnostic evaluations
-- sevabertinib for locally advanced or metastatic non-squamous non-small cell lung cancer
-- Stelara (ustekinumab), the IL-12/23 inhibitor, is the first non-TNF-targeting monoclonal antibody approved for both pediatric UC and Crohn's disease
-- Zanvastro (zilganersen) to treat Alexander disease in pediatric and adult patients

Health Quality & Safety Commission New Zealand
- Frailty care guides: Chronic obstructive pulmonary disease (COPD) - link

Medicines and Healthcare products Regulatory Agency (MHRA)
- National Commission into the Regulation of AI in Healthcare: Recommendations for a future regulatory framework - link

Monthly Index of Medical Specialities MIMS UK
- Four NICE technology appraisals for SGLT2 agents being withdrawn - link

NHS England
- Updates on controlled drugs, antibiotic prophylaxis and dental amalgam - link

National Institute for Health and Care Excellence (NICE) UK
- Psychosis and schizophrenia in adults: prevention and management (CG178)
- Durvalumab with platinum-based chemotherapy, then with or without olaparib, for untreated advanced or recurrent endometrial cancer (TA1190)
- Nemolizumab for treating moderate to severe prurigo nodularis (TA1191)
- Mirdametinib for treating symptomatic and inoperable plexiform neurofibromas associated with neurofibromatosis type 1 in people 2 to 17 years (TA1192)

Specialist Pharmacy Services NHS UK
- Defining and understanding medication adherence - link
- Choosing medicines in sulfonamide hypersensitivity - link

UK Health Security Agency
- Engagement guide for infection and antimicrobial resistance (AMR) - link
- World Antimicrobial Resistance Awareness Week (WAAW) and European Antibiotic Awareness Day (EAAD) - link

World Health Organisation (WHO)
- Fighting antimicrobial resistance through better patient care – ordering the right test from the right patient to determine the right treatment - link
- WHO guidelines for malaria - link

MEDICATION SAFETY

electronic Medicines Compendium (eMC) (UK)
- Revised SPCs
-- Agamree (vamorolone) – administration changed from “can be taken with or without a meal” to “should be taken preferably with a meal"
-- Ayvakyt (avapritinib) - drug-drug interaction information added with CYP3A substrates based on the final results from study BLU-285-1107
-- Daktarin (miconazole nitrate) Aktiv cream and 2% w/w cream - additional warning that benzoic acid, an excipient, may cause non-immunological immediate contact reactions by a possible cholinergic mechanism. Benzoic acid absorption through the immature skin of neonates is also significant
-- Erleada (apalutamide) may cause falsely elevated digoxin levels when measured by chemiluminescent microparticle immunoassay (CMIA), independently of being treated with digoxin. Interpret levels obtained by CIMA with caution and confirm with another assay before altering digoxin doses
-- Matoride XL (methylphenidate hydrochloride) information around the diagnosis, initiation and dosing added in adult patients with ADHD, including need for a cardiovascular review before starting treatment. The maximum daily dose is 72mg in adults, higher than the 54mg maximum in children
-- Ogsiveo (nirogacestat dihydrobromide) - addition of dry eye, hypersensitivity, photopsia, and vitreous floaters as new ADRs (frequency not known)
-- Paxlovid (nirmatrelvir/ritonavir) - information on dosing in severely immunocompromised patients added, suggesting a treatment duration of 10 days may help to mitigate the risk of virological rebound in patients with severe immunodepression
-- Rinvoq (upadacitinib) – rare reports of semen discolouration, mostly blue and less frequently green, have occurred predominantly in patients taking upadacitinib for ulcerative colitis or Crohn’s disease. The clinical significance is unknown
-- Ocrevus (ocrelizumab) - newly identified ADRs of COVID-19 (very common) and COVID-19 pneumonia (common)
-- Takhzyro (lanadelumab) - urticaria added to the list of injection site reactions, which are common ADRs, and the inclusion of the polysorbate 80 excipient warning about risk of allergic reactions
-- Tolvaptan tablets (Zentiva) - increasing age has no effect on tolvaptan plasma concentrations, and to add data from a safety study of 2,136 patients with autosomal dominant polycystic kidney disease, including 575 patients aged ≥50 years
-- Tropicamide 1% w/v Minims - more detailed advice and cautions for use in children, additional warnings for risk of psychotic reactions and behavioural disturbances in patients with increased susceptibility to anticholinergic drugs, and more details added in section on ability to drive
-- Trurapi (insulin aspart) - JuniorSTAR delivers 1-30 units in 0.5 unit dose increments; AllStar PRO delivers 1-80 units in 1 unit dose increments; and Trurapi in cartridges are to be used with JuniorSTAR or AllStar PRO pens as recommended
-- Varilrix (varicella-zoster virus) for injection should be given at a different site when administered at same time as another injectable vaccine. Advice is provided on use in those at risk of severe varicella, including selected immune deficiencies; response may be reduced & disseminated varicella has occurred rarely
-- Vaxneuvance (pneumococcal polysaccharide conjugate vaccine) - Introduction of statement declaring safety and efficacy of Vaxneuvance has not been established in infants less than 6 weeks
-- Vfend (voriconazole) - mavacamten, a cardiac myosin inhibitor and CYP2C19, CYP3A4 and CYP2C9 substrate, added to interactions table. Although not studied, voriconazole is likely to increase the plasma concentrations of mavacamten, with increased risk of heart failure
-- Vyloy (zolbetuximab) - gastritis (uncommon) and protein-losing gastroenteropathy (frequency unknown) added as ADRs
- Risk minimisation materials

-- Tuyory (tocilizumab) - Patient Card contains important safety information that patients or parents/guardians need to be aware of before, during and after treatment, including the risk of a new or worsening infection, complications of diverticulitis, hepatotoxicity and suppression of CRP levels

EMA
- Pharmacovigilance Risk Assessment Committee (PRAC) review will assess risk of low blood phosphate levels and related bone problems with injectable iron medicines - link

Food and Drug Administration (FDA) USA
- Approves additional information in labeling for Kybella (deoxycholic acid) injection warning of adverse reactions associated with unapproved use - link
- Adds boxed warning to labeling for ferric carboxymaltose injection (Injectafer) to describe risk of low phosphate levels - link

Medsafe (New Zealand Medicines and Medical Devices Safety Authority)
- Prescriber Update – September 2026 – includes:
-- Spotlight on cystic fibrosis transmembrane conductance regulator (CFTR) modulators
-- Rosuvastatin: Dose considerations
-- Prednisone-induced thyrotoxic periodic paralysis
-- Ocular adverse effects of stimulant medicines for ADHD
-- Alpha-gal syndrome: An emerging cause of hypersensitivity reactions to medicines

Specialist Pharmacy Services NHS UK
- SPS Medication safety update – August 2026

TGA
- Product Information safety updates - August 2026
- Information about major medicine shortages – link
-- About the shortage of transdermal HRT patches - link
-- About the shortage of Pegasys (peginterferon alfa-2a) injection - link
-- About the cyclophosphamide and ifosfamide injection shortages - link
- Tests counterfeit retatrutide product following serious adverse event report - link
- Safety review of 4-methylbenzylidene camphor (4-MBC) (in sunscreens) - link

PAPERS OF INTEREST

Age and Ageing
- Editorial: Beyond single-drug indicators: the power of unsupervised phenotyping in mitigating medication-related harm – link
- Editorial: Targeting deprescribing where it matters most – link
- Editorial: Deprescribing antihypertensive drugs in patients aged over 80 years: an evidence-based way forward – link
- Effectiveness and safety of focused deprescribing interventions targeting specific drug classes in older adults across clinical settings: an umbrella systematic literature review - link
- Editorial: Antidepressants at the threshold: what is really driving prescribing around dementia diagnosis? - link

American Journal of Health-System Pharmacy (AJHP)
- Integration of the medication regimen complexity – intensive care unit (MRC-ICU) score into an electronic health record and comparison to an institution-specific clinical monitoring score at a large, tertiary, community hospital - link
- Enlicitide Decanoate - link ; Atacicept-vymj - link
- Medication Preparation Errors Involving Very Small and Difficult-to-measure Volumes in a Pediatric Hospital: A 14-year Descriptive Study - link
- Guidance for antidepressant use during pregnancy: A commentary in response to the 2025 FDA panel - link
- Pharmacist-led steroid stewardship in inflammatory diseases: evaluating glucocorticoid use and patient outcomes - link

- Clinical pharmacist practitioner-led clinic improves Helicobacter pylori treatment and eradication testing: A quality improvement initiative - link
- Response to “Artificial intelligence and the future of the pharmacist’s role in drug information” - link

Annals of Internal Medicine
- Interventions to Improve Outpatient Follow-up for Hospitalized Patients with Alcohol Use Disorder: A Systematic Review - link
- Association Between Blood Hemoglobin Concentration and Mortality by Age and Sex: A Prospective Cohort Study - link
- Tuberculosis - link
- A Synopsis of the 2025 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline for Lipid Management for Cardiovascular Disease Risk Reduction - link
- Evaluation and Management of Anemia in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2026 Clinical Practice Guideline - link

Arthritis & Rheumatology
- Nonmelanoma Skin Cancer Risk with JAK Inhibitors Compared to Interleukin-6 Receptor Inhibitors in Rheumatoid Arthritis: Results from a National Cohort Study - link
- Risk of Cancer According to Duration of Targeted Therapy Exposure in Spondyloarthritis: A Nationwide Cohort Study from the French Health Insurance Database - link
- Updated COVID-19 Vaccines and Health Outcomes in Patients with Autoimmune Rheumatic Conditions - link

British Journal of Cancer
- Overall survival according to timing of immune checkpoint inhibitors administration in patients with advanced cancer: results from a large single-centre cohort analysis - link

British Journal of Clinical Pharmacology
- Comparing outcomes using low-dose apixaban and anti-Xa monitoring and vitamin K antagonists in patients with renal replacement therapy - link
- Hypertension in obesity: A focus on individualized pharmacotherapy and the role of body composition, on behalf of the European Society of Hypertension Working Group on Diabetes and Metabolic Risk Factors and Working Group on Lifestyle, Cardiovascular Pharmacotherapy and Adherence - link
- Medicines, misinformation and machines: Navigating infodemics in the generative AI era - link
- The potential impact of H1 antihistamines on clinical outcomes in NSCLC patients undergoing EGFR-TKIs treatment - link
- Alpha lipoic acid for prevention of radiation-induced dermatitis in breast cancer patients: A randomized-controlled trial - link
- Drug-associated central nervous system vasculitis and reversible cerebral vasoconstriction syndrome: A global disproportionality analysis of the WHO pharmacovigilance database (VigiBase) - link
- HIV and anticholinergic burden: Towards a pragmatic stewardship algorithm - link

British Journal of Psychiatry
- Impact of depressive disorders and antidepressant treatment on mortality among very old men and women - link
- Methylphenidate as a ‘study drug’: lessons from the COVID-19 infodemic for preventing non-medical use – link
- Psychotropic medications in mood disorders: to deprescribe or not? - link

British Medical Journal (BMJ)
- Prevention of altitude illness in adults: preparing people for travel to high altitude - link
- Giardia: everything you need to know about the parasite on the rise - link
- Exploring high priority potentially inappropriate prescribing cascades in older adults: population level retrospective cohort study - link
- What the age of GLP-1 generics will mean - link

- Simultaneous derivation, validation, and comparison of predictor hazard ratios for cardiovascular risk prediction equations in patients with diabetes from high versus non-high income countries: cohort study - link
- Advances in the diagnosis and management of skin and soft tissue infections - link
- Alzheimer's prevention drug trial: is a "statin for the brain" on the horizon? - link
- Diagnosis and management of lower limb cellulitis - link

BMJ Medicine
- Comparative efficacy and safety of glucagon-like peptide 1 based drugs for weight loss in adults with overweight or obesity without diabetes: network meta-analysis of randomised controlled trials - link

Circulation
- Immune Checkpoint Inhibitor Myocarditis and Myotoxicity - link
- Infective Endocarditis: Diagnosis, Antibiotic Therapy, and Management: A Scientific Statement from the American Heart Association - link

Cochrane
- Pharmacological therapies for the prevention of fractures in men - link
- Thymosin-α1 for people with chronic hepatitis B - link
- Long-term hormone therapy for perimenopausal and postmenopausal women - link
- Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus - link

Diabetes care
-The Management of Type 1 Diabetes in Adults. The Updated 2026 Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) - link

Drug and Therapeutics Bulletin
- Can we do more to address long-term harms of medicine use? Learning from the DES (diethylstilboestrol) disaster - link
- Precision medicine arrives in COPD - link

Emergency Medicine Australasia
- The Safety of Single Aminoglycoside Dose in Emergency Departments (SAD-ED) Among Patients With and Without Chronic Kidney Disease: A Retrospective Cohort Study - link

European Heart Journal
- Targeted vitamin D supplementation and major adverse cardiovascular events after myocardial infarction: the TARGET-D trial - link
- Targeting hypertension with SGLT2 inhibition: the EU-funded SGLT2 HYPE trial - link
- Whole-grain consumption and cardiometabolic risk: a meta-analysis of randomized trials - link

European Journal of Hospital Pharmacy
- Exploring the organisation, operation and inquiries of Centres for Medicines Information: insights from a narrative review and questionnaire - link
- Excreta contamination after antibody–drug conjugates administration: a systematic review and guidance for hospital pharmacists - link

International Journal of Clinical Pharmacy
- Antimicrobial stewardship in acute exacerbations of COPD: a qualitative study of hospital pharmacists' perspectives - link
- Prevalence and factors influencing medication adherence after acute myocardial infarction: a systematic review and meta-analysis - link
- Therapeutic drug monitoring in leukemia: global research trends and implications for clinical pharmacy practice—a bibliometric analysis - link

- A qualitative analysis to identify implementation strategies for a deprescribing clinical practice guideline using the CFIR-ERIC Matching Tool: perspectives from consumers and professional stakeholders - link

International Journal for Quality in Health Care
- Development and validation of a machine learning–based model for predicting fall-related injury risk in hospitalized patients - link

JAMA
- COVID-19 Vaccine Effectiveness and Safety for the 2026-2027 Respiratory Season - link
- Influenza Vaccine Effectiveness and Safety for the 2026-2027 Respiratory Season - link
- RSV Immunization Effectiveness and Safety for the 2026-2027 Respiratory Season - link
- Gene Silencer Therapy in Transthyretin Amyloid Cardiomyopathy: A Meta-Analysis of Outcomes Trials - link
- LDL Cholesterol Lowering with Evolocumab Before Percutaneous Coronary Intervention for Acute Myocardial Infarction: The AMUNDSEN Randomized Clinical Trial - link
- What Is Gastroparesis? - link
- Rheumatoid Arthritis in Adults: A Review - link
- Loberamisal for Acute Ischemic Stroke: The LAIS Randomized Clinical Trial - link
- JAMA Insights: Psilocybin - link

JAMA Cardiology
- Catheter-Based Left Atrial Appendage Closure vs Oral Anticoagulation in Patients with Atrial Fibrillation: A Systematic Review and Meta-Analysis - link

JAMA Internal Medicine
- Menopausal Hormone Therapy and Cardiovascular Risk in Midlife Women with Vasomotor Symptoms - link
- Timing of Initiation of Methadone Take-Home Dosing - link
- Primary aldosteronism - link

Journal of the American College of Cardiology
- Protocol-Based Implementation of Early Intensive Lipid Management After Acute Coronary Syndrome: The BRIDGE Trial - link

Lancet
- Series: Cardiovascular disease and pregnancy - link ; Therapeutics in Lung Cancer - link
- Induction and consolidation atezolizumab with stereotactic body radiation therapy versus radiation alone in high-risk, early-stage non-small-cell lung cancer (SWOG/NRG S1914): a multicentre, open-label, superiority, phase 3, randomised controlled trial - link
- Use of the bacterial lysate OM-85 for the primary prevention of wheezing lower respiratory illness in preschool children: a randomised, placebo-controlled trial - link

Lancet Diabetes & Endocrinology
- From adiposity to multisystem morbidity: the case for weight loss as disease modification - link
- Hypoparathyroidism: translating science from the laboratory to the clinic - link

Lancet Oncology
- An integrated lifestyle intervention for mitigation of adverse effects associated with androgen deprivation therapy for prostate cancer (STAMINA): a multicentre, randomised trial - link

Lancet Primary Care
- Major adverse cardiovascular events and mortality associated with ADHD and its treatment in adults with hypertension: a retrospective, multinational cohort study – link
- Weight-based levothyroxine dosing and long-term cardiovascular, bone, and mortality outcomes in older adults: an emulated target trial using UK primary care data - link

Lancet Psychiatry
- Association between CYP2D6 and CYP2C19 genotypes and venlafaxine treatment failure: a retrospective study on two cohorts from Norway and the UK - link
- Comparative effectiveness of mood stabiliser monotherapy versus second-generation antipsychotic monotherapy versus combination therapy for continuation and maintenance treatment after a first episode of psychotic mania in North America, Chile, and Spain: a target trial emulation using data from the BD-CAUSAL Collaboration - link

Molecular Diversity Preservation International (MDPI) – Pharmacy Journal
- Secondary Prevention Bundle for Drug-Related Problems in an Integrated Healthcare Setting: A Pragmatic Observational Implementation-Effectiveness Study - link
- The First 24 Hours of Hospital Admission: Early Opportunity for Pharmacotherapy Optimization in Elderly Patients with Chronic Kidney Disease - link
- Development and Validation of Digital Decision Aids to Support Medication Adherence in Older Adults: A Scoping Review - link

Medical Journal of Australia
- Patterns of Osteoporosis Treatment Initiation Following Low-Trauma Fracture: A Population-Based Retrospective Cohort Study in New South Wales, Australia, Using Linked Administrative Health Data - link

Nephrology Dialysis Transplantation
- Renin–angiotensin system inhibition in dialysis-dependent patients with chronic heart failure due to reduced ejection fraction: a systematic review and meta-analysis - link

New England Journal of Medicine
- Tozorakimab to Prevent COPD Exacerbations - link
- Catheter-Directed Thrombolysis in Intermediate-High–Risk Pulmonary Embolism - link
- Oveporexton for Narcolepsy Type 1 — Results from Two Phase 3 Trials - link
- Reengineering Coagulation with a Bispecific Antibody - link
- Treatment Decisions in Multiple Myeloma - link
- Tambotatug Pelitecan in Small-Cell Lung Cancer after Platinum-Based Therapy - link

Neurology
- Systematic Review of Pharmacologic Treatment for Migraine Prevention in Adults - link

Pediatrics (American Academy of Pediatrics)
- CART-Cell Therapy in Pediatric Acute Lymphoblastic Leukemia: A Review for General Pediatricians Available to Purchase - link
- Trends in GLP-1 Receptor Agonist Prescriptions for Children Ages 8 to 11 With Obesity: 2019–2026 - link

Pharmacotherapy
- Apixaban Use Before Kidney Transplantation: Is Reversal Necessary? - link
- Comparative Neurotoxicity of Polymyxin B and Colistin in Patients with Cancer - link
- Pharmacokinetics of Loading Dose Vigabatrin Administered via Enteral Tube in Participants with Post-Anoxic Status Epilepticus - link
- Safety of Nonsteroidal Anti-Inflammatory Drug Use in Traumatic Brain Injury - link
- Association Between CYP2C19 Genotype and P2Y12 Reaction Units in Patients Receiving Clopidogrel After Acute Ischemic Stroke: A Prospective, Observational Study - link

CONSULTATIONS

Agency for Clinical Innovation, NSW (ACI)
- Consultation: ED models of care – closes 2 October - link

Australian Commission on Safety and Quality in Health Care (ACSQHC)
- NSQHS Standards (third edition) - closes Friday 25 September - link

- Australian Guidelines for the Prevention and Control of Infection in Healthcare – closes Tuesday 29 September - link

TGA
- Consultation: Proposed amendments to the Poisons Standard in relation to nitrous oxide - Joint ACMS-ACCS meetings - November 2026 - closes 12 October 2026 - link
- Consultation: Proposed amendments to the Poisons Standard in relation to 4-methylbenzylidene camphor (4-MBC) - Joint ACMS-ACCS meetings - November 2026 - closes 12 October 2026 - link
- Consultation: Proposed amendments to the Poisons Standard - ACCS meeting - November 2026 - closes 12 October 2026 - link
- Additional public consultation on amending the Poisons Standard regarding ethylene oxide, propylene oxide and epichlorohydrin - closes 26 October 2026 - link

WEBINARS & PODCASTS

Australian Prescriber Podcasts
- E222 | Acne vulgaris: a clinical update

Purple Pen Podcast
- PPP 196 - Long-acting injectable buprenorphine (LAIB)

Specialist Pharmacy Service
- Pharmacogenomics in primary care and community pharmacy podcasts - link

UPCOMING EVENTS

Advanced Pharmacy Australia
- Medicines Management MM2026, 22-24 October 2026, Brisbane Convention & Exhibition Centre - register

Australian Commission on Safety and Quality in Health Care (ACSQHC)
- Registrations open – National Medicines Symposium NMS 2026, 'Medicines stewardship: safer use starts with all of us' - Wednesday, 11 November 2026 - register

Fortnightly TAG Mail – resources list 3 September 2026

NSW TAG ACTIVITIES

Email Discussion
Governance of Medicine Access Programs: How do DTCs manage MAPs? For example. do all MAPs need DTC approval? Do all DTCs sight forms re company supply? Once approved, what systems are in place for patients prescribed a MAP medicine? DTCs are requested to provide their process for management of MAPs to NSW TAG by COB 19th September 2026.

Upcoming NSW TAG meeting dates
NSW TAG Management Committee Meeting: 14th October 2026 12-1pm
NSW TAG General Members' Meeting: 29th October 2026 4-5pm
NSW TAG Annual General Meeting: 29th October 2026 5-5.30pm

TAG Mail
Searching Cumulative TAG Mail listings: Remember to search Cumulative TAG Mail listings, which are collated in 6 months batches from 2023. These cumulative listings are useful to survey whenever you have a medicine or condition you wish to explore as TAG mail covers the grey literature as well as the traditional academic literature. Just 'Control F' relevant terms to search for your query.

Contact Sasha Bennett at sasha.bennett@svha.org.au for information about any email discussions, publications or upcoming meetings.

EDITOR'S PICKS *highlighted with relevant NSW TAG and CATAG resources*

AHRQ: White paper: AI and Machine Learning Tools To (Semi-)Automate Evidence Synthesis - link
AIM: Ethics and Professionalism in AI and Medical Practice - link
BJPsych: SR and MA of placebo treatment responses across major psychiatric conditions in citalopram and escitalopram RCTs - link
BMJ: IV iron to treat anaemia before cardiac surgery (ITACS - link
BMJ: Intismeran autogene (mRNA-41567), a personalised, mRNA based cancer vaccine making headlines but experts urge caution - link
Drug Safety: System Combining Rule-based Extraction and LLM-Based Classification of Deprescribing Recommendations in Discharge Summaries- link Deprescribing Tools QUM Indicators 5.3, 5.8 and 5.9
EHJ: 2026 ESC Guidelines for the management of CVD and CKD - link CATAG toolkit
EHJ: 2026 ESC Guidelines for the management of heart failure - link QUM Indicator 5.2, CATAG Medicines Stewardship
EHJ: Safety of pharmacological treatment withdrawal after recovery from HER2 therapy-related cardiac dysfunction - link
IJCP: Development of a hybrid AI framework for pharmacotherapy optimization - link
IJQHC: Cultural determinants and strategic priorities for medication safety in acute care - link
JQPS: Elimination of the Opioid Sliding Scale and Improved Opioid Stewardship Metrics - link CATAG toolkit
JQPS: An Antimicrobial Stewardship Dashboard to Identify High-Priority Outpatient AMS Targets and Future Quality Initiatives - link
Lancet: Discontinuation of β-blockers in stable patients with previous MI, pLVEF and no HF- link
Lancet D&E: Ketoacidosis with SGLT2 inhibitors in routine clinical practice of type 2 diabetes- link NSW TAG Consumer Information Leaflet CATAG toolkit
Lancet PC: MACE & mortality associated with ADHD & its treatment in adults with hypertension - link
MDPI: Retrospective Evaluation of Pharmacist Referrals to Primary Care Following Discharge - link CATAG resource
NEJM: Anticoagulation for Atrial Fibrillation with Intermediate Stroke Risk - link
NEJM: Atorvastatin, Cardiovascular Events, and Disability-free Survival in Older Adults - link
PDA UK: Professional guidance on the safe and effective use of AI in pharmacy practice - link

REPORTS AND PUBLICATIONS – AUSTRALIA

Agency for Clinical Innovation, NSW (ACI)
The latest weekly Evidence Digest can be found here

Australian Commission on Safety and Quality in Health Care (ACSQHC)
- Updated High-Risk Medicines Education: Opioid Analgesics in Acute Settings module - link

Australian Government Department of Health
- Infection prevention and control principles and recommendations for Ebola virus disease - link

Australian Institute of Health and Welfare (AIHW)
- Chronic conditions dashboard - update

MIMS monthly updates
- New Products
-- Remibrutinib (Rhapsido) is an oral Bruton's tyrosine kinase (BTK) inhibitor. In patients with chronic spontaneous urticaria (CSU), remibrutinib prevents the release of histamine and other proinflammatory mediators that cause itch, hives, or angioedema. Rhapsido is indicated for the treatment of CSU in adult patients who remain symptomatic despite H1 antihistamine treatment. Rhapsido tablets contain remibrutinib 25 mg and are available in packs of 60.
- New Indications
-- Lorazepam (Lorazepam SXP) is now indicated for the control of status epilepticus in children greater than or equal to 6 years of age. Note: Lorazepam (Lorazepam SXP) now contraindicated in

neonates, infants, and children less than 6 years of age due to the risk of propylene glycol toxicity and possible adverse effects of benzyl alcohol.

--Tezepelumab (Tezspire) is now indicated as an add-on maintenance treatment in patients aged 18 years and older with severe chronic rhinosinusitis with nasal polyps (CRSwNP) with inadequate response to intranasal corticosteroids and a history of surgery and/or systemic corticosteroid use

TGA
- TGA approves update to indication for TRUQAP (capivasertib) - link
- Database of section 19A approvals to import and supply medicines to address medicine shortages
- AusPARs:
-- Enflonsia (clesrovimab) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants who are born during or entering their first RSV season. Enflonsia should be used in accordance with official recommendations

REPORTS AND PUBLICATIONS – INTERNATIONAL

Agency for Healthcare Research and Quality (AHRQ) USA
- White paper: Artificial Intelligence and Machine Learning Tools To (Semi-)Automate Evidence Synthesis: A Rapid Review and Evidence Map - link

electronic Medicines Compendium (eMC) (UK)
- New products
-- Comirnaty XFG (Mrna encoding xfg) 10 micrograms/dose dispersion for injection, single dose vial for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in infants and children aged 6 months to 11 years. The use of this vaccine should be in accordance with official recommendations
-- Comirnaty XFG (Mrna encoding xfg) 30 micrograms/dose dispersion for injection in pre-filled syringe for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older to be used in accordance with official recommendations
-- Eligard (leuprorelin) 22.5mg & 45mg powder and solvent for solution for injection, a gonadotropin releasing hormone analogue for hormone dependent advanced prostate cancer, and high-risk localized and locally advanced hormone dependent prostate cancer in combination with radiotherapy
-- Etcamah (camizestrant) 75 mg film-coated tablets indicated alongside a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib) for ER-positive, HER2-negative, locally advanced or metastatic breast cancer with an ESR1-mutation, without progression during first line endocrine therapy in combination with a CDK4/6 inhibitor
-- Ezmekly (mirdametinib) dispersible tablets and hard capsules - mitogen-activated protein kinase inhibitor is licensed for the treatment of symptomatic, inoperable plexiform neurofibromas in paediatric & adult patients with neurofibromatosis type 1 aged ≥2 years. It is available as hard capsules (1 & 2mg), and dispersible tablets (1mg)
-- Otulfi (ustekinumab) - biosimilar to Stelara, now available as 45mg and 90mg solution for injection pre-filled pen presentations
-- Yesintek (ustekinumab) - biosimilar to Stelara available as 45 mg/0.5 ml and 90 mg/1ml solution for injection in pre-filled pen, 90 mg/1ml in pre-filled syringe, and 130 mg/26 ml concentrate for solution for infusion
- New indications
-- Keytruda (pembrolizumab) - alongside enfortumab vedotin, as neoadjuvant treatment and then continued after radical cystectomy as adjuvant treatment, now indicated for treatment of adults with resectable muscle invasive bladder cancer who are ineligible for cisplatin-containing chemotherapy

Food and Drug Administration (FDA) USA
- New Drug approvals
-- Besremi (ropeginterferon alfa-2b-njft) - treatment for Essential Thrombocythemia
-- efsitora alfa, Weekly Insulin Jab for Type 2 Diabetes Once-weekly insulin
-- Genglycos (pariglasgene brecaparvovec-opnr), gene therapy for Glycogen Storage Disease Typ Ia
-- Imaavy (nipocalimab-aahu), first drug for Warm Autoimmune Hemolytic Anemia
-- Lisraya (brepocitinib), First Oral Drug Indicated to Treat Dermatomyositis in Adults

-- Mimrylo (rusfertide), first drug of its kind for Polycythemia Vera
-- Mounjaro FDA-approved to reduce cardiovascular risk in T2D
-- Rasonque (daraxonrasib) for metastatic pancreatic cancer
-- Stelara (ustekinumab) for pediatric Ulcerative Colitis
-- Tivicay PD tablets for oral suspension (dolutegravir) to treat HIV infection in newborns
-- Zanidatamab regimen for HER2-Positive GEA

Monthly Index of Medical Specialities (MIMS) UK
- First oral non-peptide GLP-1, orforglipron, reaches UK patients (now available privately) - link

National Institute for Health and Care Excellence (NICE) UK
- 12 SQ-HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (TA1045)
- 12 SQ-Bet SLIT for treating moderate to severe allergic rhinitis or conjunctivitis caused by tree pollen in people 5 years and over (TA1087)
- Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency (TA1189)
- Multiple sclerosis in adults: management (NG220)

NHS Networks
- NHSE and UKHSA toolkit and resource pack for use across primary care on raising awareness of urinary tract infections in older adults - link

National Institute for Health and Care Research (NIHR)
- Blood-test monitoring strategies for patients established on immunesuppressing drugs: a mixed-methods study - link

Pharmacists' Defence Association UK
- Publishes professional guidance on the safe and effective use of AI in pharmacy practice - link

Royal College of Psychiatrists (UK)
- Wim's Protocol: for the safe prescribing and monitoring of Clozapine - link

Specialist Pharmacy Services NHS UK
- Benztropine injection for acute dystonic reactions - link

UK Health Security Agency
- UKHSA publishes new meningococcal disease evidence reviews - link

MEDICATION SAFETY

electronic Medicines Compendium (eMC) (UK)
- Revised SPCs
-- Arimidex (anastrozole) - tendonitis may occur with Arimidex at an unknown frequency, with post-marketing cases reported that led to tendon rupture. Patients should be monitored for signs and symptoms of tendonitis and appropriate measures initiated for the affected tendon
-- Avodart (dutasteride) - mood alterations including depressed mood, depression and, less frequently, suicidal ideation reported in patients treated with another 5ARI
-- Convulex (valproic acid) - updated to reflect current evidence on neurodevelopmental disorders in children born to men treated with valproate. Fertility section updated with further information on the potential risk to children of fathers treated with valproate within 3 months before conception
-- Creon (pancreatin) capsules - potential hepatitis E virus (HEV) transmission. Despite measures taken during manufacturing to reduce the risk, the presence of HEV in medicinal products containing pancreas powder extracts of animal (porcine) origin is possible
-- Fluenz nasal spray suspension Influenza vaccine (live, nasal) - syncope added as an ADR of unknown frequency and corresponding warning that procedures should be in place to prevent injury from fainting and managing syncopal reactions

-- Hydrea (hydroxycarbamide) - limbal stem cell deficiency (LSCD) added as a new ADR (frequency not known). Cases of LSCD, a rare, sight-threatening ocular condition, reported in patients treated with hydroxycarbamide
-- Iqymune (human normal immunoglobulin) - exfoliative dermatitis added as an ADR with unknown frequency
-- Ngenla (somatrogon) - epiphyseal disorders added as a new ADR (frequency not known). Epiphyseal disorders may occur more frequently in patients with endocrine disorders or in patients undergoing rapid growth
-- Nuwiq (simoctocog alfa) - new illustrations for administration and added information on administration outside of the supplied infusion set
-- Opdualag (nivolumab, relatlimab) – advice given on dose management in case of suspected or confirmed Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN)
-- Rinvoq (upadacitinib) - semen discolouration added as a 'rare' ADR
-- Siklos (hydroxycarbamide) - cases of limbal stem cell deficiency reported in patients treated with hydroxycarbamide. In some cases, it improved after treatment discontinuation. If suspected, patient should be referred to appropriate eyecare specialist for corneal evaluation
-- Ultomiris (ravulizumab) - home infusions performed by a qualified healthcare professional may be considered for patients who have tolerated infusions well in the clinic
-- Uniphyllin (theophylline) prolonged release tablets – all strengths - plasma theophylline concentrations should ideally be maintained between 10 and 20 micrograms/ml. Hypokalaemia added as an ADR; dose reduction & monitoring of serum theophylline levels may be required in patients at risk of hypokalaemia
-- Wegovy (semaglutide) FlexTouch - information added around switching from Wegovy tablets to Wegovy injections. The effects of switching cannot easily be predicted because oral formulation displays higher pharmacokinetic variability in absorption compared to the injection
-- Welireg (belzutifan) - addition of following adverse effects in patients on belzutifan 120mg with advanced renal cell carcinoma: blurred vision, reduced visual acuity, increase in alanine aminotransferase and aspartate aminotransferase, arthralgia, muscle spasms and myalgia
- Risk minimisation materials
-- Alecensa (alectinib): Guidance for management of severe hypertriglyceridaemia including severe and life-threatening events, has been identified as a new adverse drug reaction of Alecensa. Advice is given on monitoring triglycerides and for development of pancreatitis, as well as management
-- Finasteride and dutasteride - Updated safety warnings for psychiatric side effects and sexual dysfunction. Letter advises of the risk of suicidal ideation with oral finasteride-containing products, with cases mainly reported in patients treated for androgenetic alopecia. Sexual dysfunction may contribute to mood alterations. A Patient Alert Card highlighting these risks is available
-- Fingolimod – a patient, parent and caregiver guide is available, detailing key points about fingolimod treatment, as is a prescriber checklist. A pregnancy-specific patient reminder card can also be downloaded, which advises patients of the risks and what to do in case of pregnancy
-- Lamzede (velmanase alfa) – Home Infusion Diary designed to record administration of velmanase alfa. Includes space for key healthcare professional contact details and guidance on action to take in the event of an infusion-associated reactions, with reporting information provided on the front and back covers
-- Molcava (ferric carboxymaltose) 50 mg iron/ml dispersion for injection/infusion - Materials include a prescriber guide, which contains prescription and administration information to minimise the risk of serious hypersensitivity, and a patient guide covering the possible risk of serious allergic reactions
-- Nplate (romiplostim): Home Administration Training - Patient DVD available, in order to help them with the process of preparation and self-administration of the correct dose of romiplostim at home. Advice is given on how to request a copy of the DVD
-- Ontozry (cenobamate): new requirements for liver monitoring due to reports of severe liver injury
-- Simponi (golimumab): patient card now available, covering important safety information such as pregnancy & vaccinations, infections, and TB screening
-- Ventolin Evohaler (salbutamol) 100 micrograms - Risk awareness dialogue aid covers counselling points for the new inhaler, which contains 200 puffs of salbutamol and does not have a dose counter. Patients should keep a record of puffs used and consider keeping a spare inhaler at places they spend their time

Food and Drug Administration (FDA) USA
- Adds boxed warning to labeling for ferric carboxymaltose injection (injectafer) to describe risk of low phosphate levels - link

Health Canada – MedEffect Notice
- Health Product InfoWatch, August 2026

Medicines and Healthcare products Regulatory Agency (MHRA) UK
- MHRA concludes review of Avacopan Vifor (previously known as Tavneos) following reassessment of benefit-risk balance - link
- Filters should be used during the administration of Parenteral Nutrition for patients in all care settings - link
- MHRA Safety Roundup - August 2026

MIMS monthly updates
- New Contraindications
-- Lorazepam (Lorazepam SXP) is now contraindicated in neonates, infants, and children less than 6 years of age due to the risk of propylene glycol toxicity and possible adverse effects of benzyl alcohol.
-- Rifampicin (Rifadin) is now also contraindicated for concomitant use with daclatasvir, sofosbuvir, and telaprevir for treatment of hepatitis C virus infections.
- Safety Related Changes
-- Ritonavir (Norvir) is no longer indicated as monotherapy for the treatment of human immunodeficiency virus (HIV)-1 infection in adults and children aged 12 years and older

Specialist Pharmacy Services NHS UK
- Examples of commonly used medicines associated with QT interval prolongation - link
- Managing medicines associated with QT interval prolongation - link
- Dealing with temperature excursions video - link

TGA
- Reporting adverse events for health professionals - link
- CAROTONE skin-brightening products found to contain undeclared prescription-only medicine - link
- Information about major medicine shortages – link
-- About the shortage of methylphenidate hydrochloride products - link

PAPERS OF INTEREST

American Journal of Health-System Pharmacy (AJHP)
- Vancomycin pharmacokinetics and dosing in critically ill adult patients on continuous renal replacement therapy: A scoping review - link
- Challenges in evaluating associations among vasopressors, enteral nutrition, and nonocclusive mesenteric ischemia - link
- Improving patient safety with triple-scan technology for insulin pen administration - link

Annals of Internal Medicine
- Adult Overweight and Obesity Management: Updates From the 2025 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guidelines - link
- Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes: An Updated Systematic Review - link
- Ethics and Professionalism in Artificial Intelligence and Medical Practice: A Position Paper from the American College of Physicians - link

Annals of Rheumatic Diseases
- Efficacy and safety of filgotinib in patients with active radiographic and non-radiographic axial spondyloarthritis: results from OLINGUITO, a phase 3 trial consisting of 2 randomised, placebo-controlled, double-blind, parallel-group studies - link

- Efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with active psoriatic arthritis: 52-week results from the randomised, double-blind, placebo-controlled phase 3 POETYK PsA-1 trial - link

Archives of Disease in Childhood
- Impacts of vaping on children and young people: a systematic review - link

Arthritis & Rheumatology
- Hepatotoxicity of Avacopan: Real-World Incidence and Confirmed Cases of Severe Drug-Induced Liver Injury in a US National Rheumatology Registry - link

British Journal of Clinical Pharmacology
- Incident low-dose quetiapine use in adults newly diagnosed with depression in primary care: A nationwide register-based study - link
- Long-acting cabotegravir and rilpivirine in people with HIV receiving chronic anticoagulation: A real-world case series - link
- Paediatric clonidine medication errors: Findings from a multicentre French study - link

British Journal of Pharmacology
- New therapeutic options for metabolic-associated steatotic liver disease - link

British Journal of Psychiatry
- Beyond control in psychiatric research: systematic review and meta-analysis of placebo treatment responses across major psychiatric conditions in citalopram and escitalopram RCTs - link
- Bridging gaps in ADHD care globally: lessons from the NHS England independent taskforce report - link
- Incidence of clozapine-associated neutropenia in patients with schizophrenia: 20-year population-based study in Hong Kong - link

British Medical Journal (BMJ)
- Intravenous iron to treat anaemia before cardiac surgery (ITACS): international, double blind, placebo controlled randomised trial - link
- Clinical review: Diagnosis and management of acute hyperkalaemia - link
- Intismeran autogene (mRNA-41567), a personalised, mRNA based cancer vaccine making headlines but experts urge caution - link
- Why executive order (EO) in US to split components of MMR vaccine into separate injections is costly and dangerous - link
- ADHD and autism costs “out of control,” NHS leaders warn - link

Circulation
- Association of Adherence to Various Dietary Patterns with Mortality Among Survivors of Myocardial Infarction: A Prospective Cohort Study - link
- Primary and Secondary Raynaud: A Scientific Statement From the American Heart Association - link
- Vasoactive Agent Selection Strategies in the Management of Cardiogenic Shock - link
- Tocilizumab Is Associated with a Lower Incidence of Major Adverse Cardiovascular Events in Giant Cell Arteritis - link
- Global Efficacy of Aficamten in Nonobstructive Hypertrophic Cardiomyopathy: Results From ACACIA-HCM - link
- Effects of Evolocumab on Mortality Outcomes in Patients Without Previous Myocardial Infarction or Stroke: A Prespecified Analysis of the VESALIUS-CV Randomized Clinical Trial - link

Clinical Infection in Practice
- Histoplasmosis in the United Kingdom: Diagnosis and management in a non-endemic setting - link

Cochrane
- Electronic cigarettes for smoking cessation - link

- Interventions for the eradication of meticillin-resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis - link
- Continuation versus discontinuation of intravenous oxytocin in the active phase of labour - link
- Alpha 1 antitrypsin augmentation therapy for alpha 1 antitrypsin deficiency-associated lung disease - link
- Methylxanthines for the prevention or treatment of intermittent hypoxemia or respiratory insufficiency in late preterm infants - link

Drug Safety
Development and Validation of a Two-Stage NLP System Combining Rule-based Extraction and LLM-Based Classification of Deprescribing Recommendations in Discharge Summaries- link

European Heart Journal
- 2026 ESC Guidelines for the management of cardiovascular disease and chronic kidney disease, in collaboration with the European Renal Association (ERA): Developed by the task force on the management of cardiovascular disease and chronic kidney disease of the European Society of Cardiology (ESC) - link
- 2026 ESC Guidelines for the management of heart failure: Developed by the task force for the management of heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS) - link
- Antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation: an individual patient data network meta-analysis - link
- Cardiovascular disease burden at cancer diagnosis: temporal trends in a national study from England - link
- Finerenone in hypertensive non-diabetic chronic kidney disease: a FIND-CKD subgroup analysis - link
- Inclisiran vs bempedoic acid for low-density lipoprotein cholesterol lowering in high-risk patients: the VICTORION-Challenge trial - link
- Safety of withdrawal of pharmacological treatment after recovery from HER2 therapy-related cardiac dysfunction: the HER-SAFE trial - link
- 2026 European Society of Cardiology Guidelines on cardiac rehabilitation - link
- Half-dose rivaroxaban vs antiplatelet therapy for preventing silent cerebral embolism after left atrial appendage occlusion: the HALO-SCE trial - link
- Adverse pregnancy outcomes and long-term cardiovascular risk: lifelong connections - link

European Journal of Hospital Pharmacy
- Accelerating biosimilar adoption by empowering hospital pharmacists: a dialogue between emerging markets and European hospital pharmacists - link
- Semaglutide-associated agranulocytosis requiring hospitalisation and granulocyte colony-stimulating factor: a case report - link

Internal Medicine Journal
- Tigecycline combination therapy for fulminant Clostridioides difficile infection: an Australian experience - link

International Journal of Clinical Pharmacy
- Development and internal validation of an interpretable machine learning model for predicting vancomycin-induced nephrotoxicity in hospitalized children - link
- Development of a hybrid artificial intelligence framework for pharmacotherapy optimization - link

International Journal for Quality in Health Care
- Cultural determinants and strategic priorities for medication safety in acute care: a multidisciplinary Delphi study - link

JAMA

- Arginine Therapy for Sickle Cell Disease Acute Pain Episodes: The STArT Randomized Clinical Trial - link
- JAMA Insights: Medications for Alcohol Use Disorder - link
- Postural Orthostatic Tachycardia Syndrome (POTS): A Review - link
- Cannabinoid Hyperemesis Syndrome - link
- Anticoagulation Monotherapy vs Antiplatelet Monotherapy After Transcatheter Aortic Valve Implant: The ACASA-TAVI Randomized Clinical Trial - link

JAMA Network Open
- Inhaled Corticosteroids Continuation in the First Trimester and Pregnancy Outcomes in Women with Asthma - link
- Methadone vs Buprenorphine-Naloxone in Opioid Overdose Survivors - link

Joint Commission Journal on Quality and Patient Safety
- Elimination of the Opioid Sliding Scale Is Associated with Improved Opioid Stewardship Metrics - link
- A Claims-Based Antimicrobial Stewardship Dashboard to Identify High-Priority Outpatient Antimicrobial Stewardship Targets and Future Quality Initiatives - link

Lancet
- Discontinuation of β-blockers in stable patients with previous myocardial infarction, preserved left ventricular ejection fraction, and no heart failure: a pooled analysis of individual patient data - link

Lancet Diabetes & Endocrinology
- Ketoacidosis with SGLT2 inhibitors in routine clinical practice of type 2 diabetes: Scandinavian cohort and nested case–control study - link

Lancet Infectious Diseases
- Oral carbapenem—a double-edged sword? - link

Lancet Neurology
- Intensive blood pressure lowering after spontaneous intracerebral haemorrhage for secondary stroke prevention (RECAP-ICH): a systematic review and individual participant data meta-analysis - link

Lancet Primary Care
- Major adverse cardiovascular events and mortality associated with ADHD and its treatment in adults with hypertension: a retrospective, multinational cohort study - link

Lancet Psychiatry
- Relapse trajectories and antipsychotic discontinuation in schizophrenia from individual participant data of five trials from the Yale Open Data Access database: a meta-analysis - link

Molecular Diversity Preservation International (MDPI) – Pharmacy Journal
- Full-Dose Distribution and Age–Dose Concordance of Suvorexant: A Retrospective Drug Utilization Study at a Japanese University Hospital - link
- Safe Handover or Lost in Transition?—A Retrospective Evaluation of Pharmacist Referrals to Primary Care Following Hospital Discharge - link
- A Novel Fixed-Dose Activated Prothrombin Complex Concentrate Regimen for Warfarin-Associated Hemorrhages: A Retrospective Cohort Comparison of Two Regimens - link

New England Journal of Medicine
- Myeloproliferative Neoplasms - link
- Eplontersen for Transthyretin Amyloid Cardiomyopathy - link
- Milvexian with Antiplatelet Therapy after Acute Coronary Syndrome Event - link
- Prasugrel versus Ticagrelor in Acute Coronary Syndromes - link
- Response-Tailored or Standard-Duration Antibiotic Treatment for Infective Endocarditis - link
- Anticoagulation for Atrial Fibrillation with Intermediate Stroke Risk - link

- Aspirin Omission at the Time of Primary Percutaneous Coronary Intervention in STEMI - link
- Atorvastatin, Cardiovascular Events, and Disability-free Survival in Older Adults - link
- Clopidogrel or Dual Antiplatelet Therapy in High-Ischemic-Risk Patients - link

Pharmaceutical Journal
- UK study to look at semaglutide for alcohol addiction and obesity - link

Pharmacotherapy
- Safety of Coadministration of Continuous Infusions of Propofol and Clevidipine: A Multi-Site Retrospective Analysis - link
- Phenobarbital Versus Benzodiazepine-Based Pathways for Alcohol Withdrawal Syndrome in Critically Ill Adults: A Systematic Review and Meta-Analysis - link

Prescrire International
- September 2026 issue includes:
-- Zuranolone (Zurzuvae°) in postpartum depression
-- In-utero exposure to PD-1 and PD-L1 inhibitors: autoimmune disorders?
-- In-utero exposure to paracetamol and neuropsychological development

CONSULTATIONS

Australian Commission on Safety and Quality in Health Care (ACSQHC)
- NSQHS Standards (third edition) - closes Friday 25 September - link
- Australian Guidelines for the Prevention and Control of Infection in Healthcare – closes Tuesday 29 September - link

TGA
- Consultation: Adoption of International Scientific Guidelines in Australia R01-2026 - Closes on 11 September 2026 - link
- Additional public consultation on amending the Poisons Standard regarding ethylene oxide, propylene oxide and epichlorohydrin - closes on 26 October 2026 - link

WEBINARS & PODCASTS

AdPha
- Connect: Around the Nation, Tuesday 8 September 2026 1pm AEST (30 minutes) - FREE quarterly webinars for Techs and Assistants - register

Australian Government Department of Health
- Webinar: Digital Transformation Tech Talk – Wednesday 4 Nov 2026 14:00-15:00 AEDT - register

Australian Prescriber Podcasts
- E221 | Antibiotic prophylaxis for dental procedures: an update

MJA Podcasts
- Emergency laparotomy - a national clinical care standard - link

UPCOMING EVENTS

Advanced Pharmacy Australia
- Medicines Management MM2026, 22-24 October 2026, Brisbane Convention & Exhibition Centre - Early Bird registration open until 9 September

Australian Commission on Safety and Quality in Health Care (ACSQHC)
- Registrations open – National Medicines Symposium NMS 2026, 'Medicines stewardship: safer use starts with all of us' - Wednesday, 11 November 2026 - register

Safer Care Victoria

- From project to practice: Creating lasting improvements in VTE prevention through collaboration and learning - 3 Sep 2026 13:00-14:00 - register

Fortnightly TAG Mail – resources list 20th August 2026

NSW TAG ACTIVITIES

New Email Discussion

Governance of Medicine Access Programs: How do DTCs manage MAPs? For example. do all MAPs need DTC approval? Do all DTCs sight forms re company supply? Once approved, what systems are in place for patients prescribed a MAP medicine? DTCs are requested to provide their process for management of MAPs to NSW TAG by COB 19th September 2026.

Upcoming NSW TAG meeting dates

NSW TAG Management Committee Meeting: 14th October 2026 12-1pm
NSW TAG General Members' Meeting: 29th October 2026 4-5pm
NSW TAG Annual General Meeting: 29th October 2026 5-5.30pm

TAG Mail

Searching Cumulative TAG Mail listings: Remember to search Cumulative TAG Mail listings, which are collated in 6 months batches from 2023. These cumulative listings are useful to survey whenever you have a medicine or condition you wish to explore as TAG mail covers the grey literature as well as the traditional academic literature. Just 'Control F' relevant terms to search for your query.

Contact Sasha Bennett at sasha.bennett@svha.org.au for information about any email discussions, publications or upcoming meetings.

EDITOR'S PICKS *highlighted with relevant NSW TAG and CATAG resources*

AJHP: Practice-enhancing publications re the ambulatory care medication-use process in 2025 - link CATAG
AWMSG: All Wales gabapentinoid resources for chronic pain - link CATAG
BJCP: The impact of medication shortages on paediatric care - link
BJCP: Higher anticholinergic burden and increased mortality following hip fracture- link NSW TAG AxTool NSW TAG Poster CATAG
BJPsych: Psychedelics in psychiatry: from promise to translation - link CATAG
BMC Med: Digital patient safety interventions in primary care - link
CPJ: Pill splitting for sustainability: Reducing the cost and environmental impact of medications - link
Cochrane: First-line systemic treatment for people with extensive-stage small cell lung cancer - link
DOM: Efficacy and safety of once-weekly semaglutide as an add-on to dose-reduced insulin glargine vs dose-titrated insulin glargine in people with T2DM and overweight - link CATAG
DOM: Effect of medications for T2DM on CV events and mortality - link
EClinMed: Safety of routine antimicrobial prophylaxis for surgery - link NSWTAGInd
EHJ: Temporal comparison of clinical practice and outcomes in heart failure - link NSWTAGInd CATAG
EJHP: Measuring treatment satisfaction in rare diseases - link CATAG1 CATAG2
EJHP: Improving drug therapy safety through pictograms - link
IMJ: Dose escalation for secondary loss of response in inflammatory bowel disease - link
IMJ Australian consensus recommendations for the management of increased meningococcal infection risk in adults with neurological diseases treated with complement inhibitors - link
IMJ: A retrospective single-centre evaluation of systemic anticancer therapy near the end of life in patients with solid organ malignancies - link
IJCP: AI-generated patient information leaflets for oral anticoagulants- link
IJQHC: Measuring Safer Opioid Use in Hospitals - link NSW TAGInd
JAMA NO: IV Thrombolysis Beyond the Conventional Time Window for Acute Ischemic Stroke - link
MJA: Estimating eligibility for GLP1RAs for chronic weight management and CVD in Australia - link

NIHR: Interventions to reduce pain at dressing change of chronic wounds - link
Paed: Early antiviral therapy in pediatric outpatients and risk of influenza-related hospitalization - link
Thorax: Macrolide de-escalation during the Australian summer on exacerbations of OAD - link
WHO: Artificial intelligence-related health research: ethics review and oversight - link

OTHER NEWS

Australian Commission on Safety and Quality in Health Care (ACSQHC)
- Antibiogram resources - link

TGA
- TGA flexes its muscle against illegal peptides and steroids - link

REPORTS AND PUBLICATIONS – AUSTRALIA

Agency for Clinical Innovation, NSW (ACI)
The latest weekly Evidence Digest can be found here

Australian Commission on Safety and Quality in Health Care (ACSQHC)
- Intravenous fluid therapy: Principles for safe, appropriate and sustainable use - link

PBS
- Rapid review of PBS medicines for relapsing-remitting multiple sclerosis (RRMS) - 11 August 2026

Safer Care Victoria
- Victorian Guideline for the Prevention of Venous Thromboembolism in Adult Hospitalised Patients - link

TGA
- COVID-19 rapid antigen self-tests that are approved in Australia - link
- Database of section 19A approvals to import and supply medicines to address medicine shortages
- AusPARs:
-- Zirdawny for routine prevention of recurrent attacks of hereditary angioedema (HAE) in adults and adolescents aged 12 years and older
- Australian prescription medicine decision summaries:
-- Exdensur (depemokimab) as an add-on maintenance treatment for severe asthma in adults and adolescents with eosinophilic airways inflammation, and for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in adults, with limited response to systemic corticosteroids or surgery.

REPORTS AND PUBLICATIONS – INTERNATIONAL

All Wales Medicines Strategy Group
- All Wales gabapentinoid resources for chronic pain - link
- History-based penicillin allergy de-labelling in adults - link

British National Formulary
- BNF + BNFC knowledge updates – August 2026
- New menopause treatment summary - link

Department of Health and Social Care
- Medicine supply management - link

electronic Medicines Compendium (eMC) (UK)
- New products
-- Foundayo (orforglipron) film-coated tablets for adult type 2 diabetes mellitus and for weight management in adults with an initial BMI ≥30 kg/m2 (obesity), or ≥27 kg/m2 to < 30 kg/m2 (overweight) in the presence of at least one weight-related comorbidity

-- Irisel (testosterone) 16.2 mg/g transdermal gel - pump formulation for adult testosterone replacement therapy for male hypogonadism when testosterone deficiency has been confirmed by clinical features and biochemical tests
-- Lutonaze (azelastine hydrochloride and fluticasone propionate) 137 micrograms/50 micrograms per actuation nasal spray for the relief of symptoms of moderate to severe seasonal and perennial allergic rhinitis if monotherapy with either intranasal antihistamine or glucocorticoid is not considered sufficient
-- Molcava (ferric carboxymaltose) 50 mg iron/ml dispersion for injection/infusion for iron deficiency when oral iron preparations are ineffective, or cannot be used, and there is a clinical need to deliver iron rapidly
-- Omlyclo (omalizumab) 300 mg pre-filled pen, biosimilar for allergic asthma, chronic rhinosinusitis with nasal polyps and chronic spontaneous urticaria
-- Rhapsido (remibrutinib) 25 mg film-coated tablet - selective Bruton's tyrosine kinase inhibitor for chronic spontaneous urticaria in adult patients with inadequate response to H1 antihistamine treatment. It is taken at a dose of 25mg twice daily.
-New/expanded indications
-- Fasenra (benralizumab) as an add-on treatment for adult and adolescent patients aged ≥12 years weighing ≥35 kg with inadequately controlled hypereosinophilic syndrome without an identifiable non-haematologic secondary cause
-- Imaavy (nipocalimab) 185 mg/mL concentrate for solution for infusion as add-on to standard therapy for treatment of generalised myasthenia gravis in adult and adolescents aged ≥12 years, who are anti-acetylcholine receptor or anti-muscle-specific tyrosine kinase antibody positive
-- Namuscla (mexiletine hydrochloride) – use added in paediatric population (aged 6 to 11 years weighing at least 20 kg and adolescents aged 12 to 17 years)

Food and Drug Administration (FDA) USA
- New Drug approvals
-- Awiqli, first once-weekly basal insulin
-- Zenbexus, iberdomide with daratumumab and hyaluronidase-fihj and dexamethasone for multiple myeloma – PI-label
-- Genglycos (pariglasgene brecaparvovec-opnr), first therapy for patients aged 8 years and older with Glycogen Storage Disease Type Ia
-- Pasatru (garetosmab-grts) to reduce new heterotopic ossification and clinician-assessed disease flare-ups in adults with fibrodysplasia ossificans progressiva
-- Replimune skin cancer drug after rejections
-- Tauklarify (florquinitau F18) for PET of the brain in adults with cognitive impairment who are being evaluated for Alzheimer disease to identify patients with tau neurofibrillary tangle pathology – PI-label

General Pharmaceutical Council UK
- New standards for the initial education and training of pharmacy technicians published - link

Medicines and Healthcare products Regulatory Agency (MHRA)
Approvals
- remibrutinib (Rhapsido) 25 mg tablets for adults with chronic spontaneous urticaria
- vimseltinib (Romvimza) for use in adults to treat tenosynovial giant cell tumours
- orforglipron for weight loss and weight management - link
- Taking medication this summer? What you need to know about sun and heat exposure - link

NHS England
- Roles and responsibilities for delivery of the UK antimicrobial resistance national action plan - link

National Institute for Health and Care Excellence (NICE) UK
- Donidalorsen for preventing recurrent attacks of hereditary angioedema in people 12 years and over (TA1183)
- Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma (TA1184)
- Acalabrutinib with venetoclax with or without obinutuzumab for untreated chronic lymphocytic leukaemia (TA1185)

National Institute for Health and Care Research (NIHR)
- Interventions to reduce pain at dressing change of chronic wounds: a mixed-methods systematic review - link
- Natalizumab and Tyruko (natalizumab biosimilar) for treating highly active relapsing-remitting multiple sclerosis after at least one disease-modifying therapy: a systematic review and economic model - link

Specialist Pharmacy Services NHS UK
- Using our annual medicines planning publication, Prescribing Outlook - link

The King's Fund (UK)
- What direction for obesity policy? Where innovation, wicked issues and many actors collide - link

UK Health Security Agency
- Addressing health inequalities in infection and antimicrobial resistant infections: a UK-wide collaborative toolkit - link
- Newborn ICU admissions drop 50% in first full year of respiratory syncytial virus (RSV) maternal vaccine programme - link

World Health Organisation (WHO)
- Artificial intelligence-related health research: ethics review and oversight - link

MEDICATION SAFETY

Australian Institute of Health Innovation, Macquarie University
- When enough is enough: antibiotic duration in electronic medication systems- link
- Mind the denuosumab gap - link

electronic Medicines Compendium (eMC) (UK)
- Revised SPCs
-- Arexvy (respiratory syncytial virus vaccine, recombinant, adjuvanted) - each dose contains 0.18 milligrams of polysorbate 80 (E433) which may cause allergic reactions
-- Bunov (buprenorphine) transdermal patches - new data on elimination half-life and interaction warnings with nalmefene and naltrexone. It recommends careful, regular monitoring in long-term pain treatment, and provides guidance on using naloxone to manage buprenorphine overdose
-- Calquence (acalabrutinib) - peripheral oedema added as very common ADR
-- Clopixol (zuclopenthixol) - dysphagia added as rare ADR. It can occur secondary to extrapyramidal symptoms as well to sialorrhoea
-- Eliquis (apixaban) - hemarthrosis added as a potential adverse event (frequency not known)
-- Elrexfio (elranatamab) - increased transaminases during treatment, which may occur with or without cytokine release syndrome. Monitor transaminases and bilirubin at baseline and during treatment, withhold or discontinue treatment according to severity
-- EpiPen Adrenaline (Epinephrine) - cases of QTc prolongation and Torsade de Pointes reported following administration of epinephrine in patients with congenital long QT syndrome or catecholaminergic polymorphic ventricular tachycardia
-- Eylea (aflibercept) - two ADRs included, retinal vasculitis (rare) and retinal occlusive vasculitis (unknown frequency)
-- Nalvee (dydrogesterone) - meningioma or history of meningioma added as a contraindication, as meningiomas (single & multiple) have been linked to dydrogesterone use. Monitor patients for signs & symptoms, and stop treatment if meningioma confirmed. Tumour shrinkage seen after discontinuation
-- Nubeqa (darolutamide) - angioedema added as a new adverse effect (frequency unknown). Symptoms may include rash, erythema, dermatitis, laryngeal oedema, face, lip and tongue swelling
-- Ontozry (cenobamate) - rare cases of severe liver injury with hepatic failure reported in people treated with cenobamate; most cases occurred when used alongside other antiseizure medications. LFTs should be checked before and throughout treatment
-- Osenvelt (denosumab) - storage allowed at temperature up to maximum of 30°C for up to 63 days. It may be returned to refrigerated storage once during this period and used until original expiry date. Discard after 63 days outside refrigeration or at expiry, whichever is sooner

-- Physeptone (methadone) - following ADRs added: hyperalgesia, hepatobiliary disorders, congenital and neuro-developmental impairment associated with opioid use disorder during pregnancy, acute pancreatitis, and sphincter of Oddi dysfunction
-- Recarbrio 500mg/500mg/250mg (cilastatin/imipenem/relebactam) powder for solution for infusion - paediatric population included from birth. Also warning on use in children with known risk factors for seizures or on concomitant treatment with medicinal products lowering the seizure threshold
-- Tetralysal (lymecycline) - cases of fixed drug eruption reported with tetracyclines
-- Tevimbra (tislelizumab) - myocarditis-myositis-myasthenia gravis overlap syndrome added as an uncommon ADR when used with chemotherapy. It warns need for early recognition and aggressive management due to morbidity and mortality risks and advises on treatment modification
-- Wellvone (atovaquone) - severe cutaneous including 'drug reaction with eosinophilia and systemic symptoms' and erythema multiforme added as ADRs
-- Zejula (niraparib tosylate monohydrate) - new study data on off-label Zejula use with dostarlimab in children aged 5 to <18 years with recurrent or refractory solid tumours. Data suggest benefits do not outweigh risks. Zejula remains unsuitable for use for patients under 18 years

Medicines and Healthcare products Regulatory Agency (MHRA) UK
- MHRA reaffirms the safety of childhood vaccination - link

Specialist Pharmacy Services NHS UK
- SPS Medication safety update – July 2026

TGA
- Product Information safety updates - July 2026
- Information about major medicine shortages – link
-- Substitutions available for shortage of dapsone 25 mg tablets - link
-- About the cyclophosphamide and ifosfamide injection shortages - link
- Melanotan II tanning peptide products found to be inconsistently dosed - link
- Established acceptable intake for nitrosamines in medicines - link - link - link

PAPERS OF INTEREST

American Journal of Health-System Pharmacy (AJHP)
- From protocol to practice: Safety interventions based on real-world implementation of the SQuID protocol - link
- Impact of an automated perpetual inventory management system on perioperative and infusion-based pharmacy inventory and operational efficiency - link
- Bridging the continuity: Practice-enhancing publications about the ambulatory care medication-use process in 2025 - link
- Acetazolamide versus metolazone as adjunctive therapy to loop diuretics in hospitalized patients with volume overload: A retrospective cohort study - link
- Association of meds-to-beds delivery with fewer readmissions at an academic medical center - link

Annals of Internal Medicine
- Real-World Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients with Atrial Fibrillation and Mitral Stenosis: A Target Trial Emulation - link
- In the clinic: Inflammatory Bowel Disease - link
- Pharmacologic treatments with lifestyle modifications in nonpregnant adults with overweight or obesity in outpatient settings: a living clinical guideline from the American College of Physicians - link

Arthritis & Rheumatology
- Anifrolumab versus Belimumab for Cardiovascular Disease Risk in Systemic Lupus Erythematosus - link
- Risk of Cancer according to Duration of Targeted Therapy Exposure in Spondyloarthritis: A Nationwide Cohort Study from the French Health Insurance Database - link

British Journal of Clinical Pharmacology

- Glucocorticoid exposure and initiation of SSRIs among patients with rheumatoid arthritis: A nested case–control study in UK primary care - link
- Correlation between severity of myelosuppression caused by piperacillin-tazobactam and factors: Analysis through a multivariate ordered logistic regression mode - link
- Systemic menopausal hormone therapy treatment patterns in Danish women—A nationwide drug utilization study - link
- Current practice and guideline adherence in renal dose adjustment for patients with chronic kidney disease: A systematic review and meta-analysis - link
- The impact of medication shortages on paediatric care: A retrospective impact analysis - link
- Higher anticholinergic burden is associated with increased medium- and long-term mortality following hip fracture: A systematic review and meta-analysis - link

British Journal of Psychiatry
- Psychedelics in psychiatry: from promise to translation - link

BMC Medicine
- Digital patient safety interventions in primary care: a systematic review and meta-analysis - link

British Medical Journal (BMJ)
- Comparative effectiveness of azithromycin versus roflumilast in patients with chronic obstructive pulmonary disease: emulated target trial - link
- Evaluation of patient centred digital adherence technology for tuberculosis treatment outcomes: pragmatic randomised controlled trial - link
- Tirzepatide and the risk of atherosclerotic cardiovascular events: population based cohort study - - link
- Pathways trial of puberty blockers in children to proceed after failed High Court challenge - link
- Evidence based interventions for bipolar disorder across phases and age groups: living umbrella review, evaluation, analysis, and communication hub (U-REACH) project - link
- GLP-1 deaths: Are weight loss drugs linked to hundreds of fatalities? - link
- What do we know about covid-19 and smell loss? - link
- Kambô: as DIY frog toxin kits are sold in the UK, what is the evidence and what are the risks? - link

Canadian Pharmacists Journal
- Pill splitting for sustainability: Reducing the cost and environmental impact of medications - link
- Editorial: AI in pharmacy practice: Is it a doomsday or a dream pill? - link

Circulation
- Bempedoic acid and first and recurrent limb outcomes in statin-intolerant patients with peripheral artery disease: insights from the CLEAR outcomes trial - link
- Effect of semaglutide on the inflammatory biomarker high-sensitivity CRP in patients with established cardiovascular disease and overweight or obesity in SELECT: a prespecified secondary analysis - link

Cochrane
- Timing, frequency, and glycaemic target values for self-monitoring in adults with type 1 diabetes mellitus - link
- First-line systemic treatment for people with extensive-stage small cell lung cancer: a network meta-analysis - link
- Subcutaneous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy - link
- Drug-eluting balloon angioplasty versus uncoated balloon angioplasty for peripheral arterial disease of the lower limbs - link

Critical Care Medicine
- Aggressive Versus Conservative Blood Pressure Reduction in Acute Intracerebral Hemorrhage: A Systematic Review and Meta-Analysis of Randomized Controlled Trials - link

Diabetes, Obesity and Metabolism

- Efficacy and Safety of Once-Weekly Semaglutide 2.0 mg as an Add-On to Dose-Reduced Insulin Glargine versus Dose-Titrated Insulin Glargine in People with Type 2 Diabetes and Overweight (SUSTAIN OPTIMIZE) - link
- Effect of Medications for Type 2 Diabetes on Cardiovascular Events and Mortality: A Comprehensive Pairwise and Network Meta-Analysis - link
- Efficacy and Safety of Oral PCSK9 Inhibitors in Adults with Hypercholesterolemia: An Updated and GRADE Assessed Systematic Review and Meta-Analysis of Randomised Controlled Trials - link

EClinical Medicine
- The effectiveness of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on binge eating in patients with obesity: a systematic review and meta-analysis - link
- Safety of routine antimicrobial prophylaxis for surgery (SAPPHIRE): a prospective multi-centre cohort study - link

European Heart Journal
- Bruton's tyrosine kinase inhibitors and cardiovascular risk: a meta-analysis - link
- Endometriosis and long-term risk of venous thromboembolism: a Danish nationwide study - link
- Temporal comparison of clinical practice and outcomes in heart failure: the JROADHF and JROADHF-NEXT studies - link
- Oral anticoagulants, cognition, and clinical outcomes in atrial fibrillation and Alzheimer's disease: a Swedish nationwide study - link
- Finerenone benefits in patients with cardio-kidney-metabolic syndrome with or without history of cancer: the FINE-HEART pooled analysis - link

European Journal of Hospital Pharmacy
- Spinal muscular atrophy (SMA): early diagnosis, therapy and economic impact - link
- Measuring treatment satisfaction in rare diseases: challenges and opportunities for hospital pharmacy - link
- Improving drug therapy safety through pictograms: opportunities, limitations and future prospects—a survey of healthcare professionals - link

Internal Medicine Journal
- Anticoagulation stewardship team oversight of enoxaparin-warfarin bridging delivered by Hospital in the Home: a pre- and post-implementation study - link
- Dose escalation for secondary loss of response in inflammatory bowel disease: 3-year outcomes and treatment persistence - link
- Adjunctive metformin therapy in type 1 diabetes in pregnancy: insights from an Australian cohort - link
- Australian consensus recommendations for the management of increased meningococcal infection risk in adults with neurological diseases treated with complement inhibitors - link
- Critical role of vaccination in preventing severe coronavirus disease 2019: perspectives from clinical outcomes in an Australian kidney transplant recipient cohort - link
- A retrospective single-centre evaluation of systemic anticancer therapy near the end of life in patients with solid organ malignancies - link

International Journal of Clinical Pharmacy
- Codesigning a pharmacist-led transition of care program in the emergency department: a qualitative participatory study - link
- Medicine shortages and glaucoma care: a time-series analysis indicating population-level consequences of a national timolol eye drop shortage - link
- AI-generated patient information leaflets for oral anticoagulants: quality, usability, readability, and reproducibility compared with FDA-referenced materials - link

International Journal for Quality in Health Care
- Measuring Safer Opioid Use in Hospitals: Development of Consensus-Based Safety and Quality Indicators - a modified Delphi study - link

JAMA
- Osimertinib With or Without Chemotherapy in Advanced Non–Small Cell Lung Cancer with EGFR and Concurrent TP53 Mutations: A Randomized Clinical Trial - link
- Total Intravenous vs Volatile Inhalational Anesthesia for Major Noncardiac Surgery: A Randomized Clinical Trial - link
- JAMA insights: Diagnosis of Celiac Disease - link

JAMA Internal Medicine
- Continuous Glucose Monitoring for Persons With and Without Diabetes - link

JAMA Network Open
- Intravenous Thrombolysis Beyond the Conventional Time Window for Acute Ischemic Stroke: A Systematic Review and Meta-Analysis - link

JAMA Pediatrics
- Effectiveness of Oseltamivir in Hospitalized Children with Laboratory-Confirmed Influenza, 2014-2023 - link

Journal of Clinical Endocrinology and Metabolism
- Central precocious puberty: an Endocrine Society clinical practice guideline - link

Lancet Infectious Diseases
- Guiding principles for pragmatic randomised trials of tuberculosis treatments - link

Lancet Psychiatry
- New clozapine regulations, old inequalities? - link

Molecular Diversity Preservation International (MDPI) – Pharmacy Journal
- A Retrospective Cohort Study to Optimize Piperacillin/Tazobactam Dosing in Routine Intensive-Care Patients via a Newly Designed Clinical Pharmacy Service Including TDM- and Algorithm-Based Recommendations - link
- The Implementation and One-Year Evaluation of a Pre-Admission Pharmacist for Obstetric Admissions - link
- Frequency and Profiles of Drug Combinations Constituting the Triple Whammy in Japan: An Analysis of a Patient Estimation Database - link

Medical Journal of Australia
- Estimating Eligibility for GLP-1 Receptor Agonists for Chronic Weight Management and Cardiovascular Disease in Australia: Cross-Sectional Analysis of National Health Survey Data - link
- Watchful Waiting Compared With Immediate Antibiotics for Urban Aboriginal and Torres Strait Islander Children With Uncomplicated Acute Otitis Media (WATCH): A Non-Inferiority Randomised Controlled Trial - link

New England Journal of Medicine
- Syncope - link

Obesity Surgery
- Optimal Timing of GLP-1 Receptor Agonist Initiation in Patients with Obesity Eligible for Metabolic Bariatric Surgery - link

Pediatrics (American Academy of Pediatrics)
- Early Antiviral Therapy in Pediatric Outpatients and Risk of Influenza-Related Hospitalization - link

Pharmaceutical Journal
- Antihistamine prescribing increased by 18% in five years - link
- How pharmacists are storing medicines in soaring temperatures - link

Pharmacotherapy
- Focused Update to International Consensus Recommendations for the Use of Prolonged-Infusion Beta-Lactam Antibiotics Among Severely Ill Adult Patients: Endorsed by the American College of Clinical Pharmacy, British Society for Antimicrobial Chemotherapy, Cystic Fibrosis Foundation, European Society of Clinical Microbiology and Infectious Diseases, Infectious Diseases Society of America, Society of Critical Care Medicine, and Society of Infectious Diseases Pharmacists - link

Thorax
- Effect of maintenance macrolide de-escalation during the Australian summer on exacerbations of obstructive airway diseases: a randomised, double-blind, placebo-controlled trial - link

CONSULTATIONS

Australian Commission on Safety and Quality in Health Care (ACSQHC)
- National Safety and Quality Assisted Reproductive Technology Service Standards – closes 6 September - link
- NSQHS Standards (third edition) - closes Friday 25 September - link

TGA
- Consultation: Seeking feedback on improvements to the Therapeutic Goods Advertising Code - closes on 3 September 2026 - link
- Consultation: Proposed changes to Required Advisory Statements for Medicine Labels (RASML) - closes on 4 September 2026 - link
- Consultation: Adoption of International Scientific Guidelines in Australia R01-2026 - Closes on 11 September 2026 - link
- Additional public consultation on amending the Poisons Standard regarding ethylene oxide, propylene oxide and epichlorohydrin - closes on 26 October 2026 - link

WEBINARS & PODCASTS

Australian Prescriber Podcasts
- E220 | Treatment of acute COVID-19 in the community

MJA Podcasts
- Who is eligible for GLP1-RAs in Australia? - link

Purple Pen Podcast
- PPP 195 - Otitis Media

UPCOMING EVENTS

Advanced Pharmacy Australia
- Medicines Management MM2026, 22-24 October 2026, Brisbane Convention & Exhibition Centre - Early Bird registration open until 9 September

Australian Commission on Safety and Quality in Health Care (ACSQHC)
- Registrations open – National Medicines Symposium NMS 2026, 'Medicines stewardship: safer use starts with all of us' - Wednesday, 11 November 2026 - register

Safer Care Victoria
- From project to practice: Creating lasting improvements in VTE prevention through collaboration and learning - 3 Sep 2026 13:00-14:00 - register

Fortnightly TAG Mail – resources list 6th August 2026

NSW TAG ACTIVITIES

TAG Mail
Searching Cumulative TAG Mail listings: Remember to search Cumulative TAG Mail listings, which are collated in 6 months batches from 2023. These cumulative listings are useful to survey whenever you have a medicine or condition you wish to explore as TAG mail covers the grey literature as well as the traditional academic literature. Just 'Control F' relevant terms to search for your query.

Upcoming NSW TAG meeting dates
NSW TAG General members' Meeting: 19th August 2026 12-1pm
Contact Sasha Bennett at sasha.bennett@svha.org.au for information about any email discussions, publications or upcoming meetings.

EDITOR'S PICKS

ARD: Cancer risk of JKis and advanced therapies in immune-mediated inflammatory diseases- link
BJCP: Environmental impact of antidepressants: Is a new prescription framework possible? - link
BJCP: MT-RNR1 genotype testing for preventing aminoglycoside-mediated ototoxicity - link
BJCP: Efficacy and safety of cannabinoids in the treatment of spasticity in multiple sclerosis - link
BJCP: Review of safety outcomes of antidiabetic medications in medical reference documents- link
BMJ: Early rasburicase and risk of kidney replacement therapy and death in adults with TLS - link
BMJ: Antihistamines for atopic dermatitis (eczema) - link
CMAJ: CV and renal outcomes of combined SGLT2 inhibitors and GLP-1 receptor agonists vs monotherapy in patients with T2DM - link
EJHP: Managing home-stored refrigerated medicines following a prolonged power outage - link
IMJ: Pharmacogenomic guidance in Australian prescribing resources vs international pharmacogenomic guidelines - link
IMJ: Dose-escalated biologic therapy improves outcomes in people with IBD - link
IJAA**:** Pharmacists in OPAT: a systematic review and meta-analysis - link
IJCP**:** Patient perspectives and experiences of collaborative pharmacist prescribing in the hospital inpatient setting - link
IJCP: AI-generated patient information leaflets for oral anticoagulants: quality, usability, readability, and reproducibility compared with FDA-referenced materials - link
IJCP: Prioritising medication management criteria to identify ED patients with potential medication-related harm - link
IJCP: Comparison of existing polypharmacy measures to a measure incorporating all modes of administration - link
IJCP: Cost-effectiveness of first-line pembrolizumab monotherapy in PD-L1–high metastatic NSCLC in Australia - link
JAMA NO: Tamsulosin Deprescribing for Lower Urinary Tract Symptoms in Older Men - link
JAGS: Interventions to Optimize Medication Management in Older Adults - link
JPPR: Advanced Pharmacy Australia Emergency Medicine Standards - link
JPPR: A real-world analysis of AI chatbot performance for medicines information enquiries - link
Lancet Psych: Clozapine and GLP-1 receptor agonists: an underrated gastrointestinal safety risk - link
MDPI:The Risks to Patients Associated with Using AI Tools in Pharmacy Practice - link
MDPI: Factors Influencing Phenoconversion in CYP-Mediated Drug Metabolism - link
PJ**:** How pharmacists can transform prescribing safety in psychiatry - link
P'therapy: Consensus Guidance for Beta-Lactam Antibiotic Dose Individualization in Acutely Ill Patients - link
T&H: Discontinuation of Oral Anticoagulation After Successful Catheter Ablation for AF- link

OTHER NEWS

Australian Commission on Safety and Quality in Health Care (ACSQHC)
- Stroke Clinical Care Standard - 2026 update
- 2026 National Model for Clinical Governance - link
- 'Sip Til Send' - Improving pre-procedural fluid management - link
- New national guidance for the safe, appropriate and sustainable use of intravenous (IV) fluids - link

REPORTS AND PUBLICATIONS – AUSTRALIA

Agency for Clinical Innovation, NSW (ACI)
The latest weekly Evidence Digest can be found here
- ADHD reforms update 2026-07-28

Australian Commission on Safety and Quality in Health Care (ACSQHC)
- Australian Passive AMR Surveillance: Resistance trends in Streptococcus pneumoniae – 2006 to 2025 - link

Australian Institute for Health and Welfare (AIHW)
- Injuries occurring among admitted patients - link
- Injury hospitalisations among health care workers - link
- Dementia in Australia - update

Macquarie University
- Don't Walk. Run. AI in healthcare - The 3rd National Policy Roadmap - link

MIMS monthly updates
- New Products
-- Pegunigalsidase alfa (Elfabrio) concentrate for infusion 20 mg per 10 mL for long-term enzyme replacement therapy in adult patients with a confirmed diagnosis of Fabry disease
-- Tafasitamab (Minjuvi) is indicated (with provisional approval) for adults with relapsed or refractory DLBCL who are not eligible for autologous stem cell transplant (ASCT) and in combination with rituximab and lenalidomide for adults with relapsed or refractory FL (Grade 1-3a). It is not indicated and is not recommended for the treatment of patients with relapsed or refractory marginal zone lymphoma outside of controlled clinical trials. See lenalidomide and rituximab product information for the contraindications to combination therapy. Minjuvi powder for infusion contains tafasitamab 200 mg and is available in packs of 1 vial. Each vial contains 40 mg/mL of tafasitamab after reconstitution
- New Indications
-- Belzutifan (Welireg) for adults with advanced renal cell carcinoma (RCC) with a clear cell component following a programmed cell death 1/ligand 1 (PD-1/L1) and a vascular endothelial growth factor (VEGF)-targeted therapy
-- Lutetium (177Lu) vipivotide tetraxetan (Pluvicto) for adults with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor pathway inhibitor (ARPI) therapy, and are considered appropriate to delay taxane-based chemotherapy, or have received prior taxane-based chemotherapy
-- Odevixibat (sesquihydrate) (Bylvay) is now also indicated for the treatment of cholestatic pruritus in Alagille syndrome (ALGS) in patients aged 6 months or older

TGA
- Adoption of International Scientific Guidelines in Australia - R01/2025 - link
- Database of section 19A approvals to import and supply medicines to address medicine shortages
- Australian prescription medicine decision summaries:
-- Tzield (teplizumab) is indicated to delay the onset of Stage 3 type 1 diabetes mellitus in adult and paediatric patients aged 8 years and older with Stage 2 type 1 diabetes mellitus

REPORTS AND PUBLICATIONS – INTERNATIONAL

Canadian Agency for Drugs and Technologies in Health
- New Hematological Malignancies in Recipients of CAR T-cell Therapies - link

Courts and Tribunals Judiciary UK
- Prevention of future deaths report – Coroner raises awareness around clozapine and smoking cessation - link

electronic Medicines Compendium (eMC) (UK)
- New products

-- Brulidine (dibrompropamidine isethionate) 0.15 %w/w Cream - Topical antibacterial to treat a range of skin conditions including surface infections, ringworm of the scalp, pyodermias, otitis externa and nappy rash. Also for use as first aid dressing for minor burns, scalds, abrasions & other open injuries
-- Doxazosin 0.4 mg/ml Oral Suspension - for hypertension and benign prostatic hyperplasia
-- Remsima (infliximab) 40mg/1ml concentrate for Solution for infusion vial – for rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriasis and psoriatic arthritis. It contains sorbitol and is contra-indicated in patients with hereditary fructose intolerance
-- Skyrizi (risankizumab) 55 mg solution for injection in pre-filled syringe - new presentation for moderate to severe plaque psoriasis in children and adolescents from the age of 6 years who are candidates for systemic therapy. The SPCs for other risankizumab products updated accordingly
-- Steqeyma (ustekinumab) 45mg and 90mg Solution for injection pre-filled pen – new formulation
-- Tolterodine tartrate 2mg/5ml Oral Suspension – for symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in patients with overactive bladder syndrome
-New indications/Extended indications
-- Braftovi (encorafenib) 50 mg hard capsules - new indication for use in combination with binimetinib for adult patients with advanced non-small cell lung cancer with a BRAF V600E mutation
-- Comirnaty 10 micrograms/dose dispersion for injection - extension of the approved indication to include infants and children aged 6 months to 11 years
-- Dapagliflozin - prolonged ketoacidosis and prolonged glucosuria have been seen with dapagliflozin, and that ketoacidosis may last longer after discontinuation than expected from the plasma half-life
-- Feraccru (ferric maltol) 30mg hard capsules - license extension to include use for the treatment of iron deficiency in adults and adolescents aged 12 years and older (previously adults only). Should not be used in children <12 years of age, as the capsules do not allow appropriate dosing
-- Noxafil (posaconazole) gastro-resistant tablets, concentrate for solution for infusion & gastro-resistant powder and solvent for oral suspension - treatment and prophylaxis indications extended to paediatric patients aged ≥2 years for the concentrate for infusion and gastro-resistant oral suspension formulations. The gastro-resistant tablet indication now also includes children aged ≥2 years weighing >40kg

European Medicines Agency (EMA)
- CHMP meeting highlights July 2026
-- positive opinion to update Covid-19 vaccine composition - link
-- negative opinion three new medicines (sufentanil / ketamine, arimoclomol citrate, catequentinib)
-- approval of 8 new medicines (obicetrapib/ezetimibe, icotrokinra hydrochloride, linerixibat, lerodalcibep, leriglitazone, ranibizumab implant, obicetrapib, ensitrelvir), a pegfilgrastim biosimilar, and three generic medicines
-- license extensions for 8 medicines (trastuzumab deruxtecan, damoctocog alfa pegol, alpelisib, evolocumab, upadacitinib, Riltrava Aerosphere, Trixeo Aerosphere, and sacituzumab govitecan)

Food and Drug Administration (FDA) USA
- New Drug approvals
-- First Nonprescription Fixed-Dose Combination of Acetaminophen and Naproxen Sodium for 12-Hour Pain Relief - link
-- Gwyn Lo - New Once-Weekly Birth Control patch
-- lutetium Lu 177 vipivotide tetraxetan with androgen receptor pathway inhibitor therapy for metastatic androgen pathway modulation-naïve or -sensitive prostate cancer
-- Lytenava (bevacizumab-vikg) to treat patients with neovascular (wet) age-related macular degeneration – label-PI - letter
-- Orzeyful (oveporexton) to treat narcolepsy type 1 - letter
-- Simtriyo (centanafadine) to treat attention-deficit hyperactivity disorder
-- vusolimogene oderparepvec-wtpg in combination with nivolumab for melanoma
-- Jideytro zidesamtinib for ROS1-positive non-small cell lung cancer

General Pharmaceutical Council UK
- New revalidation resources for pharmacists and pharmacy technicians … including a statement providing clarity on use of AI - link

Medicines and Healthcare products Regulatory Agency (MHRA)
- Approves remibrutinib for adults with chronic spontaneous urticaria - link
- Thousands of patients to benefit from new daily pill (aficamten) for serious heart condition following co-ordinated MHRA and NICE decisions - link
- Ambient voice technology-enabled products … including AI scribes - link
- Beat the heat: MHRA urges people to take extra care with medical devices this summer - link

Menopause UK
- Premature menopause is associated with the development of high blood pressure: a UK Biobank cohort study - link

Monthly Index of Medical Specialities (MIMS) UK
- Higher-dose Wegovy (semaglutide) tablets launched - 9mg and 25mg tablets can now be obtained by eligible patients through private providers for weight management, following the launch of the 1.5mg and 4mg tablets in July. Patients currently prescribed the 2.4mg weekly injection can be transitioned straight to the 25mg tablets - link

National Infusion and Vascular Access Society (NIVAS) UK
- Clinical Standards for Vascular Access & Infusion Therapy: First Edition 2026 - link

NHS England
- Clinical commissioning policy: Pasireotide for the treatment of Cushing's disease - link
- Thousands with multiple sclerosis (MS) to get "life-changing" drug (fampridine) on NHS to help them walk more freely - link
- Sickle cell and thalassaemia eLearning resources - link
- Sepsis modern service framework - link

National Institute for Health and Care Excellence (NICE) UK
- Low back pain and sciatica in over 16s: assessment and management – update (NG59)
- Osteoporosis: risk assessment (NG259)
- Acne vulgaris: management - update (NG198)
- Epilepsies in children, young people and adults – update (NG217)
- Finerenone for treating chronic heart failure with preserved or mildly reduced ejection fraction (TA1182)
- Aficamten for treating symptomatic obstructive hypertrophic cardiomyopathy (TA1181)
- DMD Care UK's guideline on orthopaedic care: NICE review (NR4)
- Harnessing the potential of AI to bring real benefits for patients - link

Specialist Pharmacy Services NHS UK
- Updated reproductive health PGDs - link
- Legal mechanisms to supply and administer medicines to individuals - link
- Medicine administration by registered and non-registered staff - link
- Preparing to use ustekinumab biosimilar - link

UK Health Security Agency
- National measles guidelines - update - link
- Respiratory syncytial virus (RSV) vaccine: Patient group direction (PGD) template ; Vaccine group direction (VGD) template ; BCG Vaccine AJV – PGD ; PCV (13-valent or 15-valent, adsorbed) - PGD ; Pneumococcal polysaccharide conjugate vaccine (PCV20) - PGD

World Health Organisation (WHO)
- Preparedness and response to bacterial meningitis outbreaks: Toolkit for frontline healthcare workers - link
- Risk reduction of cognitive decline and dementia: WHO guidelines, second edition - link

MEDICATION SAFETY

Australian Institute of Health Innovation series, Macquarie University
- Issue 37: Mind the denosumab gap: residents put at risk of fracture due to dose delays
- Issue 36: Don't be naïve to the dangers of fentanyl patches
- Issue 35: Decisions, decisions! Reducing alert fatigue through alternative decision support strategies

Australian and New Zealand College of Anaesthetists (ANZCA) & Faculty of Pain Medicine
- Propofol infusion leakages - link
- Essential medicines list - link

electronic Medicines Compendium (eMC) (UK)
- Revised SPCs
-- Alecensa (alectinib) - hypertriglyceridaemia added as common ADR, with dose-modification guidance and warning that severe cases, including life-threatening acute pancreatitis, have been reported. Triglyceride levels should be monitored before and during treatment
-- Braftovi (encorafenib) 50 mg hard capsules - new indication for use in combination with binimetinib for adult patients with advanced non-small cell lung cancer with a BRAF V600E mutation
-- Comirnaty 10 micrograms/dose dispersion for injection - extension of the approved indication to include infants and children aged 6 months to 11 years
-- Feraccru (ferric maltol) 30mg hard capsules - license extension to include use for the treatment of iron deficiency in adults and adolescents aged 12 years and older (previously adults only). Should not be used in children <12 years of age, as the capsules do not allow appropriate dosing
-- Fostair (formoterol fumarate dihydrate, beclometasone dipropionate) 200/6 micrograms[NH3.1] per actuation pressurised inhalation solution (WITHOUT dose counter) - recommendation for patients to test the inhaler (priming), before using the inhaler for the first time or if the inhaler has not been used for 14 days or more. The counter should read 121 or 180 prior to priming, and 120 or 180 after priming
-- Jeraygo (aprocitentan) - hormonal contraceptive interaction data from study ID-080-111; co-administration increased ethinyl estradiol Cmax by 21%, levonorgestrel Cmax by 38%, and levonorgestrel AUC by 26%, with corresponding updates to fertility, pregnancy and lactation guidance
-- Keytruda (pembrolizumab) solution for injection – addition of information on myocarditis myositis myasthenia gravis overlap syndrome, noting that cases with fatal outcomes have been observed. Treatment modifications for patients with the overlap syndrome have also been added
-- Lynkuet (elinzanetant) - for adult female patients with moderate to severe vasomotor symptoms caused by adjuvant endocrine therapy related to breast cancer
-- Korserdu (elacestrant dihydrochloride) - reduced dose of 86mg once daily for patients with severe hepatic impairment (Child-Pugh C); Korserdu is available as an 86mg tablet
-- Kytril (granisetron hydrochloride) - warnings on serotonin syndrome with concomitant buprenorphine and opioid administration
-- Metyrol XL (methylphenidate) MR hard capsules - various changes, including information on diagnosis, pre-treatment screening (height and weight to be recorded), updated sections on dose titration, long-term use, reproductive and developmental toxicity, and text on priapism added
-- Nicotinell (nicotine bitartrate dihydrate) – atrial fibrillation added as ADR with frequency unknown
-- Nifedipress MR (nifedipine) - nifedipine should not be used during pregnancy unless the clinical condition of the woman requires treatment with nifedipine (previously contra-indicated). It should be reserved for women with severe hypertension who are unresponsive to standard therapy
-- Norditropin FlexPro (somatropin) pre-filled injection pen updated for post-marketing "osteonecrosis of femoral head" signal as important identified risk endorsed by Novo Nordisk safety committee
-- Noxafil (posaconazole) 40mg/ml oral suspension - for adults only. Data show the suspension did not consistently achieve the target exposure in paediatric patients, hence no paediatric dosing recommendation can be made for this formulation
-- Oyavas (bevacizumab) - hyaline occlusive glomerular microangiopathy added as ADR of unknown frequency with warning from post-marketing data that this may be clinically manifested as proteinuria
-- Qaialdo (spironolactone) 10 mg/ml oral suspension - formulation is suitable for administration via nasogastric (NG) feeding tubes
-- Spexotras (trametinib dimethyl sulfoxide) - potentiation of radiation toxicity (common frequency) added as ADR in adult patients treated with trametinib tablets and dabrafenib capsules
-- Tecentriq (atezolizumab) - anaemia added as an ADR with common frequency

-- Valtrex (valaciclovir) Tablets – acute generalised exanthematous pustulosis and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) added as 'very rare' ADRs and Toxic epidermal Necrolysis (TEN) and Stevens–Johnson syndrome (SJS) added with 'frequency not known'
-- Vyepti (eptinezumab) - new immunogenicity section discussing the incidence of anti-drug antibodies and neutralising antibodies, with incidence across studies of 15.4% and 6.3%, respectively
-- Vyndaqel (tafamidis meglumine) - co-administration of tafamidis meglumine with substrates of the breast cancer resistance protein (BCRP) may increase BCRP substrate exposure. If used concurrently, monitor for BCRP substrate-related adverse reactions and consider dose reduction
-- Xromi (hydroxycarbamide) - limbal stem cell deficiency (LSCD), a rare sight-threatening ocular condition added as ADR. If LSCD is suspected, patient should be referred to an appropriate eyecare specialist. Frequency of LSCD is documented as not known
-- Yervoy (ipilimumab) - addition of Myocarditis-Myositis-Myasthenia Gravis Overlap Syndrome (TMOS) as an uncommon side effect. Early recognition & aggressive management is advised. Treatment modification guidance for those who experienced Grade 2-4 events is provided
- Risk minimisation materials
-- Avacopan Vifor, previously Tavneos (avacopan)▼: updated requirements for liver monitoring and stopping rules to mitigate risk of drug-induced liver injury and vanishing bile duct syndrome - letter
-- Ferinject (ferric carboxymaltose) Venofer (iron sucrose) - separate healthcare professional and patient educational material providing important safety information and risk minimisation guidance to support the safe and effective use, in accordance with the approved Risk Management Plan
-- Ogsiveo (nirogacestat) film-coated tablets - contraindicated in pregnant women and in women of childbearing potential not using highly effective contraception. Materials include a healthcare professionals guide describing recommendations for reducing or preventing important risks of embryo-fetal toxicity
-- Paracetamol (B.Braun Medical) - Materials include a dosing card and poster, regarding the risk of medication errors leading to accidental overdose. The poster includes a table outlining the dose and volume per administration, maximum daily dose, and appropriate IV container for different age groups

Health Canada – MedEffect Notice
- Health Product InfoWatch, July 2026 includes
-- Carbamazepine and oxcarbazepine oral suspensions and the risk of propylene glycol toxicity in neonates and young children

Medicines and Healthcare products Regulatory Agency (MHRA) UK
- Bladder Anticholinergics: review of risk of dementia - link
- No Summer Shortcut for Safe Weight Loss - link
- MHRA Safety Roundup: July 2026

MIMS monthly updates
- New Contraindications
-- Cyproheptadine hydrochloride (sesquihydrate) (Periactin) in children under 6 years of age because of the potential for fatal respiratory depression, psychiatric and CNS (central nervous system) events

Specialist Pharmacy Services NHS UK
- Managing the risks of using liquid oral phenobarbital - link
- Reviewing medicines use in renal impairment - link
- Responding to medication safety alerts and notifications - link

TGA
- Information about major medicine shortages – link
- TGA review of the benefits and risks of TAVNEOS (avacopan)
- GLP-1 RAs and rare, but severe, eye disorders - link
- GLP-1 RAs and rare vision disorder - link

PAPERS OF INTEREST

American Journal of Health-System Pharmacy (AJHP)

- Impact of a medication history software on a pharmacy-driven admission medication history and reconciliation program - link

Annals of Internal Medicine
- Public Policy Approaches to Addressing Adult Obesity: A Position Paper From the American College of Physicians - link

Annals of the Rheumatic Diseases
- Cancer risk of Janus kinase inhibitors and other advanced therapies in immune-mediated inflammatory diseases: a systematic review and Bayesian network meta-analysis of RCTs - link

Australian Prescriber
- Treatment of acute COVID-19 in the community - link
- High prevalence of syphilis in Australia: test, treat and trace - link
- Rheumatic fever and rheumatic heart disease: updates for clinical practice - link
- Acne vulgaris: a clinical update - link
- Antibiotic prophylaxis for dental procedures: an update - link
- Latest news: Consumer Medicines Line closure - link
- TGA Medicines Safety Update summary
-- Tranexamic acid: risk of serious adverse events after inadvertent spinal administration – link
-- Be alert to FluMist (influenza nasal vaccine) indicated age range - link

British Journal of Clinical Pharmacology
- Exposure to CYP2C19-metabolized drugs following acute stroke: A longitudinal cohort study to inform implementation of CYP2C19 genotype testing - link
- HLA-B*15:21 carrier status is a susceptibility factor of carbamazepine-induced nonimmediate cutaneous adverse reactions in HLA-B*15:02-negative patients: A retrospective cohort study - link
- Environmental impact of antidepressants: Is a new prescription framework possible? - link
- MT-RNR1 genotype testing for preventing aminoglycoside-mediated ototoxicity: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx) - link
- Efficacy and safety of cannabinoids in the treatment of spasticity in multiple sclerosis: A systematic review of randomized clinical trials - link
- Mobile health interventions to improve adherence to oral anticoagulant treatment: A systematic review and critical analysis - link
- Safety outcomes of antidiabetic medications: A comprehensive review of the EU summaries of product characteristics and international clinical practice guidelines - link

British Journal of General Practice
- Management and long-term serum urate control in gout: a population-based primary care cohort study - link

British Journal of Psychiatry
- Escitalopram and brain reactivity to aggressive stimuli in premenstrual dysphoric disorder - link

British Medical Journal (BMJ)
- Risk of hair loss associated with glucagon-like peptide-1 receptor agonists in adults with type 2 diabetes: target trial emulation - link
- Early treatment with rasburicase and risk of kidney replacement therapy and death in adults with tumour lysis syndrome: emulated target trial - link
- Fertility problems: assessment and treatment—summary of updated NICE guidance - link
- AI might help the NHS—but we need to build the evidence - link
- Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis - link
- Investigation and management of breakthrough ischemic stroke in anticoagulated patients with atrial fibrillation - link
- How to keep medicines safe during a heatwave - link

- Recognising and managing polymyalgia rheumatica - link
- Antihistamines for atopic dermatitis (eczema): systematic review and network meta-analysis of randomised trials - link
- Antithrombotic treatment for migraine in patients with patent foramen ovale: multicentre, randomised, active controlled, open label trial – link
- Fact check: Does Mounjaro cause hair loss? – link
- Balancing cancer innovation with sustainable care - link

Canadian Medical Association Journal (CMAJ)
- Cardiovascular and renal outcomes of combined SGLT2 inhibitors and GLP-1 receptor agonists versus monotherapy in patients with type 2 diabetes mellitus: a network meta-analysis - link

Circulation
- Incidence and Predictors of Extracranial Bleeding on Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation: A COMBINE-AF Analysis - link

Clinical Journal of Pain
- A Systematic Review and Meta-Analysis of Pharmacological and Physical Interventions Directed at the Injection Site for Reducing Distress During Vaccine Injections - link

Cochrane
- (Ultra-)short-acting insulin analogues for adults with type 1 diabetes mellitus on multiple daily injections: a network meta-analysis - link
- Timing, frequency, and glycaemic target values for self-monitoring in adults with type 1 diabetes mellitus - link
- Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced epithelial ovarian cancer - link

Diabetes, Obesity and Metabolism
- Comparative Efficacy of Insulin Delivery Modalities on Glycaemic Control in Adults With Type 2 Diabetes: A Systematic Review and Network Meta-Analysis - link

Drug and Therapeutics Bulletin
- DTB Select: Discontinuation of levothyroxine in older adults - link
- Management of urogenital gonococcal infection - link

European Heart Journal
- Cardiovascular risk–prediction models in cancer survivors: a meta-analysis - link
- Side effects in hypertension treatment: a pharmacogenomic analysis - link

European Journal of Hospital Pharmacy
- Managing home-stored refrigerated medicines following a prolonged power outage: lessons for hospital pharmacy practice - link

Internal Medicine Journal
- Hypophosphataemia following iron infusion: a narrative review of an increasingly recognised complication - link
- Dose-escalated biologic therapy improves outcomes in people with inflammatory bowel disease - link
- Vitamin B6: too much, too little, too late? An analysis of sales trends in Australia from 2023 to 2025 - link
- Comparison of pharmacogenomic guidance in Australian prescribing resources and international pharmacogenomic guidelines - link

International Journal of Antimicrobial Agents
- Pharmacists in OPAT: a systematic review and meta-analysis - link

International Journal of Clinical Pharmacy
- Patient perspectives and experiences of collaborative pharmacist prescribing in the hospital inpatient setting: a cross-sectional survey - link
- AI-generated patient information leaflets for oral anticoagulants: quality, usability, readability, and reproducibility compared with FDA-referenced materials - link
- Prioritising medication management criteria to identify emergency department patients with potential medication-related harm: Nominal Group Technique workshops with clinicians - link
- Comparative clinical evaluation of endothelin receptor antagonists in pulmonary arterial hypertension using a multi-criteria decision analysis framework - link
- Comparison of existing polypharmacy measures to a measure incorporating all modes of administration: an observational study using routinely collected data - link
- Global burden and future trends of type 2 diabetes mellitus-associated chronic kidney disease: analysis of the Global Burden of Disease Study 2021 - link
- Cost-effectiveness of first-line pembrolizumab monotherapy in PD-L1–high metastatic non-small cell lung cancer in Australia: evidence from trials and real-world practice - link
- Active surveillance and risk prediction of piperacillin/tazobactam-associated hypokalaemia: development and external validation of a clinical nomogram - link

JAMA
- Gastroparesis: A Review - link ; JAMA review: Classic Hodgkin Lymphoma - link
- JAMA Patient Page: What Is Cyclosporiasis? - link ; What Is Male Hypogonadism? - link
- JAMA Clinical Guidelines Synopsis: Ulcerative Colitis Management in Adults - link
- Long-Term Outcomes of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Peripheral Artery Disease and Type 2 Diabetes - link
- Global Burden of Elevated LDL-C: Findings From the Global Burden of Disease Study 2023 - link
- JAMA Insights: Sleep Health and Obesity - link ; Nicotine Pouches - link
- Dapagliflozin and Acute Kidney Injury Following Cardiac Surgery - A Randomized Clinical Trial - link
- Nicotine E-Cigarettes for Cigarette Smoking Cessation - Recommendations to US-Based Clinicians - link
- Initial HIV Therapy for Adults and Treatment-Associated Weight Gain: The Opti-DOR Randomized Clinical Trial – link
- Addition of High-Dose Vitamin D3 to Standard Treatment in Patients With Metastatic Colorectal Cancer: The SOLARIS Randomized Clinical Trial (Alliance A021703) - link

JAMA Internal Medicine
- Continuous Glucose Monitoring in Type 2 Diabetes and Beyond: A Review - link
- Estimated Effectiveness of 2024-2025 COVID-19 Vaccines in Adults - link

JAMA Network Open
- Tamsulosin Deprescribing for Lower Urinary Tract Symptoms in Older Men: A Randomized Clinical Trial - link

Journal of the American Geriatrics Society
- Interventions to Optimize Medication Management in Older Adults: An Umbrella Review of Systematic Review - link

Journal of Antimicrobial Chemotherapy
Ceftaroline and ceftobiprole monotherapy for the treatment of Staphylococcus aureus infections: a systematic review and Bayesian meta-analysis - link

Journal of Pharmacy Practice and Research (JPPR)
- Advanced Pharmacy Australia Emergency Medicine Standards - link
- A real-world analysis of AI chatbot performance for medicines information enquiries - link
- Feasibility and fidelity of beta-lactam antibiotic therapeutic drug monitoring in critically ill adults with sepsis: a pilot randomised controlled trial - link
- Therapeutic-dose verapamil-induced cardiogenic shock in an older patient: a case report - link

Lancet
- High-dose chemotherapy followed by autologous stem-cell transplantation versus non-myeloablative consolidation in primary CNS lymphoma (MATRix/IELSG43): a randomised phase 3 trial - link
- Seminar: Psoriasis - link

Lancet Diabetes & Endocrinology
- Type 1 diabetes in older populations - link

Lancet Infectious Diseases
- Effectiveness of nirsevimab immunisation on invasive pneumococcal disease in children nationwide in France: an observational cohort study - link
- Effectiveness of scabies treatments in Italy (SCAB-net): a prospective observational study - link

Lancet Psychiatry
- Clozapine and GLP-1 receptor agonists: an underrated gastrointestinal safety risk - link

Lancet Public Health
- Estimating optimal levels of WHO Access, Watch, Reserve (AWaRe) antibiotic use in 186 countries, territories, and areas on the basis of clinical infection and resistance burden - link

Molecular Diversity Preservation International (MDPI) – Pharmacy Journal
- The Risks to Patients Associated with Using Artificial Intelligence Tools in Pharmacy Practice: A Scoping Review - link
- Factors Influencing Phenoconversion in CYP-Mediated Drug Metabolism: A Scoping Review - link

Medical Journal of Australia
- Still Treating Yesterday's Risk? Reconsidering Antiviral Use for Mild-to-Moderate COVID-19 Cases in a Broadly Immune Population – link
- Australian Pathways for Specialist Pain Management and Early Palliative Care for People With Pancreatic Cancer: Developed Using a Community Consensus Approach - link

Nature Medicine
- A meta-analysis of the long-term effects of antihypertensive therapy on the risk of major cardiovascular disease across 51 randomized trials - link

New England Journal of Medicine
- Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer - link
- Phase 3 Trial of Weekly Oral Islatravir–Lenacapavir for HIV-1 Treatment - link

Obesity Reviews
- Incretin-Based Medications in Women and Reproduction: A Systematic Scoping Review and Consensus Guidelines for Clinical Practice - link

Obstetrics and Gynecology
- Glucagon-Like Peptide-1 Receptor Agonists and Risk of Adverse Maternal Pregnancy Outcomes: A Systematic Review and Meta-analysis - link

Pharmaceutical Journal
- How pharmacists can transform prescribing safety in psychiatry - link

Pharmacotherapy
- Consensus Guidance for Beta-Lactam Antibiotic Dose Individualization in Acutely Ill Patients: Endorsed by the American College of Clinical Pharmacy, European Society of Clinical Microbiology and Infectious Diseases, European Society of Clinical Microbiology and Infectious Diseases PK/PD of Anti-Infectives Study Group, Infectious Diseases Society of America, International Association of Therapeutic Drug Monitoring and Clinical Toxicology, Society of Critical Care Medicine, and the Society of Infectious Diseases Pharmacists - link

Prescrire International - Issue 283 July 2026 includes
- Elafibranor (Iqirvo°) in primary biliary cholangitis
- In-utero exposure to mesalazine: renal disorders, haematological disorders and possibly malformations
- GLP-1 agonists: thyroid cancer (continued)
- Extending drug shelf life: potential economic and environmental benefits
- Biosimilar drugs: consultation on streamlining their development and evaluation

Thrombosis and Haemostasis
- Discontinuation of Oral Anticoagulation After Successful Catheter Ablation for Atrial Fibrillation: Meta-Analysis of Randomized Clinical Trials - link

CONSULTATIONS

Australian Commission on Safety and Quality in Health Care (ACSQHC)
- Requirements for Haemopoietic Cellular Therapy – closes Wednesday 12 August - link
- NSQHS Standards (third edition) - closes Friday 25 September - link

TGA
- Consultation: Proposed changes to the Permissible Indications Determination - closes on 12 August 2026 – link
- Consultation: Seeking feedback on improvements to the Therapeutic Goods Advertising Code - closes on 3 September 2026 - link
- Consultation: Proposed changes to Required Advisory Statements for Medicine Labels (RASML) - closes on 4 September 2026 - link
- Consultation: Adoption of International Scientific Guidelines in Australia R01-2026 - Closes on 11 September 2026 - link

UPCOMING EVENTS

Advanced Pharmacy Australia
- Medicines Management MM2026, 22-24 October 2026, Brisbane Convention & Exhibition Centre - Early Bird registration open until 9 September

Australian Commission on Safety and Quality in Health Care (ACSQHC)
- Registrations open – National Medicines Symposium NMS 2026, 'Medicines stewardship: safer use starts with all of us' - Wednesday, 11 November 2026 - register

Fortnightly TAG Mail – resources list 23rd July 2026

NSW TAG ACTIVITIES

TAG Mail
Searching Cumulative TAG Mail listings: Remember to search Cumulative TAG Mail listings, which are collated in 6 months batches from 2023. These cumulative listings are useful to survey whenever you have a medicine or condition you wish to explore as TAG mail covers the grey literature as well as the traditional academic literature. Just 'Control F' relevant terms to search for your query.

Recent email discussions
- Use of zoledronic acid following denosumab cessation

Upcoming NSW TAG meeting dates
NSW TAG General members' Meeting: 19th August 2026 12-1pm
Contact Sasha Bennett at sasha.bennett@svha.org.au for information about any email discussions, publications or upcoming meetings.

EDITOR'S PICKS

AJHP: Effect of pharmacy admission services on medication charting activities - link
AJHP: Targeting reduction of IV smart pump programming alerts: Insights from real-world use - link
AJHP: Practice-enhancing publications about the medication-use process in 2025 - link
AIM: Patient-Centered Prescription Opioid Tapering Methods: A Randomized Clinical Trial - link
BMC Med: Opioid-specific risk of respiratory depression in non-cancer pain - link
BJCP: Anticholinergic and CNS-active drug burdens and their associations with adverse in-hospital outcomes among older inpatients - link
BJ Psych: - Understanding antidepressant change patterns in the UK Biobank - link
BMJ: Comparative effects of drugs for adults with overweight or obesity - link
Circ: Cardiovascular Risk Reduction With GLP-1 RA Drugs - link
Circ: Deprescribing in Patients with Cardiovascular Disease Experiencing Polypharmacy - link
Cochrane: Topical cyclosporine A therapy for dry eye disease - link
Cochrane: DMARDs for rheumatoid arthritis after failure of biologic or targeted synthetic therapy- link
DTB: Single National Formulary: solution or distraction? - link
EHJ: Great debate: will medical treatment of HFrEF rely on four foundational drugs - link
EJHP: Practical guide for digital solutions for PROMs & PREMs in the hospital pharmacy - link
HE: A Thematic Analysis of a Roundtable on the Complex Problem of Secondary Stroke Prevention in Australia - link
IMJ: Quality in Australian Health Care Study 2: a national imperative for safer care - link
IMJ: Viewpoint: Responding to Australia's medication shortages in palliative care - link
IJCP: Collaborative pharmacist prescribing in community heart failure clinics - link
IJCP: Exploring hospital pharmacist perspectives on ethical considerations from automated patient prioritisation - link
IJQHC: Independent pharmacist prescribing - link
ISMP Canada: Rehospitalisations linked to Medication Incidents during Transitions of Care - link
JPPR: Advanced Pharmacy Australia Nephrology Standards - link
JPPR: Modelling the RoI of a virtual clinical pharmacy service in rural & remote Australian hospitals - link
Lancet D & E: Nutritional, functional, and psychological considerations for incretin-based therapies in adults—Consensus Statement - link
Lancet HLH: Abrupt discontinuation and tapering of antipsychotics in older adults with dementia - link
Lancet ID: Nirmatrelvir for acute COVID-19 to prevent long COVID (PANORAMIC Norway) - link
Lancet Psych: Temporal course of symptom domain improvement in schizophrenia - link
MJA: Weight Loss Medication Marketing and First Nations People: Disease Awareness or Corporate Profit? - link
MJA: Self-Poisoning with Prazosin and Its Off-Label Use in Australia, 2014–2024 - link
NEJM: Rivaroxaban Then Aspirin vs. Aspirin Alone after Total Hip or Knee Arthroplasty - link
NEJM: Pharmacotherapeutic Decisions in Autism - link
NIHR: Future Directions in Personalised Medicine- link
Paed: Eliminating Inappropriate Postoperative Antibiotics - link
P'therapy: Data-Driven Medication Regimen Complexity Score for Critically Ill Patients - link
SPS NHS UK: Heatwaves and medicines: assessing and managing patient risk - link

OTHER NEWS

NSW Health

- New laws to commence 5 November 2026 - link

TGA

- New regulations strengthen controls on nicotine pouches - link ; Nicotine pouches - link

REPORTS AND PUBLICATIONS – AUSTRALIA

Agency for Clinical Innovation, NSW (ACI)

The latest weekly Evidence Digest can be found here
- ACI Continuous opioid infusion chart (adult) - Explanatory notes
- Epidural analgesia chart adult explanatory notes - link

Australian Government Department of Health
- New arrangements for nitisinone (Orfadin®) – information for prescribers – fact sheet

Australian Institute of Health and Welfare
- Australia's health 2026 - link
- Cancer data in Australia - update
- Alcohol, tobacco and other drugs in Australia – update
- Chronic musculoskeletal conditions - update

Australian Living Evidence Collaboration
- New Guideline: Drug treatments for people with influenza who are critically ill – interim advice

CATAG
- Rethinking medicines decision-making: Guiding Principles for the off -label use of medicines in Australian healthcare settings. Version 2. CATAG, 2026, p.44 - link

NHMRC Impact Case Studies
- Preventing analgesic overuse - 1 July - link

TGA
- Database of section 19A approvals to import and supply medicines to address medicine shortages
- AusPARs:
-- Redemplo (plozasiran sodium) as an adjunct to diet to reduce triglyceride levels for adult patients with familial chylomicronaemia syndrome (FCS) for whom standard triglyceride lowering therapies have been inadequate
-- Skyclarys for the treatment of Friedreich's ataxia in adults and adolescents aged 16 years and older
-- Slenyto (Melatonin) to treat insomnia in children and adolescents with ASD, certain neurogenetic disorders (ages 2-18), or ADHD (ages 6-17) when sleep hygiene measures alone have not been effective
-- Tabrecta (capmatinib) for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a MET exon 14 skipping mutation
-- Tuoyi (Zytorvi) for the treatment of nasopharyngeal carcinoma
- Australian prescription medicine decision summaries:
-- ALTUVIIIO (efanesoctocog alfa) for adults, adolescents and children with haemophilia A
-- Sodium Oxybate-Reach for the treatment of narcolepsy in adults, adolescents and children from the age of 7 years
-- Wainua (eplontersen) for the treatment of hereditary transthyretin-mediated amyloidosis (ATTRv) in adults with stage 1 or 2 polyneuropathy

REPORTS AND PUBLICATIONS – INTERNATIONAL

British National Formulary
- July BNF + BNFC knowledge updates - link

electronic Medicines Compendium (eMC) (UK)
- New products
-- Koselugo (selumetinib) 5 mg granules in capsule for opening – monotherapy for symptomatic, inoperable plexiform neurofibromas in patients with neurofibromatosis type 1 (NF1) aged 1 year to less than 7 years and for older patients with swallowing difficulties
-- Paliperidone STADA Prolonged-release suspension for injection in pre-filled syringes (75mg, 100mg and 150mg) administered on day 1 and day 8, and then monthly, is for maintenance treatment of schizophrenia in adults stabilised with paliperidone or risperidone
-- Phenobarbital Colonis 50 mg/5 ml Oral Suspension, Ethanol-free, indicated in adults and children for all forms of epilepsy, except absence seizures. It may be used as monotherapy or in combination with another antiepileptic treatment
-New/expanded indications

-- Bylvay (odevixibat sesquihydrate) - new indication for use in the treatment of cholestatic pruritus in Alagille syndrome (ALGS) in patients aged 6 months or older
-- Efmody (hydrocortisone) modified release - new indication for adrenal insufficiency (AI) in adolescents aged 12-18 years added, as well as specific posology and clinical data on safety and efficacy in this setting
-- Wegovy (semaglutide) FlexTouch pre-filled pen – all strengths - indicated in conjunction with diet and exercise for the treatment of non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis)

European Medicines Agency (EMA)
- … fast tracks review of daraxonrasib for treatment of metastatic pancreatic cancer - link

Food and Drug Administration (FDA) USA
- Considerations for potential future therapeutic use of psychedelic drugs – Sep 14 public hearing
- New Drug approvals
-- Casgevy (exagamglogene autotemcel)-first gene therapy for young children with sickle cell disease
-- gedatolisib Revtorpyk with fulvestrant, with or without palbociclib, for HR-positive, HER2-negative locally advanced or metastatic breast cancer
-- isatuximab-irfc for subcutaneous injection for multiple myeloma indications
-- (at home) starting dosage regimen for SC lecanemab Leqembi for Alzheimer's Disease - link
-- Lipfendra, enlicitide decanoate, first oral therapy that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9) to reduce low-density lipoprotein cholesterol – letter
-- Orca-T, a next-gen HSCT to reduce GVHD
-- pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph each with enfortumab vedotin-ejfv for muscle invasive bladder cancer
-- selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors
-- Trutakna (Ataciept-Vymj) for reduce proteinuria in adults with primary immunoglobulin
A nephropathy (IgAN) at risk for disease progression

General Pharmaceutical Council UK
- New standards approved for the initial education and training of pharmacy technicians - link

Medicines and Healthcare products Regulatory Agency (MHRA)
- Authorises gemcitabine delivery system for adults with BCG-unresponsive high-risk non-muscle invasive bladder cancer - link
- Approves retifanlimab (Zynyz) for the treatment of advanced Merkel cell skin cancer - link
- Approves semaglutide (Wegovy) to treat metabolic-associated steatohepatitis (MASH) in adults with moderate-to-advanced liver fibrosis - link
- Approves nerandomilast (Jascayd) to treat adult patients with idiopathic pulmonary fibrosis and progressive pulmonary fibrosis - link
- Approves first lower-carbon beclometasone inhalers for patients with asthma - link
- Provides scientific opinion about doxecitine and Doxribtimine in the treatment of thymidine kinase 2 deficiency (TK2d) - link

Monthly Index of Medical Specialities UK
- Elinzanetant (Lynkuet) approved to treat vasomotor symptoms caused by endocrine therapy for breast cancer - link

Neonatal & Paediatric Pharmacy Group UK
- Use of chlorhexidine for skin cleansing in neonates - update
- Selection of administration devices for oral liquid medicines dispensed to children - link

NHS England
- Ebola pathway action cards - link
- McArdle's disease service specification - link
- Clinical commissioning policy:

-- Dabrafenib for BRAFV600E mutation positive histiocytic neoplasms where standard care has failed (all ages) - link
-- Combination brentuximab vedotin and bendamustine for patients aged 8 years and above with relapsed or refractory classical Hodgkin lymphoma - link
-- Delayed-release mercaptamine bitartrate for patients with nephropathic cystinosis (age > 1 years) - link
-- Gemcitabine and paclitaxel albumin combination chemotherapy for the treatment of locally advanced non-metastatic pancreatic cancer (adults) - link
-- Lanreotide as a monotherapy for the treatment of symptomatic non-localised autosomal dominant polycystic liver disease (adults) - link
-- Lenacapavir for multi-drug resistant human immunodeficiency virus 1 infection (adults) - link
-- Lonafarnib for Hutchinson-Gilford progeria syndrome (12 months of age and over) - link
-- Osilodrostat phosphate for adult patients with endogenous Cushing's syndrome - link
-- Pembrolizumab in combination with dabrafenib and trametinib for patients with BRAF mutated anaplastic thyroid cancer (adults) - link
-- Prolonged-released (PR) fampridine as a treatment of adults with multiple sclerosis and associated walking impairment - link
-- Sirolimus in extracranial slow-flow vascular malformations refractory to standard therapies - link
-- Stereotactic ablative body radiotherapy for patients with localised, non-metastatic, renal cancer who are medically unfit for surgery (adults) - link
-- Stereotactic radiosurgery for essential tremor refractory to medication (adults) - link
-- Extra corporeal membrane oxygenation (ECMO) service for neonates, infants and children - link

National Institute for Health and Care Excellence (NICE) UK
- Perioperative care in adults (QS216)
- Heavy menstrual bleeding: assessment and management (NG88)
- Cemiplimab for treating recurrent or metastatic cervical cancer that has progressed on or after platinum-based chemotherapy (TA1174)
- Glycopyrronium bromide cream for treating severe primary axillary hyperhidrosis (TA1175)
- Teplizumab for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes (TA1176)
- Pembrolizumab with chemoradiotherapy for untreated locally advanced cervical cancer (TA1177)
- Deuruxolitinib for treating severe alopecia areata (TA1178)

National Institute for Health and Care Research (NIHR)
- Future Directions in Personalised Medicine: A Horizon Scan for Artificial Intelligence, Genomics Based HealthTech - link

Scottish Intercollegiate Guideline Network (SIGN) UK
- Epilepsies in children and young people: investigative procedures and management: updated guideline (SIGN 159)

Sentinel Stroke National Audit Programme
- Stroke – Atlas of Variation Report 2026

Specialist Pharmacy Services NHS UK
- Implementing medicines frameworks - link
- Medicines in dentistry: resources to support clinical decisions - link

UK Health Security Agency
- Inadvertent vaccination in pregnancy (VIP) - updated
- Hand hygiene alternatives to soap and water for reducing C. difficile - link

World Health Organisation (WHO)
- Global status report on cancer 2026: The future we choose together - link
- WHO issues updated dosing guidance for antiretroviral medicines used in newborns, infants and children - link

MEDICATION SAFETY

electronic Medicines Compendium (eMC) (UK)

- Revised SPCs

-- Adartrel (ropinirole) - “aggression” included with possible impulse control disorders manifestations

-- Adrenaline Injection BP - cases of QTc prolongation and Torsade de Pointes reported following administration in patients with congenital long QT syndrome or catecholaminergic polymorphic VT

-- Avacopan - changed posology recommendations in relation to hepatotoxicity and to amend an existing warning on hepatotoxicity

-- Bavencio (avelumab) - Myocarditis-Myositis-Myasthenia Gravis Overlap Syndrome added as a possible adverse event. The frequency of sarcoidosis has been reduced to ‘rare’ with monotherapy, and ‘frequency not known’ in combination with axitinib

-- Bramitob (tobramycin) Nebuliser Solution - Updated following PRAC conclusion that a causal relationship between tobramycin (inhalation powder, capsules) and acute kidney injury is at least a reasonable possibility

-- Budenofalk (budesonide) 3mg gastro-resistant capsules - storage precautions updated from "does not require any special storage conditions" to "do not store above 30 °C’’

-- DaTSCAN (ioflupane) 74 MBq/ml solution for injection - image interpretation requires caution in patients on serotonin-norepinephrine reuptake inhibitors, particularly venlafaxine; temporary discontinuation for at least five half-lives before scanning may be considered. Guidance is given

-- Idacio (adalimumab) 40 mg solution for injection in pre-filled pen - new excipients with known effects (sodium, polysorbates), additional data on malignancies adverse effects, clarification that Idacio remains available only as a 40 mg dose, and an increase in shelf life from 2 to 3 years

-- Imodium Dual Action Relief (loperamide/simethicone) - limited data in pregnant or breastfeeding women. Caution when loperamide used especially during first trimester. Loperamide has been detected in breast milk. Simethicone is physiologically inactive, not absorbed by GI tract & is not excreted in breast milk.

-- Lumykras (sotorasib) f/c tablets - Laboratory criteria and revised dose modification added for hepatotoxicity. Hepatotoxicity section expanded. Interstitial lung disease & pneumonitis added as ADRs, with recent (≤3 months) immunotherapy a potential risk factor for their development

-- Nutriflex products must be administered via a filter with a pore size of 0.2 µm

-- Opdivo (nivolumab) - Myocarditis-Myositis-Myasthenia Gravis Overlap Syndrome as a possible adverse event, when patients are treated with nivolumab monotherapy, and nivolumab in combination with other therapeutic agents

-- Propecia (finasteride) - MHRA wording on sexual dysfunction, reminder about the patient alert card

-- Strensiq (asfotase alfa) - all ages included in the indication of long-term enzyme replacement therapy and a section on hypophospatasia and its treatment added to mechanism of action section

-- Teraleve (fesoterodine fumarate) - some cases of angioedema may be associated with upper airway swelling which may be life-threatening, and oral hypoaesthesia added as an ADR

-- Welireg (belzutifan) f/c tablets - contraception should be continued and breastfeeding avoided for at least 1 week after the last dose, and to include information on belzutifan-mediated CYP3A4 and CYP2B6 induction. Dosing recommendations updated for renal and hepatic impairment

-- Wezenla (ustekinumab) infusion - safety and efficacy in adult and paediatric patients weighing less than 40 kg have not yet been established, new indication for use in the treatment of paediatric Crohn’s disease in those ≥40kg, and new data from pregnancies exposed to ustekinumab do not indicate an increased risk of major congenital malformations in the newborn

- Risk minimisation materials

-- Leqselvi (deuruxolitinib phosphate) - a Prescriber Guide containing important safety information that should be considered when prescribing and maintaining patients on deuruxolitinib and a patient card covering the main risks of treatment and when to seek medical help

-- Penthrox inhalation vapour, liquid (methoxyflurane) - an administration checklist and administration guide, to ensure the appropriate management of important selected risks, and a patient alert card

EMA

- Pharmacovigilance Risk Assessment Committee (PRAC) agrees new safety information on desogestrel- and etonogestrel-containing contraceptives and Litfulo (ritlecitinib) for alopecia areata - link

ISMP Canada – Safety Bulletins
- Hospital Readmissions Associated with Medication Incidents during Transitions of Care - link

Medicines and Healthcare products Regulatory Agency (MHRA) UK
- Updated guidance: Warning statements for labels and leaflets of certain medicines - link
- Botulinum toxin type A products: updated warnings regarding risk of iatrogenic botulism - link
- Domperidone: new contraindication in patients with phaeochromocytoma due to the risk of severe hypertension - link

Specialist Pharmacy Services NHS UK
- Treating urinary disorders during breastfeeding - link
- Developing direct oral anticoagulant safety across a system - link
- Using lipid-lowering medicines while breastfeeding - update
- Switching doxazosin XL tablets to doxazosin standard tablets - update
- Heatwaves and medicines: assessing and managing patient risk - link

TGA
- Information about major medicine shortages – link
-- About the cyclophosphamide and ifosfamide injection shortages - link
- Identifying medicines in long term shortage - link
- Product Information safety updates - June 2026
- Herbal preparations containing Withania somnifera (Withania, Ashwagandha) - link ; Withania somnifera (Ashwagandha) and very rare risk of liver injury - link
- Unapproved SARMs found to be significantly underdosed - link
- ITCHA SSS capsules - found to contain oxedrine - link

World Health Organisation (WHO)
- Medical Product Alert N°3/2026: Falsified DARZALEX (daratumumab) - identified in the WHO regions of the Americas and South-East Asia - link

PAPERS OF INTEREST

American Journal of Health-System Pharmacy (AJHP)
- Effect of pharmacy admission services on medication charting activities: A retrospective cohort study - link
- Neuromuscular blocking agents for acute respiratory distress syndrome: Current controversies - link
- Targeting reduction of intravenous smart pump programming alerts: Insights from real-world use - link
- Practice-enhancing publications about the medication-use process in 2025 - link
- Clinical controversies in the management of candidemia in adults and children - link

Annals of Internal Medicine
- Patient-Centered Prescription Opioid Tapering Methods: A Randomized Clinical Trial - link
- The Comparative Effectiveness of Carvedilol Versus Other Nonselective β-Blockers in Cirrhosis - link
- Comparative Effectiveness of Glucagon-like Peptide-1 Receptor Agonists Versus Oral Agents for Insulin Discontinuation in Type 2 Diabetes: A Target Trial Emulation - link
- Glucagon-like Peptide-1 Receptor Agonists and Risk for Anterior Ischemic Optic Neuropathy - link
- Glucagon-Like Peptide-1 Receptor Agonists and Risk for Ischemic Optic Neuropathy: A Target Trial Emulation - link
- Modernizing the Regulatory Framework for Dietary Supplements: A Position Paper from the American College of Physicians - link
- Olorofim in Treatment of Patients with Poorly Controlled Disseminated Coccidioidomycosis - link

Arthritis & Rheumatology
- Non-melanoma skin cancer risk with Janus kinase inhibitors compared to interleukin-6 receptor inhibitors in rheumatoid arthritis: results from a national cohort study - link

- Pharmacokinetics, effectiveness and safety of certolizumab pegol in children and adolescents with active juvenile idiopathic arthritis: 9+-year results from a multicenter, open-label study - link
- Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety up to 52 Weeks from the Randomized, Double-Blind, Phase 3 POETYK PsA-2 Trial - link

BMC Medicine
- Opioid-specific risk of respiratory depression in non-cancer pain: a retrospective cohort study - link

British Journal of Clinical Pharmacology
- Case-malformed signal detection and prioritisation using EUROmediCAT data for pharmacovigilance in pregnancy - link
- Comparative risk of ventricular arrhythmia and sudden cardiac death among acetylcholinesterase inhibitors in dementia: A population-based cohort study - link
- UGT1A1 genotype testing for irinotecan: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx) - link
- N-acetylcysteine for non-paracetamol-induced acute liver failure in children: A systematic review and meta-analysis - link
- Anti-seizure medications and DRESS in paediatric patients: A FAERS disproportionality and time-to-onset analysis - link
- Anticholinergic and central nervous system-active drug burdens and their associations with adverse in-hospital outcomes among older inpatients - link
- A regulatory perspective on the first approved EU application to reformulate an inhaled medicine with a gas propellant with reduced global warming potential - link
- Cardiovascular and neuropsychiatric outcomes with PCSK9 inhibitors in atherosclerotic cardiovascular disease: A retrospective cohort study - link
- Ceftriaxone-induced liver injury: Incidence, phenotypic characterization and predictive factors - link
- Indications and Efficacy of Progestogen-Monotherapy as Menopause Hormone Therapy: A Narrative Review - link
- Analysis of spontaneous reports of suspected adverse reactions related to medical cannabis from the Italian Phytovigilance System - link
- Ibuprofen vs. acetaminophen for acute mild-to-moderate pain management: A systematic review and meta-analysis of safety with a focus on paediatric populations - link
- Impact of the pancreatic enzyme replacement therapy (PERT) shortage on prescribing in England: Analysis of national data - link
- A study on the clinical characteristics, risk factors and economic burden of serious adverse drug reactions in hospitalized patients - link
- A British Pharmacological Society Position Statement on Medications in Pregnancy and Lactation - link
- Semaglutide vs. liraglutide and incidence of diabetes and cardiovascular disease: A target trial emulation using real-world data - link
- Evaluating the pharmacokinetics, efficacy and safety of low-dose cannabidiol – link

British Journal of Psychiatry
- Effectiveness and safety of repeat dose subcutaneous ketamine for treatment-resistant depression, and the impact of prior ketamine treatment: open label extension of the KADS study - link
- Psilocybin therapy for adult females with anorexia nervosa: pilot study - link
- Psychiatric prescribing patterns in patients with newly diagnosed bipolar disorder in the UK: 2000 to 2022 - link
- Understanding antidepressant change patterns in the UK Biobank - link

British Medical Journal (BMJ)
- Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis - link
- Advances in systemic therapies for advanced prostate cancer - link
- Retatrutide fact check: Has a man died after taking the unapproved weight loss jab? - link
- Contemporary hormonal contraception and colorectal cancer in premenopausal women: nationwide cohort study - link

- Ebola vaccine: Oxford starts UK trial against Bundibugyo strain - link
- Epidural analgesia in labour and neonatal and childhood outcomes: national population based cohort study - link
- Pregnancy outcomes of GLP-1 exposure in the first trimester - link

Circulation
- Cardiovascular Risk Reduction With GLP-1 RA Drugs - link
- Deprescribing in Patients with Cardiovascular Disease Experiencing Polypharmacy: A Scientific Statement From the American Heart Association - link
- Transforming Pulmonary Arterial Hypertension: Key Milestones and Future Perspectives - link
- Caffeine and Cardiovascular Disease: A Scientific Statement from the American Heart Association - link
- Effects of a “Food Is Medicine” Intervention on Glucose Control Among Medicaid-Insured Patients with Type 2 Diabetes: A Randomized Controlled Trial - link

Cochrane
- Prophylactic versus selective use of surfactant for preventing morbidity and mortality in preterm infants at risk of respiratory distress syndrome - link
- Topical cyclosporine A therapy for dry eye disease - link
- Blood pressure management in reperfused ischemic stroke - link
- Recombinant follicle-stimulating hormone (rFSH) versus other recombinant or urinary gonadotropins for ovarian stimulation in assisted reproductive technology cycles - link
- Disease-modifying antirheumatic drugs (DMARDs) for rheumatoid arthritis after failure of biologic or targeted synthetic therapy: a systematic review and network meta-analysis - link
- Perioperative immune checkpoint inhibitors with or without chemotherapy versus placebo with or without chemotherapy in elderly people with localised non-small cell lung cancer - link

Diabetes, Obesity and Metabolism
- Pharmacotherapy for Children and Adolescents with Overweight or Obesity: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials - link
- Cardiovascular Efficacy of GLP-1 Receptor Agonists by Kidney Function: An Updated Meta-Analysis of Randomized Trials Including the SOUL Trial - link
- Effects of Incretin-Based Therapies, Diet and Exercise Interventions, and Bariatric Surgery on Fat-Free Mass in Adults with Overweight or Obesity: A Systematic Review and Meta-Analysis - link

Drug and Therapeutics Bulletin
- Lipid-lowering for people with chronic kidney disease: a narrative review - link
- Pharmacological treatment of polyendocrine metabolic ovarian syndrome in adults - link
- Single National Formulary: solution or distraction? - link
- Review of levodopa inhalation powder (Inbrija) for Parkinson’s disease - link

European Heart Journal
- Great debate: medical treatment of heart failure with reduced ejection fraction will rely on four foundational drugs - link
- Influenza vaccination, incident atrial fibrillation, and cardiovascular outcomes - link
- Paediatric long QT syndrome: clinical outcomes and therapy in the Spanish National Registry - link
- Peripheral artery disease: advances in medical therapy - link

European Journal of Hospital Pharmacy
- Practical guide for the selection of digital solutions oriented to PROMs and PREMs in the hospital pharmacy - link

Gut
- Efficacy of gut-brain neuromodulators and brain-gut behaviour therapies for irritable bowel syndrome: systematic review and network meta-analysis - link

Health Expectations

- “Everyone's Responsibility and No-One's Responsibility”: A Thematic Analysis of a Roundtable on the Complex Problem of Secondary Stroke Prevention in Australia - link

Internal Medicine Journal
- Quality in Australian Health Care Study 2: a national imperative for safer care - link
- Corticosteroid therapy following infliximab rescue in acute severe ulcerative colitis: should they be continued? - link
- Driving in hepatic encephalopathy - link
- Improving primary aldosteronism diagnosis and treatment: outcomes from an endocrine hypertension service - link
- Effect of catheter ablation and pharmacotherapy on long-term mortality in young patients with atrial fibrillation - link
- Complexity and comorbidities: critical considerations for methicillin-resistant Staphylococcus aureus bacteraemia outcomes in the Northern Territory - letter
- Glucagon-like peptide-1 receptor agonists and venous thromboembolism: an unresolved question for Australian prescribers – letter
- Viewpoint: Responding to Australia's medication shortages in palliative care: the need for a multi-agency coordinated response - link
- Tolerability of hormonal treatments in acute hepatic porphyria patients - link
- Limited lenalidomide exposure and access to rescue plerixafor can eliminate haemopoietic progenitor cell first collection failure in bortezomib, lenalidomide and dexamethasone treated transplant eligible multiple myeloma patients - link
- Increasing utilisation of intravenous iron among Australian women of reproductive age, 2013–2024: an Australian population-based study - link
- Australasian chronic lymphocytic leukaemia consensus statement: 2026 update - link

International Journal of Clinical Pharmacy
- Consumers’ experiences and perspectives on reporting adverse drug reactions using digital tools: a qualitative study - link
- Causes and types of voluntarily reported unintentional medication discrepancies in care transitions: a cross-sectional study - link
- Budget impact analysis of medication reviews by junior pharmacists in polypharmacy patients: a hospital perspective - link
- Collaborative pharmacist prescribing in community heart failure clinics: a pre-post intervention comparison - link
- Roles and impacts of pharmacists in attention-deficit hyperactivity disorder services: a scoping review - link
- Validation of an updated French national tool for reporting pharmacist interventions for all healthcare products - link
- Exploring hospital pharmacist perspectives on ethical considerations from automated patient prioritisation: a qualitative study - link

International Journal for Quality in Health Care
- Independent pharmacist prescribing: How it can work and how to support its implementation - link

JAMA
- Ceperognastat in Early Symptomatic Alzheimer Disease - link
- Alcohol-Related Liver Disease - link
- JAMA Insights: Surgical and Endoscopic Therapies for GERD - link
- JAMA Patient Page: What is Low Back Pain? - link ; Hepatitis B - link ; What Is Ebola? - link ; What Is Prepregnancy Care and Counseling? - link
- Low Back Pain: A Review - link ; Hip Fractures: A Review - link

JAMA Cardiology
- Dual Antiplatelet Therapy Duration in Patients at High Bleeding Risk: A Systematic Review and Meta-Analysis - link

JAMA Internal Medicine
- Interim Estimated Effectiveness of 2025-2026 COVID-19 Vaccines in Adults Using a Test-Negative Design - link
- Evaluating Inflammatory Joint Pain in Older Adults—Practical Diagnostic Clues for Primary Care Clinicians - link

JBI Evidence Synthesis
- Effectiveness and safety of intranasal fentanyl for pain management in infants aged 0 to 6 months: a systematic review - link

Journal of Pharmacy Practice and Research (JPPR)
- Trends in sodium-glucose co-transporter-2 inhibitor prescribing at an Australian metropolitan hospital, 2014–2024 - link
- Early mirogabalin uptake for chemotherapy-induced peripheral neuropathy: a pharmacy practice signal from post-marketing oncology care - letter
- Advanced Pharmacy Australia Nephrology Standards - link
- Modelling the return on investment of a virtual clinical pharmacy service in rural and remote Australian hospitals - link

Lancet
- Metabolic traits in obesity and normal BMI in industrialised countries: a multi-country analysis of national population-based studies - link
- Systemic light chain and transthyretin amyloidosis—treatment advancements and future directions - link
- Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTÉ): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trial - link

Lancet Diabetes & Endocrinology
- Nutritional, functional, and psychological considerations for incretin-based therapies in adults—an EASO, EFAD, and ECPO Consensus Statement - link

Lancet Digital Health
- Predicting the risk of serious muscle disorders in individuals eligible for statin treatment in England: derivation and validation of a clinical prediction model - link

Lancet Healthy Longevity Home
- Abrupt discontinuation and tapering of antipsychotics in older adults with dementia: a target trial emulation study - link

Lancet Infectious Diseases
- Global, regional, and national burden of tuberculosis and multidrug-resistant tuberculosis by HIV status, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023 - link
- Efficacy and safety of rivaroxaban, colchicine, and famotidine–loratadine with specialist supportive clinical care for fatigue in patients with post-COVID-19 condition in the UK: a multisite, open-label, randomised controlled trial - link
- Nirmatrelvir for acute COVID-19 to prevent long COVID (PANORAMIC Norway): a double-blind, randomised, placebo-controlled trial - link

Lancet Primary Care
- Pharmacogenomic-informed antidepressant prescribing for moderate-to-severe depressive symptoms in Australian general practice (PRESIDE): a double-blind, randomised controlled trial - link

Lancet Psychiatry
- Association of GLP-1 receptor agonists with alcohol use disorder-related and substance use disorder-related hospital admissions during treatment and after discontinuation: a Swedish register-based within-individual observational study - link

- Temporal course of symptom domain improvement in schizophrenia: individual participant data analysis of six antipsychotic drug trials - link

Molecular Diversity Preservation International (MDPI) – Pharmacy Journal
- Factors Influencing Phenoconversion in CYP-Mediated Drug Metabolism: A Scoping Review - link
- Sublingual Tropicamide Eye Drops for the Management of Clozapine-Induced Hypersalivation: A Case Series of Seven Patients - link

Medical Journal of Australia
- Still Treating Yesterday's Risk? Reconsidering Antiviral Use for Mild-to-Moderate COVID-19 Cases in a Broadly Immune Population - link
- Weight Loss Medication Marketing and First Nations People: Disease Awareness or Corporate Profit? - link
- Australian Pathways for Specialist Pain Management and Early Palliative Care for People with Pancreatic Cancer: Developed Using a Community Consensus Approach - link
- Self-Poisoning With Prazosin and Its Off-Label Use in Australia, 2014–2024: Analysis of NSW Poisons Information Centre Data - link

New England Journal of Medicine
- Adjuvant Pembrolizumab plus Belzutifan for Renal-Cell Carcinoma - link
- Rituximab versus Ocrelizumab in Newly Diagnosed Relapsing Multiple Sclerosis - link
- Ensartinib in Resected ALK-Positive Non–Small-Cell Lung Cancer – link
- Meningococcal B Vaccine to Prevent Neisseria gonorrhoeae Infection - link
- Rivaroxaban Then Aspirin vs. Aspirin Alone after Total Hip or Knee Arthroplasty - link
- Pharmacotherapeutic Decisions in Autism - link
- Continuous or Fixed-Duration Maintenance Therapy in Multiple Myeloma - link
- Extended Dual Antiplatelet Therapy for Multivessel Coronary Artery Disease - link
- Andes Virus — A Clinical Review - link
- Platelet-Activating Anti–Platelet Factor 4 Disorders - link

Pediatrics (American Academy of Pediatrics)
- Disparities in Nirsevimab Uptake Over 2 Seasons - link
- Eliminating Inappropriate Postoperative Antibiotics: A Stepped-Wedge Cluster Randomized Trial - link
- Use of Leucovorin After the FDA Announcement of Its Use for Autism Spectrum Disorders - link
- Influenza Vaccine Effectiveness Against Pediatric Death in the United States: 2016–2025 - link
- Averting the Unthinkable: Immunization to Prevent Childhood Deaths from Influenza - link

Pharmacotherapy
- Comparison of Bayesian and First-Order Estimations of Vancomycin Area Under the Curve in Pediatrics Using One- and Two-Concentration Methods - link
- A Data-Driven Medication Regimen Complexity Score for Critically Ill Patients: MRC-ICU 2.0 - link
- Comment on “Pharmacokinetic Analysis of Intravenous Push Cefepime in Critically Ill Patients With Sepsis” - letter - response

CONSULTATIONS

Australian Commission on Safety and Quality in Health Care (ACSQHC)
- Standards for First Nations Cultural Safety Review - closes Thursday 30 July - link
- Venous Thromboembolism Prevention Clinical Care Standard Review – closes Friday 31 July - link
- Requirements for Haemopoietic Cellular Therapy – closes Wednesday 12 August - link
- NSQHS Standards (third edition) - closes Friday 25 September - link

Australian Living Evidence Collaboration
- Consultation: feedback on our new recommendations “Drug treatments for people with influenza who are critically ill” – closes 7th August 2026 - link

TGA

- Consultation: Radiopharmaceutical regulation in Australia - closes on 31 July 2026 – link
- Consultation: Proposed changes to the Permissible Indications Determination - closes on 12 August 2026 – link
- Consultation: Seeking feedback on improvements to the Therapeutic Goods Advertising Code - closes on 3 September 2026 - link

WEBINARS & PODCASTS

Australian Prescriber Podcasts
- E218 | Diagnosis and management of irritable bowel syndrome
- E219 | Sodium valproate: balancing benefits and risks especially in people of childbearing potential

MJA Podcasts
- Improving the health of young Indigenous Australians – link
- NAIDOC Indigenous Collection for MJA - link

Purple Pen Podcast
- PPP 193 - Childhood Cancer in First Nations People with Dr Jessica Buck
- PPP 194 – Sport and Exercise Pharmacy with Alison Hooper

UPCOMING EVENTS

Advanced Pharmacy Australia
- Medicines Management MM2026, 22-24 October 2026, Brisbane Convention & Exhibition Centre - Early Bird registration open until 9 September

Australian Commission on Safety and Quality in Health Care (ACSQHC)
- Registrations open – National Medicines Symposium NMS 2026, 'Medicines stewardship: safer use starts with all of us' - Wednesday, 11 November 2026 - register

Safer Care Victoria
- CCOPMM (Consultative Council on Obstetric and Paediatric Mortality and Morbidity) and VPCC Consent, Ethics & Responsibility Symposium, Fri 31 Jul 2026 09:00-16:30 – free registration

Fortnightly TAG Mail – resources list 2nd July 2026

NSW TAG ACTIVITIES

TAG Mail
MEMBERS' PICKS section added to TAG Mail. Please contribute articles that members may find useful/interesting. Email Sasha your contributions.

Searching Cumulative TAG Mail listings: Remember to search Cumulative TAG Mail listings, which are collated in 6 months batches from 2023. These cumulative listings are useful to survey whenever you have a medicine or condition you wish to explore as TAG mail covers the grey literature as well as the traditional academic literature. Just 'Control F' relevant terms to search for your query.

Recent email discussions
- Use of zoledronic acid following denosumab cessation

Upcoming NSW TAG meeting dates
NSW TAG General members' Meeting: 19th August 2026 12-1pm
Contact Sasha Bennett at sasha.bennett@svha.org.au for information about any email discussions, publications or upcoming meetings.

EDITOR'S PICKS

AJHP: Integration of smart infusion pumps with eMR improves safety and staff productivity - link

BJCP: Codeine toxicity via breast milk - link
BJCP: Dapagliflozin vs. empagliflozin on major adverse cardiovascular events in HF-rEF: - link
BJP: Acceptability and accuracy of point-of-care monitoring of lithium levels - link
Circ: AHA Strategies for Optimizing Heart Failure Care in the Older Adult - link
Cochrane: Biologic drugs for induction and maintenance of remission in Crohn's disease - link
EJHP: 'Making Medicines Work for You' screener for adherence barriers in HF patients - link
IJCP: Testing of a quality assessment tool for medication review type 2a reports - link
IJCP: Research trends and emerging topics in antifungal therapeutic drug monitoring - link
IJCP: Interventions targeting prescribing appropriateness in older adults attending acute care - link
IJQCP: Prevalence of chemical restraint use in hospital care - link
IJQCP: Pharmacist-led continuity of care interventions for patients on oral anticancer therapy - link
IMJ: Approach to thyroid disorders associated with immune checkpoint inhibitors and TKIs - link
IMJ: Viewpoint: Denosumab discontinuation and fracture risk: getting the balance right – link
ISMP Canada: Palliative Care at Home Part 1: Multi-incident analysis; Part 2: Fatal incident anlysis
JAMA IM: Multilevel Stewardship Intervention for Use of Anticoagulation-Antiplatelet Therapy - link
JPPR: Acceptance of analgesic stewardship team recommendations at a metropolitan hospital network - link
Lancet: Safety and efficacy of mRNA vaccines: a mechanistic and public health perspective - link
Lancet Psych: International cannabis policies and their association with cannabis use, cannabis use disorder, and other psychiatric disorders - link
MDPI: Experiences of Treating Problematic OTC and Prescription-Only Medication Use in Substance Misuse Services - link
MDPI: Cumulative Anticholinergic Burden and Risk of Delirium Among Older Adults with Alzheimer's Disease - link
NEJM: Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas - link
RSAP: Effect of a collaborative intervention by pharmacists and dentists on smoking cessation - link
SPS UK: Prescribing and administering intravenous paracetamol safely - link
SPS UK: Managing fire risk with emollients and other skin products - link
SPS UK: Stability challenges in aseptic services - link

OTHER NEWS

Australian Commission on Safety and Quality in Health Care (ACSQHC)
- National standards to ensure safe, high-quality virtual care for all Australians - link

Australian Government Department of Health
- Concerns regarding the public health risks associated with unapproved peptide products - link

REPORTS AND PUBLICATIONS – AUSTRALIA

Agency for Clinical Innovation, NSW (ACI)
The latest weekly Evidence Digest can be found here

Australian Commission on Safety and Quality in Health Care (ACSQHC)
- Updated guidance on paediatric end-of-life care - link
- Revised Open Disclosure Framework now available - link

Australian Institute of Health and Welfare
- First Nations Burden of Disease Study 2022 - update

MIMS monthly updates
- New Products
-- Abaloparatide (Eladynos) for osteoporosis in postmenopausal women at increased risk of fracture. Eladynos is contraindicated in women who are pregnant or breastfeeding; are of childbearing potential; have pre-existing hypercalcaemia; have severe renal impairment; have unexplained elevations of serum alkaline phosphatase; have known risks for osteosarcoma such as those who

have received prior external beam or implant radiation therapy involving the skeleton; have skeletal malignancies or bone metastases. Eladynos solution for injection contains abaloparatide 2 mg per mL
-- Futibatinib (Lytgobi) for adults with locally advanced or metastatic intrahepatic cholangiocarcinoma with a FGFR2 fusion or rearrangement that have progressed after at least one prior line of systemic therapy. Lytgobi tablets contain futibatinib 4 mg.
-- Insulin degludec (Tresiba) is an ultra-long acting basal insulin for diabetes mellitus in adults, adolescents and children from the age of 1 year. Tresiba Penfill solution for injection contains insulin degludec 100 units per mL and is available in packs of five 3 mL cartridges
-- Pneumococcal 21 valent polysaccharide conjugate vaccine (Capvaxive) for active immunisation for the prevention of pneumococcal disease caused by S. pneumoniae serotypes (3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15B, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B) in adults ≥18 years of age. Contraindicated in individuals with a history of a severe allergic reaction to the active substances and diphtheria toxoid. Capvaxive solution for injection contains 84 mcg of pneumococcal purified capsular polysaccharide antigen (4 mcg each of serotypes) conjugated to approximately 65 mcg of diphtheria CRM197 protein. Available in 0.5 mL prefilled syringes.
-- Tezepelumab (Tezspire) as an add-on maintenance treatment in patients aged ≥12 years with severe asthma who are inadequately controlled despite optimal therapy including medium or high dose inhaled corticosteroids plus another non-steroidal medicinal product for maintenance treatment. Tezspire solution for injection contains tezepelumab 210 mg per 1.9 mL available in a prefilled pen
- New Presentation
-- Selpercatinib (Retevmo Tablets) now available as tablets containing selpercatinib 40 mg or 80
- New Indications
-- Daratumumab (rch) (Darzalex SC) now also indicated in combination with lenalidomide and dexamethasone; or bortezomib, lenalidomide and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant
-- Melatonin (Slenyto) is now indicated for the treatment of insomnia in children and adolescents aged 2-18 years with neurogenetic disorders with aberrant diurnal melatonin secretion and/or nocturnal awakenings, where sleep hygiene measures have been insufficient
-- Sotatercept (Winrevair) in combination with standard therapy now indicated for adults with pulmonary arterial hypertension (PAH) in World Health Organization (WHO) Functional Class (FC) IV

PBS
- Principles of broad (multi-cancer) listings for programmed cell death-1/programmed death ligand-1 (PD-(L)1) inhibitors- for sponsors - 23 June 2026

TGA
- Accessing MDMA (3,4-methylenedioxy-methamphetamine) & psilocybine as a psychiatrist - updated checklist
- Database of section 19A approvals to import and supply medicines to address medicine shortages
- AusPARs:
-- Filsuvez (Birch bark dry extract - 84-95% triterpenes**)** for the treatment of partial thickness wounds associated with dystrophic and junctional epidermolysis bullosa (EB) in patients 6 months and older
-- Livdelzi (seladelpar) for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate response to UDCA alone, or as monotherapy in those unable to tolerate UDCA
-- Rhapsido (remibrutinib) for chronic spontaneous urticaria (CSU) in adults who remain symptomatic despite H1 antihistamine treatment
- Australian prescription medicine decision summaries:
-- Cifoban (sodium citrate dihydrate) for use in adults and children for regional citrate anticoagulation (RCA) in continuous venovenous haemodialysis (CVVHD), continuous venovenous haemodiafiltration (CVVHDF), sustained low efficiency (daily) dialysis (SLEDD) and therapeutic plasma exchange (TPE) via membrane plasma separation
-- Tabrecta (capmatinib) for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a MET exon 14 skipping mutation
-- Zirdawny (donidalorsen) for routine prevention of recurrent attacks of hereditary angioedema (HAE) in adults and adolescents aged 12 years and older

Prescription medicine registrations - link

REPORTS AND PUBLICATIONS – INTERNATIONAL

BBC Health News
- What does hot weather do to the body? - link

British Menopause Society
- Menopausal 'brain fog' or dementia? - a practical guide for clinicians - tool

Canadian Agency for Drugs and Technologies in Health
- Utilization of Potentially Inappropriate Medications in Patients with Major Neurocognitive Disorder - link

electronic Medicines Compendium (eMC) (UK)
- New/extended indications
-- Bylvay (odevixibat sesquihydrate) - new indication for the treatment of cholestatic pruritus in Alagille syndrome (ALGS) in patients aged 6 months or older
-- Koselugo (selumetinib hydrogen sulfate) - indication extension to include treatment of adults, based on results from the KOMET study. Warnings and precautions, interactions and undesirable effects updated in line with KOMET study data
- New products
-- Sarclisa (isatuximab) 1400 mg solution for injection. New subcutaneous formulation for the same indications as the solution for infusion; patients currently receiving the IV formulation may switch to subcutaneous at any time during their treatment, once cycle 1 is completed
-- Tevimbra (tislelizumab) 100 mg/10 ml Infusion for non-small cell lung cancer, small cell lung cancer, gastric or gastroesophageal junction adenocarcinoma, oesophageal squamous cell carcinoma and nasopharyngeal carcinoma
-- Tuyory (tocilizumab) - biosimilar is available as a 20mg/mL concentrate for solution for infusion (vial), and a 162mg/0.9mL solution for injection (pre-filled pen and pre-filled syringe). It is licensed for use in all indications of the reference product (RoActemra)

ENDO 2026
- Conference report: GLP1 Receptor Agonists and the Risk of Significant Hypotension Among Patients with Metabolic Cardiovascular Renal Disease - link

European Medicines Agency (EMA)
- European CHMP recommendations - June 2026
-- approval of 5 new medicines in the EU: Hopledo [levodopa / carbidopa]; insulin efsitora alfa; Denosumab Ascend [biosimilar]; Nylaspeg [pegfilgrastim biosimilar], and trofinetide
-- extending indications for datopotamab, Imvanex vaccine, Ixchiq vaccine, pirtobrutinib, inclisiran, MenQuadfi vaccine, ruxolitinib, darunavir/cobicistat, upadacitinib, ustekinumab, Symtuza [darunavir/cobicistat/emtricitabine/tenofovir alafenamide], & teclistamab
-- refusal of the marketing authorisation for three new medicines (Tacquell [autologous melanoma-derived tumour infiltrating lymphocytes, ex vivo-expanded]; narsoplimab; Xervyteg [allogeneic faecal microbiota, pooled])
-- revoking marketing authorisation for avacopan (Tavneos) after concluding the Advocate study was conducted in breach of good clinical practice principles & the data could no longer be relied upon for demonstrating its effectiveness for the treatment of severe, active granulomatosis with polyangiitis or microscopic polyangiitis

Food and Drug Administration (FDA) USA
- New Drug approvals
-- allogeneic regulatory T cell-based immunotherapy with HSPC and T cells-vldq (Tregzi) for use in matched donor hematopoietic stem cell transplantation for adults with hematologic malignancies - link
-- palbociclib (Ibrance) with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of HR-positive, HER2-positive metastatic breast cancer

-- Risankizumab for children with psoriasis, PsA
-- Topical Roflumilast (Zoryve) approved for psoriasis down to age 2
-- sacituzumab govitecan-hziy as monotherapy and in combination with pembrolizumab for first-line treatment of triple-negative breast cancer
-- Tryngolza (olezarsen), first treatment shown to reduce the risk of acute pancreatitis in adults with severe hypertriglyceridemia
-- Lumvoa (Veligrotug-Vvze), first treatment for thyroid eye disease

Health Services Safety Investigation Body
- Learning report - Patient safety across regional care pathways: learning from an HSSIB investigation pilot - link
- Investigation report - Online prescribing: opportunities to improve patient safety - link

Medicines and Healthcare products Regulatory Agency (MHRA)
- Update on the PATHWAYS clinical trial investigating the effects of puberty-suppressing medication in children and young people who experience gender incongruence - link
- Warning on promoting newly licensed prescription-only medicines and unlicensed medicines for weight management - link
- MHRA Safety Roundup: June 2026

Monthly Index of Medical Specialities (MIMS) UK
- Low-dose atropine eye drops (Ryjunea) for childhood myopia launched in UK - link
- GLP-1s on the horizon: Including an oral small-molecule GLP-1 agonist, a dual GLP-1/glucagon agonist, and a triple GIP/GLP-1/glucagon agonist - link

National Institute for Health and Care Excellence (NICE) UK
- Mirvetuximab soravtansine for treating folate receptor-alpha-positive platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (TA1169)
- Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable (TA1170)
- Seladelpar for previously treated primary biliary cholangitis (TA1171)
- Atogepant for treating migraine (TA1172)
- Pirtobrutinib for treating relapsed or refractory chronic lymphocytic leukaemia after a BTK inhibitor (TA1173)
- Advanced breast cancer: diagnosis and treatment (CG81)
- Perioperative care in adults (QS216)

National Institute for Health and Care Research (NIHR)
- Alpha2 agonists for sedation to produce better outcomes for adults with critical illness: a synopsis of the A2B RCT with cost-effectiveness and process evaluation - link
- Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis: a synopsis of MS-STAT2, a multicentre, randomised controlled, double-blind, phase 3 clinical trial - link

UK Health Security Agency
- MenB vaccine (Bexsero®): one-off, time-limited offer Autumn 2026 patient group direction template - link

World Health Organisation (WHO)
- New WHO report outlines critical steps to confront fungal disease and antifungal resistance - link
- TAG-TP statement on immunomodulators and host-directed therapies for Bundibugyo virus disease - link

MEDICATION SAFETY

electronic Medicines Compendium (eMC) (UK)
- Revised SPCs

-- Alka-Seltzer XS (aspirin, caffeine, paracetamol) tablet - Kounis syndrome (acute myocardial ischaemia with or without myocardial infarction occurring as part of a hypersensitivity reaction) included as a new ADR (frequency not known)
-- Alvesco (ciclesonide) - avoidance of concomitant administration recommended with potent CYP3A4 inhibitors, as interaction could lead to an increased risk of systemic corticosteroid side effects. Monitoring recommended, if concomitant use cannot be avoided
-- Botox Allergan (botulinum toxin type a) - reports of iatrogenic botulism after botulinum toxin injections. Patients and caregivers should seek urgent medical advice if they notice symptoms suggesting botulinum toxin spread, or if swallowing, speech, or breathing difficulties develop
-- Buvidal (buprenorphine) prolonged-release solution for injection - new warnings advising it may lower the seizure threshold & should be used with caution in patients with seizure disorders, head injury, intracranial lesions or raised cerebrospinal pressure. Seizures listed new ADR (frequency not known)
-- Calceos (calcium carbonate and colecalciferol) 500mg/400IU interacts with bisphosphonates, fluroquinolones, ferrous salt and zinc added. Recommendation to take at least two hours apart. Also includes statement that the safety and efficacy of Calceos have not been established in children
-- Cyklokapron (tranexamic acid) 100 mg/mL solution for injection/infusion - updated to remove terminology of “mild”, “moderate” or “severe” renal impairment and replacing it with clearer guidance on dosing recommendations based on absolute serum creatinine concentration
-- Gaalin (galantamine) prolonged release - nightmare as an uncommon ADR
-- Lorviqua (lorlatinib) - no dose adjustments are recommended for patients with mild or moderate hepatic impairment. A reduced starting dose of lorlatinib is recommended in patients with severe hepatic impairment (Child-Pugh C) from 100mg to 50mg orally once daily
-- Migraleve and Migraleve Pink (paracetamol, codeine, buclizine) tablets - new treatment goals/discontinuation guidance & shorter use recommendations; strengthened opioid safety warnings (tolerance, hyperalgesia, sleep-related breathing disorders); added hepatobiliary risks, gabapentinoid interaction, new ADRs and dependence wording
-- Mysimba (naltrexone hydrochloride and bupropion hydrochloride) - detail on serious skin reactions including Stevens-Johnson syndrome and acute generalised exanthematous pustulosis (AGEP) added. AGEP also added as an ADR with frequency not known
-- Omjjara (momelotinib dihydrochloride monohydrate) - addition of erythema multiforme and hypersensitivity as known ADRs
-- Opzelura (ruxolitinib) 15 mg/g cream - updated to note that cases of herpes zoster reactivation have been reported in patients treated with topical ruxolitinib. If a patient develops herpes zoster, temporary interruption of ruxolitinib cream therapy should be considered until the episode resolves
-- Rezzayo (rezafungin) - cases of anaphylactic reaction reported. If an anaphylactic reaction occurs, rezafungin should be discontinued and appropriate treatment administered
-- Ropiqual XL, Requip (ropinirole) prolonged-release - aggressive behaviours added as one of the behavioural symptoms of impulse control disorders, that can occur in patients treated with dopamine agonists including ropinirole. Consider dose reductions/tapered discontinuation
-- Rotarix (live attenuated rotavirus vaccine) oral suspension in squeezable tube - anaphylactic reaction added as an ADR with a frequency not known and warning/precaution
-- Sabril (vigabatrin) - revised guidance to discontinue vigabatrin if no meaningful response after an adequate trial, with gradual withdrawal. Strengthened vision monitoring recommended, at baseline and 3–6 monthly assessments during and after discontinuation of therapy
-- Tecvayli (teclistamab) - tumour flare (unknown frequency) added as an ADR. Manifestations include localised pain and symptoms of nerve & spinal compression due to transient tumour enlargement. Tumour flare does not imply treatment failure or tumour progression. Monitoring recommended
-- Thiotepa Riemser (thiotepa) - new contraception advice. Women of childbearing potential must use effective contraception during treatment & for at least 6 months after stopping, with a pre-treatment pregnancy test. Men must not father a child during treatment and for 3 months after cessation
-- Winrevair (sotatercept) - new indication for adults with WHO Functional Class II–IV & updated warnings on thrombocytopenia. Serious bleeding events, with gingival bleeding now listed as very common adverse reactions (ARs). Urinary tract infection and back pain added as new AR
-- Yimmugo (human normal immunoglobulin) - during the shelf-life, the product may be kept at room temperature (up to 25°C) for a single period not exceeding 12 months (previously stated 6 months). Information on polysorbate 80 content (5 micrograms per mL) also added

- Risk minimisation materials
-- Tevimbra (tislelizumab) patient card containing important safety information for patients and healthcare providers on immune-mediate adverse reactions, which may occur any time during or even after treatment

EMA
- … starts review of Rifadin (rifampicin) oral suspension and syrup - link

Health Canada – MedEffect Notice
- Health Product InfoWatch, June 2026 includes:
-- Summary Safety Review: Finasteride and dutasteride - link ; Givlaari (givosiran) ; Tramadol-containing products - link
-- Safety brief: Vitamin B6 health products and peripheral neuropathy

Health Quality & Safety Commission New Zealand
- New eLearning supporting safer use of anti-seizure medicines in pregnancy: balancing the risks and potential harm - link

ISMP Canada – Safety Bulletins
- Palliative Care at Home – Part 1: Multi-incident analysis; Part 2: Analysis of a fatal incident

MIMS monthly updates
- New Contraindications
-- Suxamethonium chloride dihydrate (Suxamethonium Medsurge) in patients with inherited atypical or low serum level of pseudocholinesterase, end stage hepatic failure, acute or chronic renal failure; in patients recovering from major trauma or severe burns (the period of greatest risk of hyperkalaemia is from about 5 to 90 days after the injury and may be further prolonged if there is delayed healing due to persistent infection); a patient who is not fully anaesthetised; in patients with neurological deficits involving acute major muscle wasting (upper and/or lower motor neurone lesions); in patients who have been immobilised for prolonged periods of time; in patients with cerebral palsy; and in patients with a personal or family history of congenital myotonic diseases such as myotonia congenita and dystrophia myotonica
-- Tranexamic acid (Tranexamic-AFT) for intrathecal or epidural administration
- Safety Related Changes
-- Entrectinib (Rozlytrek) no longer has provisional approval and is now not indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have either progressed following treatment or have no satisfactory alternative therapy.
-- Terlipressin (acetate) (Glypressin Solution) is no longer contraindicated in patients with current or recent ischaemic cardiovascular disease.

Specialist Pharmacy Services NHS UK
- Minocycline monitoring - link
- Prescribing and administering intravenous paracetamol safely - link
- Managing fire risk with emollients and other skin products - link
- Stability challenges in aseptic services - link

TGA
- Adverse drug reaction reporting using Best Practice: Installing the ADR reporting template; Using the ADR reporting template
- Grakcu capsules may pose a serious risk to your health and should not be taken - link
- Sexual enhancement supplements found to contain undeclared prescription medicines - link
- Information about major medicine shortages – link
-- About the changes to the supply of insulin products - link
-- About the shortage of Catapres (clonidine) 150 mcg tablets - link
-- About the shortage of methylphenidate hydrochloride products - link

-- About the shortage of Bicillin L-A (benzathine benzylpenicillin tetrahydrate) prefilled syringe for injection - link
-- About the cyclophosphamide and ifosfamide injection shortages - link
-- About the shortage of transdermal HRT patches - link

PAPERS OF INTEREST

American Journal of Health-System Pharmacy (AJHP)
- Iodixanol-induced acute generalized exanthematous pustulosis: Cross-reactivity to other iodinated contrast media - link
- Integration of smart infusion pumps with electronic medical records improves safety and staff productivity at a large academic healthcare system - link

Annals of Internal Medicine
- Care of Patients Receiving Glucagon-Like Peptide-1 Receptor Agonists - link

Arthritis & Rheumatology
- Efficacy and Safety of Nanoencapsulated Sirolimus plus Pegadricase: Results from the Randomized, Placebo-Controlled Phase 3 Trials - link
- Adverse Events After Same-Day COVID-19 and Influenza Vaccination Versus Influenza Vaccination Alone: A Target Trial Emulation - link

British Journal of Clinical Pharmacology
- Comparative effectiveness and safety of proton pump inhibitors after myocardial infarction on dual antiplatelet therapy: Insights from a target trial emulation - link
- Evaluating effectiveness of risk minimization through healthcare professional surveys: A review of post-authorization studies, 2022–2024 - link
- Codeine toxicity via breast milk: Can this occur and implications for opiate therapy in children - link
- Comparative effectiveness of dapagliflozin vs. empagliflozin on major adverse cardiovascular events in patients with heart failure with reduced ejection fraction: A real-world prospective cohort study - link
- Do consumers and healthcare professionals report the same adverse event differently? A paired analysis of duplicate vaccine safety reports in Norway - link

British Journal of Psychiatry
- Acceptability and accuracy of point-of-care monitoring of lithium levels - link

British Medical Journal (BMJ)
- Detrimental effects of conflicts of interest in GLP-1 therapy guidance - link
- Puberty blockers: MHRA reapproves controversial trial paused over safety concerns - link
- 10-Minute Consultation: Discussing and prescribing analgesia in pregnancy - link
- BMJ Editorial: Use of traditional medicine must follow evidence of efficacy and safety - link

Circulation
- Strategies for Optimizing Heart Failure Care in the Older Adult: A Scientific Statement from the American Heart Association - link
- Consumption of Fructose-Containing Food and Beverage Sources in Childhood Through to Adulthood and Risk of Hypertension: A Prospective Cohort Study - link
- Perioperative Anemia and Patient Blood Management in Cardiac Surgery: A Scientific Statement from the American Heart Association - link
- Heart Failure Occurring in the Perinatal Period: A Scientific Statement from the American Heart Association - link

Cochrane
- Biologic drugs for induction and maintenance of remission in Crohn's disease: a network meta-analysis - link
- (Ultra-)short-acting insulin analogues for adults with type 1 diabetes mellitus on multiple daily injections: a network meta-analysis - link

- Long-term effects of weight-reducing drugs in people with hypertension - link

Diabetes, Obesity and Metabolism
- The Effect of Semaglutide on Quality of Life in Adults with Overweight or Obesity: A Brief Systematic Review and Meta-Analysis - link

European Heart Journal
- AHA/ACC/ESC/WHF Expert Consensus Document: Second Universal Definition of Heart Failure (2026): AHA/ACC/ESC/WHF Consensus Document - link

European Journal of Hospital Pharmacy
- Chemical and visual compatibility of fluconazole injection with parenteral medications used in neonatal intensive care settings - link
- Use of the 'Making Medicines Work for You' screener to identify medication adherence barriers in heart failure patients - link
- Chemical and visual compatibility of dexmedetomidine injection with parenteral medications used in neonatal intensive care settings - link
- Reuse of fixed-dose monoclonal antibodies in oncology: retrospective and pharmacoeconomic analysis in a chemotherapy reconstitution unit - link

Health Quarterly
- An "Early Warning" Risk Assessment Strategy to Enable Proactive Management of Supply Shortages in Canada – link
- Advancing a Digitally Enabled Supply Chain as a Strategy to Strengthen Resilience of Canada's Healthcare Supply Chain - link

Internal Medicine Journal
- Crossover effect: causal machine learning reveals opposing mortality responses to mean arterial pressure targets among phenotypically distinct hypertensive patients with septic shock - link
- Approach to thyroid disorders associated with immune checkpoint inhibitors and tyrosine kinase inhibitors - link
- Triple combination cystic fibrosis transmembrane receptor modulator effects on glycaemia and insulin kinetics in cystic fibrosis with and without diabetes - link
- Viewpoint: Denosumab discontinuation and fracture risk: getting the balance right – link
- Medication discontinuation in the era of elexacaftor/tezacaftor/ivacaftor: an Australian survey and qualitative interview - link

International Journal of Clinical Pharmacy
- Development and reliability testing of BRANT-MERQS-2A: A quality assessment tool for medication review type 2a reports - link
- Research trends and emerging topics in antifungal therapeutic drug monitoring: a bibliometric analysis with implications for clinical pharmacy practice - link
- A qualitative exploration of healthcare professionals' perspectives on the role of pharmacists in screening older adults for depression during medication reviews - link
- Evidence on interventions that target prescribing appropriateness in older adults attending the emergency department and other acute care settings: a scoping review - link

International Journal for Quality in Health Care
- Anticholinergic burden and quality of life: expanding the evidence for person-centred care - link
- Prevalence of chemical restraint use in hospital care: a consensus and cross-sectional study - link
- Methodological evaluation of the psychometric properties of medication-related quality indicators in residential aged care homes: a systematic review - link
- Pharmacist-led continuity of care interventions for patients receiving oral anticancer therapy: a systematic review and meta-analysis - link

JAMA

- Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR-Variant Non–Small Cell Lung Cancer: The HARMONi-A Randomized Clinical Trial - link
- Vibriosis - link
- JAMA Patient Page: Amyotrophic Lateral Sclerosis - link

JAMA Internal Medicine
- Multilevel Stewardship Intervention for Use of Anticoagulation-Antiplatelet Therapy - link
- Prenatal Acetaminophen (Paracetamol) Use and the Risk of Autism and/or Attention-Deficit/Hyperactivity Disorder Among Sibling-Matched Cohorts - link

Journal of Pharmacy Practice and Research (JPPR)
- Evaluation of the acceptance rate of analgesic stewardship team recommendations at a metropolitan hospital network - link
- Outcomes of pharmacist-led deprescribing interventions in older adults living in long-term care facilities: a scoping review - link

Lancet
- Benzylpenicillin versus flucloxacillin or cloxacillin for the treatment of penicillin-susceptible Staphylococcus aureus bacteraemia (SNAP): an international, multicentre, open-label, non-inferiority randomised controlled trial - link
- Cervical cancer mortality trends following HPV vaccination in England, 2001–24: an analysis of population-based mortality data - link
- Efficacy and safety of tirofiban after successful endovascular reperfusion in acute ischaemic stroke (ATTRACTION) in China: a multicentre, double-blind, randomised controlled trial - link
- Safety and efficacy of mRNA vaccines: a mechanistic and public health perspective - link

Lancet Diabetes & Endocrinology
- 1-year outcomes of semaglutide, tirzepatide, and sleeve gastrectomy in obesity in type 2 diabetes: a retrospective cohort study - link

Lancet Infectious Diseases
- Efficacy, safety, and immunogenicity of an Escherichia coli-produced nine-valent human papillomavirus vaccine: a multicentre, double-blind, randomised, controlled, phase 3 trial - link

Lancet Psychiatry
- International cannabis policies and their association with cannabis use, cannabis use disorder, and other psychiatric disorders - link
- Relationships between cannabis use and mental disorders: assessing the coherence of evidence from studies with different methodologies - link

Molecular Diversity Preservation International (MDPI) – Pharmacy Journal
- Automated Processes and Artificial Intelligence in Generating Candidates for Oncology Drug Repurposing: Three-Year Scoping Review of Data - link
- Sodium-Glucose Co-Transporter 2 Inhibitors and Hyperkalemia-Related Discontinuation of Renin-Angiotensin-Aldosterone System Inhibitors During Mineralocorticoid Receptor Antagonist Therapy: A Real-World Cohort Study - link
- “The Most High-Risk People Are Given the Most High-Risk Drugs in the Most High-Risk Way”: Experiences of Treating Problematic Over-the-Counter and Prescription-Only Medication Use in Substance Misuse Services - link
- Cumulative Anticholinergic Burden and Risk of Delirium Among Older Adults with Alzheimer’s Disease - link

New England Journal of Medicine
- Cefazolin for Methicillin-Susceptible Staphylococcus aureus Bacteremia - link
- A Pragmatic Trial of a 6-Month Strategy for Rifampicin-Resistant Tuberculosis - link
- Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas - link
- Long-Acting Treatment and Advanced HIV Disease — Addressing a Public Health Priority - link

- Phase 3 Trial of Oral Infigratinib in Children with Achondroplasia - link

Pharmaceutical Journal
- Conference report: More than half of those who stop GLP-1s restart within a year - link

Pharmacotherapy
- The Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of a Single Oral Dose of Zongertinib in Healthy Male Volunteers - link

Prescrire International – July 2026 includes:
- Elafibranor (Iqirvo°) in primary biliary cholangitis
- In-utero exposure to mesalazine: renal disorders, haematological disorders and possibly malformations
- GLP-1 agonists: thyroid cancer (continued)
- Extending drug shelf life: potential economic and environmental benefits

Research in Social and Administrative Pharmacy
- Effect of a collaborative intervention by pharmacists and dentists on smoking cessation - link

Stroke
- Intensive Versus Conventional Blood Pressure Lowering After Successful Endovascular Thrombectomy: OPTIMAL-BP 1-Year Outcomes - link

CONSULTATIONS

TGA
- Consultation on increasing transparency of Good Manufacturing Practice (GMP) inspection outcomes – closes 13 July 2026 – link
- Consultation: Radiopharmaceutical regulation in Australia - closes on 31 July 2026 – link
- Consultation: Proposed changes to the Permissible Indications Determination - closes on 12 August 2026 – link

WEBINARS & PODCASTS

Australian Government Department of Health
- Overview of the National Health and Medical Research Strategy - link

Australian Prescriber Podcasts
- E217 | Emergency contraception: an overview

UPCOMING EVENTS

Advanced Pharmacy Australia
- Medicines Management MM2026, 22-24 October 2026, Brisbane Convention & Exhibition Centre -– Scholarships closing 19 July - Early Bird registration open until 9 September

Australian Commission on Safety and Quality in Health Care (ACSQHC)
- Registrations open – National Medicines Symposium NMS 2026, 'Medicines stewardship: safer use starts with all of us' - Wednesday, 11 November 2026 - register

FIP
- Pharmacists and patient safety: Building safer care with patients, online 30 June 2026, 15:00-16:30 CEST - register
- Recent Advances in Formulation Approaches to Enable Oral Delivery of Poorly Water-Soluble Drugs, online 9 July 2026, 16:00-17:00 CEST - register

Safer Care Victoria
- Turning insight into action: Improving IV medication safety across services, Tue, 07 Jul 2026 01:00pm - 02:00pm - register